Document:

Co-Promotion Strategic Marketing Services Agreement

 Exhibit 10.13 
 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN
REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
 EXECUTION VERSION 
 CO-PROMOTION AND
STRATEGIC MARKETING SERVICES AGREEMENT 
 between 
 ASTRAZENECA UK LIMITED 
 and 
 ABRAXIS BIOSCIENCE, INC. 
 DATE: APRIL 26, 2006 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	 1
	  	Definitions	  	3
			
	 2
	  	Construction	  	20
			
	 3
	  	Co-Promotion Rights	  	20
			
	 3.1
	  	Grant of Rights	  	20
	 3.2
	  	Reservation of Rights	  	20
	 3.3
	  	ROW Rights for the Product	  	20
	 3.4
	  	Rights for Nab-Docetaxel	  	21
			
	 4
	  	Sales Force Composition	  	22
			
	 4.1
	  	Designated Sales Forces; Alignment	  	22
	 4.2
	  	Vacancies	  	24
	 4.3
	  	Sales Force Incentives	  	25
	 4.4
	  	Sales Meetings	  	25
	 4.5
	  	Non-Solicitation	  	25
	 4.6
	  	Contracting and Pricing	  	25
	 4.7
	  	Promotional Materials; Statements about the Products	  	26
	 4.8
	  	Compliance with Laws and Policies	  	27
			
	 5
	  	Training	  	28
			
	 5.1
	  	Training Plans and Materials	  	28
	 5.2
	  	Training Programs	  	29
	 5.3
	  	Return of Training Materials	  	29
	 5.4
	  	Information Technology	  	29
			
	 6
	  	Detail Requirements	  	30
			
	 6.1
	  	Performance of Details	  	30
	 6.2
	  	Performance Correction	  	31
	 6.3
	  	Failure to Perform Required Number of Details	  	31
	 6.4
	  	Permissible Details	  	31
			
	 7
	  	[Intentionally Omitted]	  	32
			
	 8
	  	Reporting and Auditing	  	32
			
	 8.1
	  	Recordkeeping	  	32

  

 (i) 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

					
	 8.2
	  	Monthly Tracking Reports	  	32
	 8.3
	  	Net Sales Reports	  	34
	 8.4
	  	Shared Expenses Reports	  	36
	 8.5
	  	Detail Audits	  	36
	 8.6
	  	Detail Message Audits	  	37
	 8.7
	  	Financial Audits	  	37
			
	 9
	  	Fees and Expenses	  	39
			
	 9.1
	  	Signing Fee	  	39
	 9.2
	  	Co-Promotion Compensation	  	39
	 9.3
	  	Shared Expenses	  	40
	 9.4
	  	Other Expenses	  	41
	 9.5
	  	Residual Compensation	  	41
	 9.6
	  	New Indication Fee	  	42
	 9.7
	  	Form of Payment	  	43
			
	 10
	  	Committees	  	43
			
	 10.1
	  	Governance Structure	  	43
	 10.2
	  	Joint Operating Committee (“JOC”)	  	43
	 10.3
	  	Joint Brand Team	  	44
	 10.4
	  	Dispute Resolution	  	46
			
	 11
	  	Business Plan	  	47
			
	 11.1
	  	Business Plan	  	47
	 11.2
	  	Preparation and Adoption of Business Plans	  	49
	 11.3
	  	Material Amendments of Business Plan	  	50
	 11.4
	  	Additional Expenses	  	51
			
	 12
	  	Product Supply	  	51
			
	 12.1
	  	Orders for Products; Terms of Sale	  	51
	 12.2
	  	Returned Product	  	51
	 12.3
	  	Recalled Product	  	52
	 12.4
	  	Supply; Regulatory Requirements	  	52
	 12.5
	  	Failure of Supply	  	53
			
	 13
	  	Regulatory Matters	  	55
			
	 13.1
	  	Ownership of Regulatory Documentation and Approvals	  	55
	 13.2
	  	Regulatory Reporting	  	55
	13.3	  	Adverse Event, Field Alert and Product Quality Complaint Notification and Reporting`1	  	56
	 13.4
	  	Requests for Medical Information	  	58

  

 (ii) 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

					
	 14
	  	Noncompetition	  	59
			
	 14.1
	  	Noncompetition	  	59
	 14.2
	  	[Intentionally Omitted]	  	61
	 14.3
	  	Remedies	  	62
			
	 15
	  	Confidentiality	  	63
			
	 15.1
	  	Confidential Information	  	63
	 15.2
	  	Exceptions to Confidentiality	  	63
	 15.3
	  	Authorized Disclosure	  	64
	 15.4
	  	Notification	  	64
	 15.5
	  	Destruction of Confidential Information	  	64
	 15.6
	  	Remedies	  	65
			
	 16
	  	Intellectual Property Rights	  	66
			
	 16.1
	  	Intellectual Property	  	66
	 16.2
	  	No Ownership or Rights in Intellectual Property	  	66
	 16.3
	  	Intellectual Property Infringement	  	69
			
	 17
	  	Representations and Warranties	  	71
			
	 17.1
	  	Representations and Warranties of Each Party	  	71
	 17.2
	  	Representations and Warranties of Abraxis	  	72
			
	 18
	  	Indemnification	  	74
			
	 18.1
	  	Indemnification of Abraxis	  	74
	 18.2
	  	Indemnification of AstraZeneca	  	74
	 18.3
	  	Notice of Claim	  	75
	 18.4
	  	Indemnification Procedures	  	75
			
	 19
	  	Generic Product; Net Sales Failure	  	78
			
	 19.1
	  	Generic Product	  	78
	 19.2
	  	Net Sales Failure	  	78
	 19.3
	  	Consequences of Termination for Net Sales Failure	  	79
			
	 20
	  	Change of Control	  	80
			
	 21
	  	Term and Termination	  	80
			
	 21.1
	  	Term	  	80
	 21.2
	  	Termination	  	80
	 21.3
	  	Effect of Termination or Expiration	  	82
	 21.4
	  	Return of All Materials	  	83
	 21.5
	  	Survival	  	83

  

 (iii) 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

					
	 22
	  	Governing Law, Jurisdiction; Dispute Resolution	  	83
			
	 22.1
	  	Governing Law	  	83
	 22.2
	  	Jurisdiction	  	84
	 22.3
	  	Dispute Resolution	  	84
			
	 23
	  	Force Majeure	  	84
			
	 24
	  	Waiver and Non-Exclusion of Remedies	  	85
			
	 25
	  	Notices	  	86
			
	 25.1
	  	Notice Requirements	  	86
	 25.2
	  	Address for Notice	  	86
			
	 26
	  	Entire Agreement	  	87
			
	 27
	  	Amendment	  	87
			
	 28
	  	Assignment	  	87
			
	 29
	  	No Benefit to Others	  	88
			
	 30
	  	Counterparts	  	89
			
	 31
	  	Severability	  	89
			
	 32
	  	Further Assurance	  	89
			
	 33
	  	Publicity	  	89
			
	 34
	  	Relationship of the Parties	  	90
		
	Schedules	  	
		
	 Schedule 9.6 — New Indication Fee
	  	
		
	 Schedule 17.2.1 — Product Patents
	  	

  

 (iv) 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 CO-PROMOTION AND STRATEGIC MARKETING SERVICES AGREEMENT 
 This Co-Promotion and Strategic Marketing Services Agreement (the “Agreement”) is dated as of the 26th day of April 2006 by and between

  

	(1)	ASTRAZENECA UK Limited, a company incorporated under the laws of England and Wales with offices at 15 Stanhope Gate, London W1K 1LN, England (“AstraZeneca”); and

  

	(2)	Abraxis Bioscience, Inc., a Delaware corporation with offices at 11777 San Vicente Boulevard, Suite 500, Los Angeles, California 90049, USA (“Abraxis”);

 Recitals 
  

	a.	WHEREAS, Abraxis possesses the exclusive right to develop, market, promote and sell the Product (as defined herein) in the Territory (as defined herein); 

 

	b.	WHEREAS, AstraZeneca has significant experience in the marketing and promotion of prescription pharmaceutical products not only in the Territory but worldwide;

  

	c.	WHEREAS, AstraZeneca and Abraxis wish to collaborate with each other to co-promote the Product in the Territory on the terms and conditions set forth herein;

  

	d.	WHEREAS, Abraxis wishes to access and secure certain strategic, technical and marketing services of AstraZeneca; 

  

	e.	WHEREAS, Abraxis and AstraZeneca wish to potentially collaborate and access AstraZeneca’s strategic market knowledge in respect of oncology in the ROW Territory (as defined in
Section 3.3) and Abraxis wishes to provide AstraZeneca with an opportunity to co-promote the Product in the ROW Territory under the circumstances set forth in Section 3.3 of this Agreement; 

  

	f.	WHEREAS, Abraxis and AstraZeneca wish to potentially collaborate and access AstraZeneca’s strategic market knowledge in respect of oncology in the ROW Territory and Abraxis
wishes to provide AstraZeneca with an opportunity to co-promote [***] in the [***] (as defined in Section 3.4) under the circumstances set forth in Section 3.4 of this Agreement; and 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	g.	WHEREAS, simultaneously herewith, Abraxis and AstraZeneca are entering into an Asset Purchase Agreement providing for the sale by AstraZeneca and the purchase by Abraxis of
AstraZeneca’s local anesthetic business in the United States and its territories and possessions, which Asset Purchase Agreement and related agreements provide for a long term product supply agreement; and AstraZeneca providing Abraxis with an
opportunity to purchase AstraZeneca’s local anesthetic business outside of the United States and its territories and possessions, subject to and in accordance with the terms of such Asset Purchase Agreement. 

  

 Page 2 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 Agreement 
 NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree
as follows: 
  

	1	Definitions 

 Unless otherwise specifically
provided in this Agreement, the following terms shall have the following meanings: 
 “A&P Expenses” means all costs and
expenses: 
  

	 	•	 	incurred by AstraZeneca or Abraxis and paid or payable to a third party (including individuals who are independent contractors engaged to perform services but excluding employees
and contract sales forces) by AstraZeneca or Abraxis in connection with the marketing, advertising, and promotion of the Product in the Territory, including: (A) marketing and marketing research costs; (B) non-personal promotion and
advertising costs (including costs of direct-to-consumer advertising, journal advertising, Promotional Materials, direct mail, reminder promotions and web-based promotions); (C) public relations costs; (D) non-salary training expenses
(including training materials and travel and lodging costs incurred directly in connection with training of a Designated Sales Force); (E) joint AstraZeneca and Abraxis promotional and sales meetings (it being acknowledged and agreed that the
costs and expenses of each Party’s own regional and national sales meetings shall not constitute A&P Expenses), and (F) meeting and facilities rental and administration costs; provided that neither the costs and expenses of a third
party sales force nor the costs or expenses of compensation and benefits paid or granted to employees of AstraZeneca or Abraxis and their respective Affiliates shall constitute A&P Expenses; 

  

	 	•	 	incurred by AstraZeneca or Abraxis in connection with producing training materials and in training AstraZeneca’s and Abraxis’ trainers pursuant to Section 5.1 (it
being acknowledged and agreed that each Party shall be responsible for all other costs of training its Designated Sales Forces); 

  

 Page 3 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	•	 	fees incurred by AstraZeneca and Abraxis for services from distributors, wholesalers and group purchasing organizations; 

  

	 	•	 	incurred by AstraZeneca and Abraxis to commission the third-party vendor as contemplated by the applicable Business Plan; and 

  

	 	•	 	incurred by AstraZeneca or Abraxis otherwise in accordance with the applicable Business Plan. 

 “Abraxis Trademarks” means the names and marks ABRAXIS®, “Abraxis Bioscience,” and “Abraxis Oncology” and associated logos of Abraxis. 
 “Act” means the Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidances, guidelines and requirements of
the FDA as may be in effect from time to time. 
 “Adverse Event” means the development of an undesirable medical condition
or the deterioration of a pre-existing medical condition following or during exposure to the Product, whether or not considered causally related to the Product, the exacerbation of any pre-existing condition(s) occurring during the use of the
Product, or any other adverse experience or adverse drug experience described in the FDA’s Investigational New Drug safety reporting and NDA post-marketing reporting regulations, 21 C.F.R. 312.32 and 314.80, respectively, as they may be amended
from time to time. For purposes of this Agreement, “undesirable medical condition” shall include symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver) or the abnormal results of an investigation (e.g., laboratory
findings, electrocardiogram), including unfavorable side effects, toxicity, injury, death or other serious adverse reaction, overdose, sensitivity reactions or failure of the Product to exhibit its expected pharmacologic/biologic effect. 

 

 Page 4 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Affiliates” means, with respect to a Person, any Person that controls, is
controlled by or is under common control with such first Person. For purposes of this definition only, “control” means (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through
ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interests of such
Person. For the purposes of this Agreement, an Affiliate of Abraxis shall include any Permitted Control Entity. 
 “Agency”
means any governmental or regulatory authority in the Territory, including the FDA. 
 “Applicable Laws and Guidelines”
means the American Medical Association Guidelines on Gifts to Physicians from Industry, the PhRMA Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines, and the PhRMA Code on Interactions with Healthcare Professionals,
and all federal, state and local laws, and the rules and regulations of all Agencies, in effect from time to time applicable to the marketing, promotion, distribution and sale of the Product in the Territory, including the Act (including guidances
and guidelines published by the FDA on its publicly available web site), PDMA, all applicable provisions of the Social Security Act, the requirements of the Medicare Anti-Kickback statute, Section 1128B(b) of the Social Security Act
(42U.S.C.§1320(a)-7b(b)), obligations of disclosure and reporting contained in the Social Security Act, including without limitation, the reporting obligations set forth in 42 U.S.C. §§ 1320a-3a and 1320(a)-7(b), all state fraud and
abuse statutes, the “Safe Harbor Regulations” that are found at 42 C.F.R. §1001.952 et seq., and consumer protection and false claims statutes and regulations. 
 “AstraZeneca Pipeline Compounds” means [***]. 
 “AstraZeneca Trademarks” means the trademark ASTRAZENECA® and associated logos of AstraZeneca. 
 “Baseline” for a Fundamental Requirement means (i) with respect to the initial Calendar Year, two (2) times the amount of the Fundamental Requirement with respect to the Shared 

  

 Page 5 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
Expense budget and the Mandatory Detail Requirement, and one (1) time the amount of the Fundamental Requirement with respect to the Mandatory
Representative Requirement, in each case, for the initial Calendar Year as set forth in the Business Plan for such initial Calendar Year, and (ii) with respect to the Calendar Year commencing January 1, 2007, and each successive Calendar
Year, the amount of such Fundamental Requirement for such Calendar Year as set forth in the Business Plan for such Calendar Year, except that the Baseline for the Shared Expense budget for the Extraordinary Shared Expense Calendar Year shall not
include the amount of the Extraordinary Shared Expense Increase. 
 “Business Day” means a day other than Saturday, Sunday
or any day on which banks located in the United States or the United Kingdom are authorized or obligated to close. 
 “Business
Plan” means, with respect to the initial Calendar Year, the plan delivered pursuant to Section 11.2.1, and with respect to each subsequent Calendar Year, the plan developed consistent with the provisions of Sections 11.1 and 11.2,
in each case as such plan may be amended from time to time in accordance with Section 11.3. 
 “Business Policies”
means those policies delivered to Abraxis on the date hereof, as amended from time to time by AstraZeneca in accordance with Section 4.8. 
 “Calendar Quarter” means each of the three (3) consecutive month periods ending on March 31, June 30, September 30, and December 31. 
 “Calendar Year” means the period from the Effective Date through December 31, 2006 (sometimes referred to herein as the
“initial Calendar Year”) and each successive period of twelve (12) consecutive calendar months commencing on January 1 and ending on December 31. 
 “cGMP Requirements” has the meaning ascribed to it in Section 12.4.1. 
 “Change of Control,” with respect to any Person (the “Subject Person”), means an event in which: 
  

	 	•	 	 any other Person or group of Persons (other than a Parent Entity of the Subject Company, and other than in the case of Abraxis, Permitted Control Entities) 

  

 Page 6 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
acquires beneficial ownership of securities of the Subject Person representing more than fifty percent (50%) of the voting power of the then outstanding
securities of the Subject Person with respect to the election of directors of the Subject Person; or 

  

	 	•	 	the Subject Person enters into a merger, consolidation, scheme of arrangement or similar transaction with another Person (other than, in the case of Abraxis, Permitted Control
Entities), unless (i) the members of the Board of Directors of the Subject Person immediately prior to such transaction constitute more than fifty percent (50%) of the members of the Board of Directors of the Subject Person (or a Parent
Entity of the Subject Person) immediately following such transaction, and (ii) the Persons who beneficially owned the outstanding voting securities of the Subject Person immediately prior to such transaction beneficially own securities of the
Subject Person representing at least fifty percent (50%) of the voting power with respect to the election of directors of the Subject Person immediately following such transaction, or a Parent Entity of the Subject Person beneficially owns
securities of the Subject Person representing one hundred percent (100%) of the voting power with respect to the election of directors of the Subject Person immediately following such transaction; or 

  

	 	•	 	the Subject Person sells to any Person(s) (other than, in the case of Abraxis, Permitted Control Entities), in one or more related transactions, properties or assets
(i) representing more than fifty percent (50%) of the Subject Person’s consolidated total assets or (ii) from which more than fifty percent (50%) of the Subject Person’s consolidated operating income for its most recent
fiscal year was derived. 

 For purposes of this definition, a “Parent Entity” of a Subject Person means any Person
that acquires directly or indirectly, by merger or otherwise, the capital stock of the Subject Company if the holders of securities that represented 100% of the voting power with respect to the election of directors (“Voting Stock”) of the
Subject Company 

  

 Page 7 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
immediately prior to such acquisition directly own 100% of the Voting Stock of the Parent Entity immediately after such acquisition and in the exact same
percentages as they owned Voting Stock in the Subject Company immediately prior to such acquisition. 
 “Chargeback” means a
credit or rebate issued to a pharmaceutical wholesaler or other distributor by Abraxis or any of its subsidiaries in connection with the sale of the Product by such wholesaler or distributor to a customer at a discount price pursuant to a contract
between Abraxis or any of its subsidiaries and such customer. 
 “Compensation” has the meaning ascribed to such term in
Section 9.2. 
 “Competing Product” means [***]. 
 “Confidential Information” means any and all confidential information or material, that, at any time before or after the date hereof,
has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party pursuant to this Agreement or in connection with the transactions contemplated hereby or any discussions or negotiations with respect thereto; any
data, ideas, concepts or techniques contained therein; and any modifications thereof or derivations therefrom. Confidential Information may be provided or communicated either orally, visually, in writing, by delivery of materials containing
Confidential Information or in any other form now known or hereafter invented. 
 “Control” or “Controlled”
means, with respect to any intellectual property right of a Party, that the Party or its Affiliate owns or has a license to such intellectual property right and has the ability to grant access, a license, or a sublicense to such intellectual
property right to the other Party as provided in this Agreement without violating an agreement with any third party. 
 “Corrective
Plan” has the meaning ascribed to such term in Section 8.6.2. 
 “Designated Sales Force” means the Abraxis
Sales Force or AstraZeneca Sales Force, as the case may be (which shall include at least the number of Full-Time Representatives (or, if a Primary-Time Representative Election is made by a Party, from and after the Primary-Time Effective Date, with
respect to such Party, at least the number of Primary-Time Representatives) as is necessary to comply with the Mandatory Representative Requirement in effect from time to time) that is assigned to the Promotion of the Product in the Territory.

  

 Page 8 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Detail” means that part of an “in person,” face-to-face sales call during
which a Representative, who is fully trained and knowledgeable with respect to the Product, including its Product Label and Insert and the use of the Promotional Materials, makes a full presentation of the Product to a medical professional with
prescribing authority such that the relevant characteristics of the Product are described by the Representative in a fair and balanced manner consistent with the requirements of this Agreement and Applicable Laws and Guidelines and in a manner that
is customary in the industry for the purpose of promoting a prescription pharmaceutical product. Any activities performed by market development specialists, managed care account directors and other personnel that are not conducting face-to-face
sales calls as provided in the preceding sentence shall not constitute a “Detail,” and E-details and presentations made at conventions or similar gatherings shall not constitute a “Detail.” When used as a verb, “Detail”
means to engage in a Detail. For a sales call to constitute a “Detail,” the Product must be the only product presented during such sales call; provided, however, that if a Party makes a Primary-Time Representative Election,
from and after the Primary-Time Effective Date, a sales call made by a Representative of such Party in which another product is presented in addition to the Product shall constitute eighty percent (80%) of a Detail if such sales call otherwise
complies with the requirements set forth in this definition and no more than two (2) products are presented during such sales call, and the Product is presented first and receive approximately eighty percent (80%) or more of the total call
time. 
 “Detail Cost” means [***]. 
 “Disclosing Party” means the Party disclosing its Confidential Information. 
 “Effective Date” means July 1, 2006. 
 “Employment Laws” means all federal, state or local
statutes, laws, ordinances, regulations or guidelines relating to (a) employment (including Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Employee Retirement Income Security 

  

 Page 9 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
Act, the Rehabilitation Act of 1973, the Family and Medical Leave Act, the Fair Labor -Standards Act, the Immigration and Reform Control Act of 1986, the
National Labor Relations Act, the Americans With Disabilities Act and all other applicable federal, state or local statutes, laws, ordinances or regulations, (b) safety and health (including the Occupational Safety and Health Act of 1970) and
(c) the payment of taxes and required taxes and payments with respect to employees (including the Internal Revenue Code of 1986). 
 “Extraordinary Shared Expense Calendar Year” has the meaning ascribed to it in Section 11.2.3. 
 “Extraordinary Shared Expense Increase” has the meaning ascribed to it in Section 11.2.3. 
 “FDA” means the United States Food and Drug Administration and any successor agency having substantially the same functions. 
 “First Residual Period” has the meaning ascribed to it in Section 9.5 
 “FSS” means the listing of prices published by the United States General Services Administration at which the Product is sold to eligible federal government agencies pursuant to 48 C.F.R. 538 et seq., as in effect from time
to time. 
 “Force Majeure” has the meaning defined in Section 23. 
 “Force Majeure Party” means a Party prevented or delayed in its performance under this Agreement by an event of Force Majeure.

 “Full-Time Representative” of a Party means a Representative who is a full-time employee of the Party, who spends
100% of his or her Detailing time Detailing the Product and who is not Detailing or Promoting any other pharmaceutical product. 
 “Fundamental Requirement” has the meaning ascribed to such term in Section 11.2.3. 
 “GAAP”
means U.S. generally accepted accounting principles as modified from time to time. 
  

 Page 10 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Generic Drug” means any drug approved by the FDA under section 505(b)(2) or 505(j)
of the Act, that relied in whole or in part on data developed for, or the approval of, a drug that has been previously approved under section 505(b)(1) and that is listed in FDA’s Orange Book. 
 “GPO Administration Fee” means any administration fee paid to a group purchasing organization, buying group or similar organization
pursuant to a contract between Abraxis and such group purchasing organization, buying group or similar organization relating to the sale of the Products by Abraxis to members of or participants in such group purchasing organization, buying group or
similar organization, but not including any such fees that are treated as Shared Expenses under the applicable Business Plan. 
 “Hardware” means the Laptops and the Territory Management Devices. 
 “IFF” means the industrial
funding fee payable to the VA in connection with the sale of the Products to the VA under the FSS, as in effect from time to time. 
 “Incentive” means a credit, rebate or discount (other than a prompt payment discount) made to, or for the account of, a customer pursuant to a contract between Abraxis or any of its subsidiaries and such customer, relating
to the sale of Products by Abraxis to such customer. 
 “IND” means an Investigational New Drug Application filed in
accordance with the Act and applicable regulations and requirements of the FDA as from time to time amended and in effect. 
 “Indemnification Claim Notice” has the meaning defined in Section 18.3. 
 “Indemnified
Party” means a Person seeking to recover Loss under Sections 18.1 or 18.2. 
 “Indemnifying Party” means the Party
from whom recovery of Loss is sought under Sections 18.1 or 18.2. 
 “Information Technology” means the Hardware and the
Software. 
 “Initial Training Program” has the meaning ascribed to such term in Section 5.2.1. 
  

 Page 11 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Joint Brand Team” has the meaning ascribed to it in Section 10.3.1.

 “Knowledge of Abraxis” means the knowledge of Abraxis’ chief executive officer, [***], after inquiry of their direct
reports. 
 “Laptops” means the laptop computers, including, but not limited to, IBM or Lenovo ThinkPads and any successor
devices provided by AstraZeneca to Abraxis in accordance with the terms hereof for use by Abraxis Representatives in accordance with the terms hereof. 
 “Larger Clawback Amount” means an amount equal to [***] multiplied by a fraction, the numerator of which is the number of days remaining in the Term as of the date of termination of the
Agreement and the denominator of which is the total number of days in the Term. 
 “LIBO Rate” means an interest rate
per annum equal to the rate per annum (rounded upward, if necessary, to the nearest 1/100 of one percent (1%)) appearing on Telerate Markets Page 3750 (or any successor page) as the London interbank offered rate for deposits in U.S. dollars at
approximately 11:00 A.M. (London time) two (2) Business Days prior to the due date for the applicable payment for a one (1) month period. 
 “Loss” means any and all liabilities, claims, demands, causes of action, damages, loss and expenses, including interest, penalties and reasonable lawyers’ fees and disbursements. 
 “Mandatory Detail Requirement” has the meaning ascribed to such term in Section 11.1.1. 
 “Mandatory Representative Requirement” has the meaning ascribed to such term in Section 11.1.1. 
 “Marketing Approval” means any approval or authorization of the FDA necessary to commercially distribute, sell or market the Product in
the United States as a treatment for the approved indication. 
 “Message Standards” has the meaning ascribed to such term
in Section 8.6.2. 
  

 Page 12 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Miscellaneous Expenses” means all costs and expenses incurred by AstraZeneca or
Abraxis and paid or payable to a third party by AstraZeneca or Abraxis for professional and patient advocacy group relations and medical education costs (including speakers’ programs, symposia and conference presentations) directly related to
the Product; advisory boards costs; grants; and Phase IV Studies. 
 “[***]” means nanoparticle albumin-bound [***],
currently identified internally by Abraxis as [***]. 
 “NDA” means a New Drug Application filed in accordance with
Section 505(b)(1) of the Act and applicable regulations and requirements of the FDA as from time to time amended and in effect. 
 “Net Sales,” with respect to any period, means the amount of net sales recognized during such period by Abraxis or its Affiliates, in accordance with GAAP from sales of the Product in the Territory during such period, to
third parties (excluding sales to Affiliates for resale), less the following to the extent not already accounted for in net sales recognized by Abraxis in accordance with GAAP: 
  

	 	(i)	customary trade, cash and quantity discounts specifically identified, actually paid or incurred; 

  

	 	(ii)	discounts, refunds, rebates, Chargebacks, GPO Administration Fees, retroactive price adjustments and any other allowances actually made that reduce the gross invoiced amount of
sales, including without limitation any institutional rebate or discount for government subsidy or reimbursement programs such as Medicare or Medicaid in the United States; 

  

	 	(iii)	credits and allowances for product returns actually given consistent with Abraxis’ then current policy; 

  

 Page 13 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(iv)	any invoiced amounts that are not collected by Abraxis or its Affiliates, including bad debts; 

  

	 	(v)	taxes, including value added taxes and sales taxes, and other fees imposed on the sale, use or distribution of the Product; and 

  

	 	(vi)	as an allowance for transportation costs, distribution expenses, special packaging and related insurance charges, one percent (1%) of Net Sales less the adjustments in items
(i) – (v) above to the extent not already accounted for in net sales recognized by Abraxis in accordance with GAAP. 

 Any of the deductions specified above that involve a payment or credit shall be taken as a deduction in the Calendar Quarter in which the payment or credit is accrued by Abraxis. For purposes of determining Net Sales, the Product shall be
deemed to be sold when the sale of such Product is recognized by Abraxis in accordance with GAAP. Sales, transfers or dispositions of Product for charitable, pre-clinical, clinical, regulatory or governmental purposes, and sales or transfers of
Product among Abraxis Affiliates shall be excluded from Net Sales. If, as part of any managed care program or arrangement, the Product is sold with other products such that it is not possible to determine which of the deductions set forth above are
specifically attributable to the Product, Abraxis shall apportion the deductions across the bundle of Products on a fair and reasonable basis, such basis to be disclosed in the Quarterly Net Sales Reports referred to in Section 8.3. For
avoidance of doubt, Net Sales shall not be reduced based on the amount of any license fee, milestone payment, royalty or similar payment paid or required to be paid by Abraxis to license any intellectual property from a third party in order to
develop, manufacture or market the Product in the Territory or any amount paid as damages or as part of any settlement with any third party owner of intellectual property. 
 “New Indication Fee” has the meaning ascribed to it in Section 9.6. 
  

 Page 14 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “NorthStar” means the NorthStar software used by AstraZeneca and made available to
Abraxis to maintain a database containing, among other things, information regarding medical professionals Detailed by Representatives entered via Territory Management Devices, or any successor or compatible software selected by AstraZeneca.

 “PDMA” means the Prescription Drug Marketing Act of 1987, as amended, and the rules, regulations and guidelines
promulgated thereunder as in effect from time to time. 
 “Parties” means, unless otherwise specified, AstraZeneca and
Abraxis, and “Party” means either of AstraZeneca or Abraxis. 
 “Permitted Control Entity” means the Chief
Executive Officer of Abraxis as of the date of this Agreement, any trust for his benefit or for the benefit of any members of his immediate family, and any other entity in which he and/or any members of his immediate family separately or
collectively hold a majority of the outstanding equity interests. For purposes of this definition, such Chief Executive Officer’s immediate family means his spouse and his direct lineal descendants (whether by blood or adoption). 
 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or agency of a government. 
 “Phase IV Studies” means those clinical studies set forth in the applicable Business Plan that are (i) conducted as part of the
Product’s overall clinical development and life cycle management program and (ii) not included in the original NDA submission for the Product, including investigator initiated trials, Phase IIIb studies, clinical experience trials, and
studies conducted to fulfill commitments made as a condition of NDA approval. 
 “PIR” has the meaning ascribed to such term
in Section 13.4.1. 
 “Primary-Time Representative” of a Party means a Representative who is a full-time
employee of the Party, who spends no less than 80% of his Detailing time Detailing the Product, who is Detailing no more than one other pharmaceutical product and who spends no more than 20% of his or her Detailing time Detailing such other
pharmaceutical product 
  

 Page 15 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Primary-Time Representative Election” means the election described in
Section 4.1.1. 
 “Primary-Time Effective Date” has the meaning ascribed to such term in Section 4.1.1.

 “Product” means any pharmaceutical product in finished form that contains the compounds paclitaxel and albumin and
is available for prescription for any current or future FDA-approved oncology indication, regardless of formulation, dosage, dosage form or method of delivery of such product, including without limitation the product currently sold by Abraxis under
the trademark Abraxane®. 
 “Product Copyrights” means all copyrightable subject matter, and the copyrights therein, included in the Product Labels and Inserts, the
Promotional Materials, and the Product training materials developed and produced in accordance with Section 5.1. 
 “Product
Labels and Inserts” means (i) all labels and other written, printed or graphic matter affixed to any container, packaging or wrapper utilized with the Product, or (ii) any written material physically accompanying the Product,
including Product package inserts. 
 “Product Patents” means all current and future U.S. issued patents and patent
applications that (i) are owned or Controlled by Abraxis during the Term, and (ii) claim the Product or a method of making or using the Product. 
 “Product Quality Complaint” means any and all manufacturing or packaging-related complaints related to the Product, including (i) any complaint involving the possible failure of the Product to
meet any of the specifications for the Product; (ii) any dissatisfaction with the design, package or labeling of the Product; or (iii) any Adverse Event that may involve the quality of the Product, including lack of effect, infection or
request for testing. 
 “Product Trademarks” means the (i) Trademark Abraxane® and the registrations thereof, (ii) any other Trademarks relating to the Products
and the registrations thereof, (iii) any pending or future trademark registration applications relating to the Products, (iv) any 

  

 Page 16 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
unregistered Trademark rights relating to the Product as may exist through use prior to or as of the date hereof, (v) any current or future
modifications or variants of any of the foregoing Trademarks and (vi) any future Trademarks adopted by Abraxis or its Affiliates for use in connection with the Products. 
 “Promotion” means those activities normally undertaken by a pharmaceutical company’s sales force to implement marketing plans and
strategies aimed at encouraging the appropriate use of a particular prescription or other pharmaceutical product, including detailing. When used as a verb, “Promote” means to engage in such activities. 
 “Promotional Materials” means all written, printed, graphic material or information to be delivered electronically, other than Product
Labels and Inserts, intended for use by Representatives in Promoting the Product in the Territory, including visual aids, file cards, premium items, reprints, drug information updates, website content, press releases that constitute
“labeling” under the Act and any other promotional support items. 
 “Promotional Plan” has the meaning ascribed
to such term in Section 11.1.1. 
 “Receiving Party” means the Party receiving Confidential Information. 
 “Recipients” has the meaning ascribed to such term in Section 15.1. 
 “Regulatory Authority” means, in a particular country or jurisdiction, any applicable government regulatory authorities involved in
granting regulatory approval of the Product in such country or jurisdiction, including without limitation, in the Territory, the FDA, any other applicable governmental or regulatory authority in the United States having jurisdiction over the Product
and any successor government authority having substantially the same function. 
 “Representative” means a pharmaceutical
sales representative employed by (or contracted by in accordance with the terms hereof) either AstraZeneca or Abraxis to Detail the Product. 
 “Residual Compensation” has the meaning ascribed to such term in Section 9.5 
 “Retraining
Program” has the meaning ascribed to such term in Section 8.6.3. 
  

 Page 17 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Sales Force” means the full set of Representatives, field sales managers, district
sales managers, regional sales managers, national sales managers, trainers, market development specialists, managed care account directors and other members customarily comprising a pharmaceutical company’s sales force. 
 “Sales Force Management Plan” has the meaning ascribed to such term in Section 11.1.1. 
 “Sales InSite” means a Web-based application and any successor or compatible applications selected by AstraZeneca that interfaces with
AstraZeneca’s Microsoft Outlook software and offers Sales InSite tools that enable Representatives to utilize features including promotions, TimeTrax reporting, PIR submission and adverse incident reporting. 
 “Second Residual Period” has the meaning ascribed to it in Section 9.5 
 “Shared Expenses” means A&P Expenses and Miscellaneous Expenses. 
 “Signing Fee” has the meaning ascribed to such term in Section 9.1. 
 “Smaller Clawback Amount” means an amount equal to (a) [***], less (b) (i) the aggregate amount of all [***] with
respect to the period from the Effective Date through the date of termination, multiplied by (ii) 0.75. 
 “Software” means Compass, NorthStar, Sales InSite or other successor software selected by AstraZeneca. 
 “Strategic Targeting Plan” has the meaning ascribed to such term in Section 11.1.1. 
 “Target
Prescriber” means a medical professional with prescribing authority (including nurse practitioners and physician assistants with actual prescribing authority) who is identified in the applicable Strategic Targeting Plan. 
 “Term” has the meaning defined in Section 21.1.1. 
 “Termination Period” has the meaning ascribed to such term in Section 20. 
  

 Page 18 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Territory” means the fifty (50) states of the United States of America and the
District of Columbia, but not Puerto Rico or any other territories or possessions of the United States. 
 “Territory Management
Devices” means the electronic devices to assist in territory management, including NEC Mobil Pro’s and any successor or compatible devices selected by AstraZeneca for use by the Representatives. 
 “Third Party Claim” means any claim of a third party for which indemnification is sought under Section 18.3. 
 “Trademark” means any trademark, trade dress, brand mark, trade name, brand name, fictitious name, logo, symbol or domain name.

 “Trimester” means each of the periods of four consecutive calendar months during the Term ending on
April 30, August 31 and December 31. 
 “Turnover” means, with respect to any period, the percentage
obtained by dividing (a) the number of a Party’s Full-Time Representatives (and, if a Primary-Time Representative Election is made by a Party, with respect to the applicable period beginning on or after the Primary-Time Effective Date, the
number of such Party’s Primary-Time Representatives) who were employed on such Party’s Designated Sales Force at the beginning of such period and who were not continuously employed on such Designated Sales Force during such period, by
(b) the total number of Full-Time Representatives (and, if a Primary-Time Representative Election is made by a Party, with respect to the applicable period beginning on or after the Primary-Time Effective Date, the total number of such
Party’s Primary-Time Representatives) on such Designated Sales Force at the beginning of such period (it being understood that a person may be employed continuously on a Designated Sales Force during any period in a series of different
positions on such Designated Sales Force). 
 “Two-Year Forecast Period” has the meaning ascribed to such term in
Section 11.1.1. 
 “Two-Year Net Sales Forecast” has the meaning ascribed to such term in Section 11.1.1.

  

 Page 19 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “VA” means the United States Department of Veterans Affairs. 
  

	2	Construction. 

 Except where the context
requires otherwise, whenever used, the singular includes the plural, the plural includes the singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase
“and/or.” Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The headings of this Agreement are for convenience of reference only and do not define, describe, extend or
limit the scope or intent of this Agreement or the scope or intent of any provision contained in this Agreement. The term “including” or “includes” as used in this Agreement means including, without limiting the generality of any
description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall be applied against any Party. 
  

	3	Co-Promotion Rights 

  

	3.1	Grant of Rights. Abraxis hereby grants to AstraZeneca the exclusive right, jointly with Abraxis and its Affiliates, to Promote and Detail the Product in the Territory during
the Term all in accordance with the terms and conditions set forth in this Agreement. Neither Abraxis nor AstraZeneca shall grant any rights to, or permit or authorize, any other Person (other than each Party’s Affiliates or contractors hired
by each Party in the performance of each such Party’s obligations hereunder, as permitted by this Agreement) to Promote or Detail the Product in the Territory during the Term. 

  

	3.2	Reservation of Rights. Nothing herein shall be construed to provide AstraZeneca with any rights to develop, manufacture, supply, or distribute the Product. Abraxis shall
retain the exclusive rights to develop, manufacture, supply, and distribute the Product. 

  

	3.3	 ROW Rights for the Product. Abraxis agrees that it shall notify AstraZeneca in writing at least [***] before Abraxis enters into any definitive agreement
granting any Person (other than any Affiliate of Abraxis, [***] or any of its Affiliates) the right to commercially sell, 

  

 Page 20 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
or to promote exclusively or together with Abraxis or any of its Affiliates, the Product in any country in the ROW Territory (defined below) (any such
agreement, a “ROW Agreement”). Any such notice (a “ROW Notice”) shall identify the country or countries proposed to be subject to the ROW Agreement and shall set forth proposed terms for a ROW Agreement between
Abraxis and AstraZeneca with respect to such country or countries. AstraZeneca may notify Abraxis of AstraZeneca’s interest in negotiating a ROW Agreement with respect to the countries covered by the ROW Notice. In the event that AstraZeneca
delivers such notice (a “ROW Response Notice”) to Abraxis within [***] Business Days of its receipt of the ROW Notice, Abraxis shall negotiate in good faith with AstraZeneca proposed principal terms of a ROW Agreement with respect
to the country or countries covered in the ROW Notice during the [***] day period after Abraxis’ receipt of the ROW Response Notice. In the event that AstraZeneca and Abraxis are unable to negotiate mutually acceptable principal terms of a ROW
Agreement during such [***] day period, or AstraZeneca fails to deliver a ROW Response Notice to Abraxis within the required [***] Business Day period, Abraxis may, at any time during the [***] day period after the conclusion of such [***] Business
Day or [***] day period, as applicable, enter into a ROW Agreement with any other Person covering the country or countries subject to the ROW Notice so long as in the reasonable judgment of Abraxis the transaction subject to such ROW Agreement and
all related agreements are no less favorable, in the aggregate, to Abraxis than the transaction contemplated by the proposed terms set forth in the ROW Notice. “ROW Territory” means any country outside the Territory (excluding
[***]). 
  

	3.4	 Rights for [***]. Abraxis agrees that it shall notify AstraZeneca in writing at least [***] days before Abraxis enters into any definitive agreement granting
any Person (other than any Affiliate of Abraxis) the right to commercially sell, or to promote exclusively or together with Abraxis or any of its Affiliates, [***] in any country in the [***] Territory (defined below) (any such agreement, a
“[***] Agreement”). Any such notice (a “[***] Notice”) shall identify the country or countries proposed to be subject to the [***] Agreement and shall set forth proposed terms for a [***] Agreement between
Abraxis 

  

 Page 21 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
and AstraZeneca with respect to such country or countries. AstraZeneca may notify Abraxis of AstraZeneca’s interest in negotiating a [***] Agreement
with respect to the countries covered by the [***] Notice. In the event that AstraZeneca delivers such notice (a “[***] Response Notice”) to Abraxis within [***] Business Days of its receipt of the [***] Notice, Abraxis shall
negotiate in good faith with AstraZeneca proposed principal terms of a [***] Agreement with respect to the country or countries covered in the [***] Notice during the [***] period after Abraxis’ receipt of the [***] Response Notice. In the
event that AstraZeneca and Abraxis are unable to negotiate mutually acceptable principal terms of a [***] Agreement during such [***] day period or AstraZeneca fails to deliver a [***] Response Notice to Abraxis within the required [***] Business
Day period, Abraxis may, at any time during the [***] day period after the conclusion of such [***] Business Day or [***] day period, as applicable, enter into a [***] Agreement with any other Person covering the country or countries subject to the
[***] Notice so long as in the reasonable judgment of Abraxis the transaction subject to such [***] Agreement and all related agreements are no less favorable, in the aggregate, to Abraxis than the transaction contemplated by the proposed terms set
forth in the [***] Notice. “[***] Territory” means any country in which Abraxis receives regulatory approval needed to sell commercially and promote [***]; provided that no country outside the Territory shall be deemed to be
included in the [***] Territory unless Abraxis has entered into a ROW Agreement covering such country. 
  

	4	Sales Force Composition 

  

	4.1	Designated Sales Forces; Alignment. 

  

	 	4.1.1	 At all times during the Term, each of Abraxis and AstraZeneca shall use at least eighty-five (85) Full-Time Representatives to Detail the Product, subject to
adjustment based on adjustments made to the Mandatory Representative Requirement as set forth in the applicable Business Plan. Beginning [***], each Party shall have the right to elect, by delivery of at least ninety (90) days’ advance
written notice to the other Party, to satisfy its Mandatory Representative 

  

 Page 22 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Requirement and the requirement set forth in the first sentence of this Section 4.1.1 by using Primary-Time Representatives instead of Full-Time
Representatives beginning no sooner than the later of [***] or the start of the Trimester next to begin after such ninety (90) day notice period (such beginning date, the “Primary-Time Effective Date”); provided,
however, that, if a Party makes such election, for purposes of determining such Party’s compliance with the Mandatory Representative Requirement, the requirement set forth in the first sentence of this Section 4.1.1 and any other
requirement for Full-Time Representatives, in each case from and after the Primary-Time Effective Date, each Primary-Time Representatives shall be counted as eighty percent (80%) of a Full-Time Representative. From time to time, a Party may,
with the consent of the other Party not to be unreasonably withheld, substitute for up to five (5) Full-Time Representatives of such Party (and, if a Primary-Time Representative Election is made by such Party, with respect to the applicable
period beginning on or after the Primary-Time Effective Date, up to five (5) Primary-Time Representatives of such Party), full- or part-time employees of such Party who together will expend, in the aggregate, that amount of time and effort
Detailing and Promoting the Product as would be required hereunder to be expended by the Full-Time Representatives (or Primary-Time Representatives) of such Party for whom they are being substituted. 

  

	 	4.1.2	Subject to Section 4.1.4, (i) neither AstraZeneca nor Abraxis shall Promote or Detail the Product except by means of its Designated Sales Forces and (ii) each
Party’s Designated Sales Forces shall consist solely of employees of such Party. 

  

	 	4.1.3	 Subject to the following sentence, Abraxis’ Designated Sales Force shall be closely aligned by territory ([***]) with the corresponding AstraZeneca Designated
Sales Forces to ensure coordination between the respective Designated Sales Forces. Subject to Section 4.1.1, either Party may realign its Designated Sales Forces during the Term; provided, however, that any such re-alignment shall not affect
or relieve such Party’s obligations under this 

  

 Page 23 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Agreement. Each Party shall comply with the provisions of each Sales Force Management Plan that specifies the minimum number of Full-Time Representatives
(provided that, if a Primary-Time Representative Election is made by a Party, with respect to the applicable period after the Primary-Time Effective Date, such Party may, subject to the proviso in Section 4.1.1, satisfy such minimum with
Primary-Time Representatives) and other members of the Sales Force to be provided by such Party in each designated local market in the Territory. 

  

	 	4.1.4	Neither Party may use a third party (other than an Affiliate of such Party) contract sales force to satisfy (i) its Mandatory Representative Requirement or (ii) its
Mandatory Detail Requirement, without the prior written consent of the other Party. Either Party may use a contract sales force to provide (i) Representatives in excess of its Mandatory Representative Requirement or (ii) Details in excess
of its Mandatory Detail Requirement subject to the other Party’s prior written consent, not to be unreasonably withheld or delayed. 

  

	 	4.1.5	Minimum Qualifications. Except as may be set forth to the contrary in any Sales Force Management Plan, each of AstraZeneca’s and Abraxis’ Representatives and sales
managers engaged in the Promotion of the Product at any time during the Term shall (i) have been graduated from an accredited four-year college (except for such Persons who are Representatives or managers of AstraZeneca or Abraxis as of the
date of this Agreement) and (ii) have satisfactorily completed the Product sales training program specified in Section 5. In addition, at least [***] of each Party’s Representatives, and at least [***] of each Party’s sales
managers, engaged in the Promotion of the Product at any time during the Term must have been promoting [***] in the Territory for at least [***] prior to the date that such person commences Promoting the Product. 

  

	4.2	 Vacancies. Beginning with the Calendar Year commencing January 1, 2007, each of Abraxis and AstraZeneca shall ensure that each Party’s set of
Full-Time Representatives 

  

 Page 24 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
(or, if a Primary-Time Representative Election is made by a Party, with respect to any applicable period beginning on or after the Primary-Time Effective
Date, the Party’s set of Primary-Time Representatives) has a vacancy rate of not more than [***] for any month during the Term. 

  

	4.3	Sales Force Incentives. The incentive compensation for each of Abraxis’ and AstraZeneca’s Designated Sales Forces shall be structured to provide that the
Product’s weighting shall be (a) at least [***] of total incentive compensation paid to each member of each such Designated Sales Force during each Calendar Year during the Term, and (b) no more than [***] of incentive compensation
for each Calendar Year during the Term related to the Product paid to each member of Abraxis’ and AstraZeneca’s Designated Sales Forces shall be based on non-financial objectives or similar metrics to be identified from time to time in the
Business Plan. 

  

	4.4	Sales Meetings. Each Party shall permit the other Party’s sales and marketing management personnel, upon the request of such other Party, to attend and participate in
those portions of its sales meetings that relate solely to the Product; provided that each Party shall ensure that significant portions of any sales meeting with respect to the Product shall relate solely to the Product. 

  

	4.5	Non-Solicitation. During the Term and for a period of [***] thereafter, neither Party shall, and shall not permit any of its Affiliates to, actively recruit or solicit any
member of any Designated Sales Force or any other staff of the other Party or its Affiliates engaged in the marketing, Promotion or Detailing of the Product. For the avoidance of doubt, nothing shall limit a Party or any of its Affiliates from
engaging in general recruitment through advertisements or recruiting through “head-hunters” so long as the staff of the other Party is not specifically targeted in such recruitment effort. 

  

	4.6	Contracting and Pricing. The Joint Brand Team, as hereinafter defined, shall be principally responsible for managing the Product across all market segments in the Territory
and contract strategy. Abraxis shall have sole responsibility for and sole control over: (a) contract creation; (b) government reporting, rebate processing, FSS calculations and pricing schedules; (c) contract compliance, monitoring
and audits; and (d) contract administration and claims processing. 

  

 Page 25 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	4.7	Promotional Materials; Statements about the Products. 

  

	 	4.7.1	During the Term, the Joint Brand Team shall develop and produce all Promotional Materials to be used by each of the Parties in connection with the Promotion of the Product in
accordance with the terms of the applicable Promotion Plan and this Section 4.7. It is understood and agreed that no Promotional Materials will be used unless they have been reviewed and approved by both Parties by way of a collaborative
promotional material regulatory review process agreed to by the Parties, provided that, until Promotional Materials have been so approved by both Parties, Promotional Materials that were developed and approved by Abraxis prior to the
Effective Date may be used for transitional purposes by Abraxis for up to ninety (90) days after the Effective Date. The Joint Brand Team shall appoint a single-source vendor to supply the Promotional Materials. Promotional Materials shall
include the AstraZeneca Trademarks and the Abraxis Trademarks, except as prohibited by Applicable Law. The size and prominence of the AstraZeneca Trademarks and the Abraxis Trademarks on the Promotional Materials shall be as determined by the Joint
Brand Team. 

  

	 	4.7.2	Each Party shall, and shall cause its Representatives to, use only the Promotional Materials provided by the Joint Brand Team in connection with the Promotion of the Product. Each
Party shall ensure that the Promotional Materials are used only in the form provided and not changed in any way (including by underlining or otherwise highlighting any text or graphics or adding any notes thereto) by any members of its Designated
Sales Forces. 

  

	 	4.7.3	 AstraZeneca shall, and shall cause its Representatives to, immediately cease the use of any Promotional Materials when instructed to do so by the Joint Brand Team
and, in Abraxis’ reasonable judgment, where required by Applicable Laws and Guidelines, to protect the goodwill represented by the Product Trademarks, or 

  

 Page 26 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
to avoid infringing a third-party mark or copyright. Each Party shall, and shall cause its Representatives to, use the Promotional Materials only for the
purposes contemplated by this Agreement. All Promotional Materials in the possession of AstraZeneca or its Representatives shall be returned to Abraxis upon termination of this Agreement. 

  

	 	4.7.4	Each Party shall, and shall cause its Representatives to, make only such statements and claims regarding the Product, including as to efficacy and safety, as are consistent with the
Product Labels and Inserts and the Promotional Materials. Neither Party shall, and shall cause its Representatives not to, make any untrue or misleading statements or comments about the Product, competitors or other products.

  

	4.8	Compliance with Laws and Policies. 

  

	 	4.8.1	AstraZeneca and Abraxis shall perform all of its obligations under this Agreement in compliance with all material aspects of (i) Applicable Laws and Guidelines,
(ii) Business Policies and (iii) Employment Laws. AstraZeneca will provide Abraxis with prior notice of any modification to Business Policies made after the Effective Date, and for the purposes of this Agreement such modifications shall be
effective and binding on Abraxis only with the consent of Abraxis, such consent not to be unreasonably withheld or delayed. Each Party shall instruct its Sales Force not to take any action inconsistent with this Agreement that could jeopardize the
goodwill or reputation of the Product or the other Party. 

  

	 	4.8.2	 AstraZeneca and Abraxis shall be responsible for the compliance in all material respects by its respective personnel assigned to Promotion and Detail of the
Product, whether as employees or independent contractors or agents, with Employment Laws, Business Policies and Applicable Laws and Guidelines. Each Party shall report to the other on or before twenty (20) Business Days after the end of each
Calendar Quarter all allegations it has received and/or investigations it, or to its knowledge any Agency, has commenced with respect to the alleged 

  

 Page 27 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
failure by a member of its Designated Sales Force to comply in any material respect with Employment Laws, Business Policies and Applicable Laws and
Guidelines, and what action, if any, was taken as a result. 

  

	5	Training 

  

	5.1	Training Plans and Materials. 

  

	 	5.1.1	As part of the annual Business Plan, the Joint Brand Team shall (i) establish training objectives and training plans for members of the Parties’ Designated Sales Forces
who are hired or assigned to Promote the Product and (ii) develop and produce all training programs and materials (including Product sales orientation assessment tests and refresher tests) to be used by each of the Parties for initial and
refresher training of the members of its Designated Sales Forces; it being understood and agreed by the Parties that in the event of any dispute between the Parties with respect to such objectives or plans or the content of any such programs or
materials, such dispute shall be resolved by way of the dispute resolution process set forth in Section 10.4 of this Agreement. 

  

	 	5.1.2	Such training materials and programs shall, collectively, address the following matters: disease entity; Product knowledge; competitive product knowledge; contracting and
reimbursement, selling skills; targeting; compliance with Applicable Laws and Guidelines, Business Policies and Employment Laws; coordination with counterparts of the other Party’s Designated Sales Forces; administration; and other information
the Parties deem necessary or appropriate. All training materials shall be subject to the same review process as Promotional Materials. 

  

	 	5.1.3	Prior to the Effective Date, AstraZeneca and Abraxis shall agree on a plan to train the Sales Force trainers to ensure that each Party is able to fulfill its obligations under
Section 5.2. Following the Effective Date, each Party shall be responsible for training its Sales Force trainers. 

  

 Page 28 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	5.2	Training Programs. 

  

	 	5.2.1	Each Party shall provide training materials to, and hold in-person meetings for, each member of its Designated Sales Forces prior to his or her commencement of Promotion of the
Product hereunder to ensure that he or she is properly trained with respect to all matters described in Section 5.1.2 and able to satisfy his or her Promotion responsibilities under this Agreement (the “Initial Training
Program”). 

  

	 	5.2.2	Each Party shall assign to its Designated Sales Forces only those Representatives and district sales managers who demonstrate a thorough knowledge of the Product and all other
matters described in Section 5.1.2 by achieving a minimum [***] score on a Product sales orientation assessment test and subsequent (refresher) tests and satisfactory completion of a series of role play scenarios of a Detail of the Product. The
Parties shall maintain and make available to each other upon request individual records of such test results. 

  

	 	5.2.3	Each Party shall use only those training materials developed and produced in accordance with Section 5.2.1 in connection with its Initial Training Program and any refresher
training required by the Joint Brand Team. 

  

	5.3	Return of Training Materials. AstraZeneca shall cause any member of its Designated Sales Force who leaves the employ of AstraZeneca or ceases to participate in the Promotion
of the Product hereunder to return to Abraxis all training materials related to the Product. 

  

	5.4	 Information Technology. As soon as reasonably practical after the Effective Date, Abraxis shall evaluate the feasibility of Abraxis Representatives using the
Information Technology in connection with the Promotion of the Product. Thereafter, AstraZeneca shall, to the extent requested by Abraxis, and at Abraxis’ expense, provide to Abraxis Laptops on which Compass is installed and Territory
Management Devices on which NorthStar is installed (with requisite peripherals) to enable Abraxis to equip Abraxis 

  

 Page 29 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Representatives on the Abraxis Sales Force with such Hardware and Software, provided, however, it is understood and agreed that Abraxis shall be responsible
for obtaining any and all required licensing rights from third parties to use the Software. To the extent that any Abraxis Representative is equipped with such Information Technology in accordance with the foregoing, Abraxis shall ensure that its
Representatives maintain and use such Information Technology in all material respects in accordance with AstraZeneca’s policies and procedures. Abraxis, at its sole expense, shall reimburse AstraZeneca for replacement of Hardware and Software
lost, damaged or destroyed while in the care, custody and control of Abraxis or any member of the Abraxis Sales Force, to the extent that Abraxis requests such replacement. AstraZeneca shall also provide to Abraxis whatever is reasonably necessary
(in terms of software, hardware, training and other support) that is usable specifically for the purpose of enabling Abraxis to generate appropriate sales management reports and otherwise comply with Abraxis’ reporting obligations under this
Agreement. Should Abraxis elect that its Representatives use the Information Technology, AstraZeneca’s obligation to provide Laptops, Hardware and Software at Abraxis’ expense and AstraZeneca’s obligation to provide software and other
support at AstraZeneca’s expense shall apply for the Term of the Agreement. Whether or not Abraxis elects that its Representatives use the Information Technology, Abraxis and AstraZeneca shall cooperate with respect to all recordkeeping,
reporting, Promotional Material ordering and other communication functions necessary to enable Abraxis and AstraZeneca to coordinate their activities under this Agreement. 

  

	6	Detail Requirements 

  

	6.1	Performance of Details 

  

	 	6.1.1	In each Trimester during the Term, each Party shall perform the number of Details required to be performed by such Party as set forth in the Business Plan for such Trimester. The
Parties acknowledge and agree that during each Trimester each Party shall be required under the Business Plan to perform an equal number of Details. 

  

 Page 30 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	6.1.2	In each Trimester during the Term, each Party shall ensure that (i) at least [***] of the number of Details it actually performed in such Trimester were made to Targeted
Prescribers; (ii) no more than [***] of the Details it actually performed in such Trimester were made to [***] or more prescribers at one time and (iii) it achieves all other performance objectives and criteria set forth in the Business
Plan for such Trimester, including reach and frequency goals. 

  

	6.2	Performance Correction. AstraZeneca and Abraxis shall discuss each report delivered pursuant to Sections 8.2 and 8.3 promptly after the delivery thereof. In the event
that any such report indicates that either Party may not achieve the required performance criteria with regard to Detailing activity and sales force management for the then-current Trimester, the Parties shall use good faith efforts jointly to
develop and implement corrective action to enable such Party to achieve such criteria. 

  

	6.3	Failure to Perform Required Number of Details. 

  

	 	6.3.1	If during any Trimester beginning on or after January 1, 2007 a Party (the “Defaulting Party”) performs a number of Details that is less than [***] of such
Party’s Trimesterly Details Requirement (defined below) for such Trimester, then such Defaulting Party shall pay to other Party, within thirty (30) days after the end of such Trimester, an amount (the “Detail Shortfall
Amount”) equal to the product of (i) the [***], multiplied by (ii) (A) such Defaulting Party’s Trimesterly Details Requirement for such Trimester, less (B) the number of Details actually performed by such Defaulting
Party during such Trimester. With respect to any Trimester beginning on or after January 1, 2007, a Party’s “Trimesterly Details Requirement” shall be equal to the Mandatory Detail Requirement for the Trimester set forth
in the Business Plan. 

  

	6.4	 Permissible Details. For purposes of determining compliance by either Party with any of its Detail performance requirements set forth in this Agreement,
(a) Details in excess of one hundred twenty percent (120%) of the number of Details required to be performed by such Party as set forth in the Business Plan for the applicable period and (b) Details made 

  

 Page 31 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
to persons other than Target Prescribers in excess of fifteen percent (15%) of the number of required Details required to be performed by such Party as
set forth in the Business Plan for the applicable period, in each case shall not be taken into account. 
  

	7	[Intentionally Omitted] 

  

	8	Reporting and Auditing 

  

	8.1	Recordkeeping. 

  

	 	8.1.1	Subject to Section 8.1.3, Abraxis shall keep, or shall cause to be kept, complete and accurate books and records (financial and otherwise) pertaining to the performance of its
obligations hereunder, including records of all information necessary to determine Net Sales and records of Shared Expenses incurred in sufficient detail to calculate all fees and expenses payable pursuant to this Agreement and to prepare all
reports required hereunder. 

  

	 	8.1.2	Subject to Section 8.1.3, AstraZeneca shall keep, or shall cause to be kept, complete and accurate books and records (financial and otherwise) pertaining to the performance of
its obligations hereunder, including records of Shared Expenses incurred by it in sufficient detail to calculate all fees and expenses payable pursuant to this Agreement and to prepare all reports required hereunder. 

  

	 	8.1.3	All financial books and records maintained by the Parties pursuant hereto shall be maintained in accordance with GAAP. 

  

	8.2	Monthly Tracking Reports. 

  

	 	8.2.1	 Within ten (10) Business Days after the end of each calendar month during the period commencing on the Effective Date and ending at the end of the calendar
month in which the expiration of the Term or termination of this Agreement occurs, each Party shall submit to the other Party a written report containing the following information with respect to such calendar month (provided that, with respect to
each calendar month ending on or prior to December 31, 2006, the 

  

 Page 32 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
information set forth in clauses (b) and (c) need only reflect a good faith estimate of the Party providing the information):

  

	 	(a)	the total number of Details performed by such Party; 

  

	 	(b)	the reach and frequency of the Details performed by such Party as measured against the reach and frequency goals for such period set forth in the applicable Strategic Targeting
Plan; 

  

	 	(c)	the number of Details performed by such Party made to Target Prescribers; 

  

	 	(d)	the number of Full-Time Representatives (and, if a Primary-Time Representative Election is made by such Party, with respect to the applicable period beginning on or after the
Primary-Time Effective Date, the number of Primary Time Representatives) on such Party’s Designated Sales Forces as of the end of such period and Turnover and vacancies of Full-Time Representatives (or Primary Time Representatives) for such
period, by function and by region; 

  

	 	(e)	notification of each vacancy of a Full-Time Representative (and, if a Primary-Time Representative Election is made by such Party, with respect to the applicable period beginning on
or after the Primary-Time Effective Date, each vacancy of a Primary-Time Representative) on such Party’s Designated Sales Forces existing as of the end of the prior month that has been filled and the name and contact information for the person
filling such vacancy; 

  

	 	(f)	 the name and contact information of any persons substituting for Full-Time Representatives (or Primary-Time Representatives) of such Party in accordance with
Section 4.1.1 and the manner in which such persons, 

  

 Page 33 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
together, expend, in the aggregate, that amount of time and effort Detailing and Promoting the Product as would be required hereunder to be expended by the
Full-Time Representatives (or Primary-Time Representatives) of such Party for which they are being substituted; and 

  

	 	(g)	such other information as the Parties deem reasonably necessary or appropriate. 

  

	8.3	Net Sales Reports. 

  

	 	8.3.1	Within two (2) Business Days after the end of each calendar week during the Term, Abraxis shall submit to AstraZeneca a written report containing the following information with
respect to such week: 

  

	 	(a)	a good faith estimate of (i) the gross amount invoiced by Abraxis or its Affiliates to Persons that are not Affiliates of Abraxis for the sale of the Product in the Territory
and (ii) the number of units of the Product sold in the Territory to Persons who are not Affiliates of Abraxis. 

  

	 	8.3.2	Within ten (10) Business Days after the end of each calendar month during the Term, Abraxis shall submit to AstraZeneca a written report containing the following information
with respect to such month: 

  

	 	(a)	a good faith estimate of the gross amount invoiced by Abraxis or its Affiliates to Persons that are not Affiliates of Abraxis for the sale of the Product in the Territory;

  

	 	(b)	a good faith estimate of the number of units of the Product sold to third parties; including a breakdown of (i) units of Product shipped to direct customers, including
wholesalers and GPOs; and (ii) orders of units of Product received from direct customers, including wholesalers and GPOs; and 

  

 Page 34 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(c)	a good faith estimate of the number of units of the Product in the inventory of wholesalers. 

  

	 	8.3.3	Within twenty (20) Business Days after the end of each Calendar Quarter during the Term, Abraxis shall submit to AstraZeneca a written report containing the following
information with respect to such Calendar Quarter: 

  

	 	(a)	a reasonably detailed calculation of Net Sales (including the gross amount invoiced by Abraxis or its Affiliates to Persons that are not Affiliates of Abraxis for the sale of the
Product in the Territory and all deductions therefrom necessary to ascertain Net Sales); and 

  

	 	(b)	a good faith estimate of the number of units of the Product sold to third parties; including a breakdown of (i) units of Product shipped to direct customers, including
wholesalers and GPOs; and (ii) orders of units of Product received from direct customers, including wholesalers and GPOs. 

  

	 	8.3.4	Within sixty (60) days after the end of each Calendar Quarter during the Term and during the First Residual Period and Second Residual Period, Abraxis shall deliver to
AstraZeneca a report (“Quarterly Net Sales Report”), setting forth in full detail for such Calendar Quarter, the following information: (a) Net Sales of the Product in the Territory, (b) the gross amount invoiced to
Persons that are not Affiliates of Abraxis for the sale of the Product in the Territory, (c) the amounts and types of deductions taken from the gross invoiced amount of sales to arrive at the amount of Net Sales for such Calendar Quarter,
(d) the number of units of the Product sold to third parties and orders cancelled or rejected during such Calendar Quarter, (e) the number of units of the Product provided at no charge, and (f) the Compensation or Residual
Compensation due under this Agreement for the such Calendar Quarter. Abraxis shall highlight in each Quarterly Net Sales Report any adjustments made from the reports referred to in Section 8.3.3. Abraxis shall deliver the Quarterly Net Sales
Report to AstraZeneca at the time that Abraxis pays AstraZeneca the Compensation or Residual Compensation due for the sale of Products during such Calendar Quarter. 

  

 Page 35 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	8.4	Shared Expenses Reports. Within ten (10) days after the end of each calendar month during the period commencing on the Effective Date and ending at the end of the
calendar month in which the expiration of the Term or termination of this Agreement occurs, each Party shall submit to the other a written report containing a detailed description of all Shared Expenses incurred by such Party during such month in
accordance with the applicable Business Plan. 

  

	8.5	Detail Audits. 

  

	 	8.5.1	Subject to Section 8.7, no more than once during any twelve (12) consecutive month period during the Term, each Party shall have the right, upon thirty (30) days
written notice to the other Party, to engage a jointly agreed auditor to conduct an audit during regular business hours of the other Party’s Detailing activities to confirm the accuracy of the Detail and Detail related-information contained in
the reports delivered by such other Party within the two (2) year period immediately preceding such audit pursuant to Section 8.2. Subject to Section 8.7, such audit shall be at the auditing Party’s expense.

  

	 	8.5.2	If the results of such audit identify an overstatement of Details in such reports by five percent (5%) or more in any Trimester, then the audited Party, in addition to its
other obligations under this Agreement (including the provisions set forth in Section 6.3), shall bear the expense of such audit and shall implement promptly corrective actions reasonably acceptable to the auditing Party to ensure accurate
reporting thereafter. At any time within twelve (12) months after the completion of an audit that identifies an overstatement of Details by five percent (5%) or more in any Trimester, the auditing Party shall have the right to engage a
jointly agreed auditor to conduct, at the audited Party’s expense, a subsequent audit of the audited Party’s Detailing activities, to ensure that the audited Party has corrected its reporting deficiencies. 

  

 Page 36 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	8.6	Detail Message Audits. 

  

	 	8.6.1	Periodically, the Joint Brand Team shall select an auditor to conduct market research in order to evaluate the effectiveness of the Details performed by AstraZeneca’s and
Abraxis’ Designated Sales Forces and the content of the Product message delivered. 

  

	 	8.6.2	If such market research indicates in accordance with the standards set forth in the then current Business Plan (the “Message Standards”) that the Parties are
delivering Product messages substantially different from those agreed upon in the Business Plan, then, within ten (10) Business Days after receipt of such notice, the Joint Brand Team shall develop a plan of action designed to correct such
failure that is reasonably satisfactory to the Joint Brand Team (the “Corrective Plan”). The Parties shall implement the Corrective Plan within thirty (30) days after approval thereof by the Joint Brand Team.

  

	 	8.6.3	Following implementation of the Corrective Plan, the Joint Brand Team shall, at its discretion, select an auditor to conduct independent market research in order to evaluate whether
the Corrective Plan has been effectively implemented. If such market research indicates, in accordance with the Message Standards, that the Corrective Plan has not been effectively implemented, the Joint Brand Team shall develop a comprehensive
retraining program for the Designated Sales Forces of the Parties (the “Retraining Program”). Each of the Parties shall, at its sole expense, conduct such Retraining Program within sixty (60) days of the date of notice from the
Joint Brand Team that such a Retraining Program is required. 

  

	8.7	Financial Audits. 

  

	 	8.7.1	 AstraZeneca, at its expense, shall have the right, no more than once during any twelve consecutive month period during the Term, upon thirty (30) days written
notice to Abraxis, to have the books and records kept by Abraxis pursuant to Section 8.1 (and all related work papers and other information and documents) 

  

 Page 37 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
examined by an independent accounting firm of national standing reasonably acceptable to Abraxis during regular business hours to verify
(i) Abraxis’ calculations of the amounts payable pursuant to this Agreement by Abraxis; and (ii) the accuracy of the information contained in the reports delivered by Abraxis pursuant to Sections 8.2, 8.3 and 8.4, in each case, within
the two (2) year period immediately preceding such audit. If AstraZeneca shall dispute any such calculation or information, AstraZeneca shall promptly notify Abraxis, and Abraxis and AstraZeneca shall use good faith efforts to resolve such
dispute. If Abraxis and AstraZeneca are unable to resolve such dispute within thirty (30) days after AstraZeneca notifies Abraxis of such dispute, then an independent accounting firm mutually agreed to by Abraxis and AstraZeneca (the costs of
which shall be paid one-half by Abraxis and one-half by AstraZeneca) shall resolve such dispute and such accountant’s resolution shall be final and binding on the Parties. Each Party shall cooperate with such accountant’s investigation.

  

	 	8.7.2	Abraxis, at its expense, shall have the right, no more than once during any twelve consecutive month period during the Term, upon thirty (30) days written notice to Abraxis, to
have the books and records kept by AstraZeneca pursuant to Section 8.1 (and all related work papers and other information and documents) examined by an independent accounting firm of national standing reasonably acceptable to AstraZeneca,
during regular business hours, to verify the accuracy of the information contained in the reports delivered by AstraZeneca pursuant to Sections 8.2, 8.3 and 8.4, in each case, within the two (2) year period immediately preceding such audit. If
Abraxis shall dispute any such information, Abraxis shall promptly notify AstraZeneca and AstraZeneca and Abraxis shall use good faith efforts to resolve such dispute. If Abraxis and AstraZeneca are unable to resolve such dispute within thirty
(30) days after Abraxis notifies AstraZeneca of such dispute, then an independent accounting firm mutually agreed to by Abraxis and AstraZeneca (the costs of which shall be paid one-half by Abraxis and one-half by AstraZeneca) shall resolve
such dispute and such accountant’s resolution shall be final and binding on the Parties. Each Party shall cooperate with such accountant’s investigation. 

  

 Page 38 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	8.7.3	If, as a result of the procedures set forth in Section 8.7.1 or 8.7.2 above, any amount paid by either Party pursuant to the terms hereof shall be found to have been
incorrectly calculated, the appropriate Party, within sixty (60) days, shall pay to the other Party the amount necessary to correct such payment error. 

  

	9	Fees and Expenses 

  

	9.1	Signing Fee. Within five Business Days of the execution of the Agreement by the Parties, AstraZeneca shall pay to Abraxis a fee (the “Signing Fee”) of two
hundred million dollars ($200,000,000). 

  

	9.2	 Co-Promotion Compensation. For each Calendar Quarter during the Term (other than the final Calendar Quarter of the Term), Abraxis shall pay AstraZeneca, for
its services described in this Agreement, compensation (“Compensation”) of twenty-two percent (22%) of Net Sales of the Product in the Territory recognized during such Calendar Quarter. For the final Calendar Quarter of the
Term, Abraxis shall pay AstraZeneca, for its services described in this Agreement, Compensation of twenty-two percent (22%) of the Average Final Net Sales (defined below). Notwithstanding the foregoing if only a portion of the final Calendar
Quarter of the Term falls during the Term, the Compensation that AstraZeneca shall be entitled to receive for such Calendar Quarter shall be determined by multiplying the Compensation it would have received for such Calendar Quarter pursuant to the
prior sentence by a fraction, the numerator of which shall be the number of days of such Calendar Quarter that occur during the Term and the denominator of which is the total number of days in such Calendar Quarter. “Average Final Net
Sales” shall be equal to (x) (a) the Net Sales of the Product in the Territory recognized by Abraxis during the penultimate Calendar Quarter of the Term, plus (b) the Net Sales of the Product in the Territory recognized by
Abraxis during the final Calendar Quarter of the Term, plus (c) the Net Sales of the Product in the Territory recognized by Abraxis during the first Calendar Quarter beginning after the expiration of the Term, divided by 

  

 Page 39 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
(y) three (3). Any Compensation that AstraZeneca is entitled to receive pursuant to this Section 9.2 for Net Sales of the Product in the Territory
recognized by Abraxis during a Calendar Quarter or portion thereof shall be paid within sixty (60) days after the end of such Calendar Quarter, provided, that, the Compensation for the final Calendar Quarter of the Term shall be
paid within sixty (60) days after the end of the first Calendar Quarter beginning after the Term. The Compensation payable by Abraxis to AstraZeneca under this Section shall not be reduced, by setoff or otherwise, based on the amount of any
license fee, milestone payment, royalty or similar payment paid or required to be paid by Abraxis to license any intellectual property from a third party in order to develop, manufacture or market the Product in the Territory or any amount paid as
damages or as part of any settlement with any third party owner of intellectual property used in order to develop, manufacture or market the Product in the Territory. 

  

	9.3	Shared Expenses. 

  

	 	9.3.1	Each Party shall be responsible for and shall pay, in accordance with the terms hereof, as follows: AstraZeneca shall pay fifty percent (50%) of all Shared Expenses and Abraxis
shall pay fifty percent (50%) of all Shared Expenses, in each case incurred by such Party during the Term in accordance with the applicable Business Plan. The Parties will, to the extent feasible, attempt to avail themselves of
AstraZeneca’s purchasing relationships in incurring Shared Expenses. 

  

	 	9.3.2	 Within twenty (20) days after the end of each Calendar Quarter or portion thereof that occurred during the Term, the Parties shall notify each other as to
(i) the total amount of Shared Expenses incurred by each Party in accordance with the applicable Business Plan during such Calendar Quarter (or the portion of such Calendar Quarter occurring during the Term) and (ii) the total amount of
Shared Expenses incurred by each Party pursuant to this Section 9.3 with respect to such Calendar Quarter (or the portion of such Calendar Quarter occurring during the Term). Each Party shall remit any payments to the other as are necessary to
allow 

  

 Page 40 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
for the equal sharing of total Shared Expenses stipulated in this Section 9.3, such payments to be made no later than sixty (60) days following the
Calendar Quarter to which such payments relate. 

  

	9.4	Other Expenses. Each Party shall bear and be solely responsible for all costs and expenses incurred by it in connection with the Promotion of the Product and the performance
of its obligations hereunder that are not Shared Expenses incurred by such Party in accordance with the applicable Business Plan. 

  

	9.5	Residual Compensation. 

  

	 	9.5.1	Abraxis shall pay AstraZeneca residual compensation (“Residual Compensation”) equal to ten percent (10%) of Net Sales of the Product in the Territory
recognized by Abraxis during the one year period following the expiration or termination of the Term (the “First Residual Period”) and five percent (5%) of Net Sales of the Product in the Territory recognized by Abraxis during
the one year period following the First Residual Period (the “Second Residual Period”). However, if this Agreement is terminated prior to the expiration of the Term, AstraZeneca shall only be entitled to Residual Compensation
pursuant to this Section 9.5 as follows: 

  

	 	(a)	If AstraZeneca elects to terminate this Agreement pursuant to Sections 12.5 (Failure of Supply), 21.2.1(a) (Material Breach) by reason of an intentional breach by Abraxis,
21.2.1(b) (Termination for Insolvency), or 21.2.1(d) (Termination for violation of law); and 

  

	 	(b)	To the extent provided in Section 19.3.1 (If Abraxis Fails to Meet Detail Minimum). 

 Notwithstanding anything in this Agreement to the contrary, in the event that at any time during the First Residual Period or the Second Residual Period an event occurs that would have given Abraxis the right to
terminate this Agreement 

  

 Page 41 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
pursuant to Sections 21.2.1(a) by reason of a breach by AstraZeneca of its obligations under Sections 4.5 (Non-Solicitation), 14 (Noncompetition) or 15
(Confidentiality), Abraxis shall have the right, exercisable by delivery of a written notice to AstraZeneca, to terminate immediately the First Residual Period or Second Residual Period, as applicable, and AstraZeneca’s right to receive
Residual Compensation. 

  

	 	9.5.2	Abraxis shall pay AstraZeneca any Residual Compensation that AstraZeneca is entitled to receive pursuant to this Section 9.5 for Net Sales of the Product in the Territory
recognized during a Calendar Quarter within sixty (60) days after the end of such Calendar Quarter. Notwithstanding the foregoing if only a portion of a Calendar Quarter falls during the First Residual Period or the Second Residual Period, as
applicable, the Residual Compensation that AstraZeneca shall be entitled to receive for such Calendar Quarter shall be determined by multiplying the Residual Compensation it would have received for such Calendar Quarter pursuant to 9.5.1 by a
fraction, the numerator of which shall be the number of days of such Calendar Quarter that occur during the First Residual Period or the Second Residual Period, as applicable, and the denominator of which is the total number of days in such Calendar
Quarter. 

  

	9.6	New Indication Fee. 

  

	 	9.6.1	If the Product receives Marketing Approval from the FDA for the following indications within the following timeframes, then, within ten (10) Business Days of Abraxis receiving
such Marketing Approval from the FDA and providing written evidence of such Marketing Approval to AstraZeneca, AstraZeneca shall pay Abraxis a fee (a “New Indication Fee”) determined as follows: 

  

	 	(a)	If the Product receives Marketing Approval from the FDA for the treatment of [***] during the Term prior to [***], then the New Indication Fee shall be [***].

  

 Page 42 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(b)	If the Product receives Marketing Approval from the FDA for the treatment of [***] during the Term prior to [***], then the New Indication Fee shall be determined as set forth in
Schedule 9.6. 

  

	9.7	Form of Payment. All payments made by either Party required under this Agreement shall be in U.S. Dollars and shall be made by wire transfer of immediately available funds to
an account designated in writing by the receiving Party. If a Party fails to pay when due any amount payable by it hereunder, the Party shall be required to pay interest at the LIBO Rate, plus three percent (3%) on such amount for the period
from the date on which such payment is due until such amount is paid in full. 

  

	10	Committees 

  

	10.1	Governance Structure. 

 During the Term, unless
otherwise expressly set forth in this Agreement, management of and oversight for all of the activities of the Parties related to the Promotion of the Product hereunder shall be provided by the committee structure set forth in this Section 10.

  

	10.2	Joint Operating Committee (“JOC”). 

  

	 	10.2.1	The Parties shall establish a JOC that shall have overall responsibility for ensuring that the Parties fulfill their obligations hereunder. The JOC shall consist of two
(2) senior executives representing each Party. Either Party may remove any of its representatives on the JOC and appoint a substitute therefor from time to time. The JOC shall be chaired initially by a representative from Abraxis for a period
of twelve (12) months and thereafter the chairmanship of the JOC shall be chaired on an alternating basis for periods of twelve (12) months by a representative of each Party, except in the case of the last chairperson who shall serve for
such lesser time period as necessary to serve out the remainder of the Term. 

  

	 	10.2.2	 The JOC shall (i) review and approve the annual Business Plan and any proposed amendments thereto submitted by the Joint Brand Team; (ii) oversee the
activities 

  

 Page 43 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
of the Joint Brand Team; (iii) resolve any disputes arising in the Joint Brand Team, (iv) provide a forum for discussion and information exchange
regarding the clinical development of the Product, and (v) undertake all other responsibilities deemed necessary in connection with the management of the activities of the Parties hereunder. 

  

	 	10.2.3	The JOC shall meet every three (3) months in the first year of the Term, and thereafter, the JOC shall meet at least every six (6) months during the Term at a location
determined from time to time by the chair; provided that the JOC shall meet more frequently if required to resolve disputes arising in the Joint Brand Team or to consider amendments to the Business Plan proposed by the Joint Brand Team.

  

	10.3	Joint Brand Team 

  

	 	10.3.1	 The Parties shall establish a joint brand team (the “Joint Brand Team”) (consisting of a leadership team and an operating team) that shall have
responsibility for the development and implementation of marketing strategies for the Product in the Territory and shall supervise, guide and coordinate the Parties’ Promotional activities in the Territory. The Joint Brand Team shall consist of
representatives of each Party and will be managed by a leadership team led by two general managers, one of which will represent each Party. Either Party may remove any of its representatives on the leadership team of the Joint Brand Team and appoint
a substitute therefor from time to time. The Parties acknowledge and agree that they have approved of the individuals each Party has nominated to fill the position of Joint Brand Team general manager as of the Effective Date. Each Party’s
representatives on the Joint Brand Team leadership team, including any replacement for the initial general managers of the Joint Brand Team, must be approved by the other Party, which approval will not be unreasonably withheld. It is understood and
agreed that at a minimum AstraZeneca’s representatives on the Joint Brand Team leadership team will include: a finance representative, an 

  

 Page 44 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
attorney, a brand director, a national sales director, a managed markets/contracting representative and a scientific affairs representative. Key metrics
contained in the current annual Business Plan will, in part, comprise objectives of the Joint Brand Team’s general managers and the other members of the Joint Brand Team. 

  

	 	10.3.2	The operating team of the Joint Brand Team shall (i) define operational tactics for implementing the product strategy; (ii) establish clear project metrics and tracking
against the operational plan; (iii) create and manage the day-to-day budget for the Product consistent with the budgeting procedures in the Business Plan; (iv) convey to the leadership team any issues that materially affect the agreed
financial metrics set forth in the Business Plan; (v) submit requests for additional resources to the leadership team; and (vi) produce an annual operational plan and an annual promotional tactics plan. The operating team shall meet
weekly; every other meeting will be face to face. The operating team meetings will be chaired on an alternating basis by the brand directors representing each Party, or their respective nominees. 

  

	 	10.3.3	 The leadership team of the Joint Brand Team shall (i) commencing with the Business Plan for the second Calendar Year during the Term, prepare and submit the
annual Business Plan and brand scorecard (covering commercial and development strategy, operational implementation details, head count requirements, budget, forecasts and key performance metrics) to the JOC for approval no later than October 1
of the year prior to the Calendar Year to which the Business Plan relates (ii) review performance of the Parties against the applicable Business Plan and scorecard, including progress of Shared Expenses against the budget for such activities in
the applicable Business Plan and progress of Product sales against the forecast included in the applicable Business Plan, and report to the JOC thereon, (v) review potential amendments to the then-current Business Plan, (vi) make all key
decisions that will be expected to impact the Joint Brand Team’s ability to implement the strategy and metrics set forth in the 

  

 Page 45 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
applicable Business Plan; and (vii) establish subcommittees or working groups, if necessary or appropriate, to address specific issues related to the
marketing and Promotion of the Product in the Territory. 

  

	 	10.3.4	The Joint Brand Team leadership team shall meet at least monthly during the Term at alternate locations determined by the general managers unless otherwise agreed by the two general
managers. The general managers will rotate responsibility for chairing the leadership team meetings. 

  

	10.4	Dispute Resolution. 

  

	 	10.4.1	The Parties acknowledge and agree that it is their intention that most, if not all, decisions will be taken by consensus at the Joint Brand Team level. If the general managers of
the Joint Brand Team are unable to resolve any disagreement regarding the Parties’ development or execution of the strategy for the Promotion of the Product in the Territory or the content of the Business Plan for a Calendar Year, within
fifteen (15) days of one Party notifying the other in writing of a disagreement, such disagreement shall be referred to the JOC, and if the JOC is unable to resolve any such disagreement within thirty (30) days (or at its next regularly
scheduled meeting, at the option of the Party that notifies the other Party of the disagreement), such issue shall be referred to a senior representative for Abraxis whose decision on such issue shall be final and binding on the Parties (provided
that Abraxis’ ability to make decisions relating to Fundamental Requirements shall be subject to the limitations set forth in Section 11.2.3 and 11.3): provided, however, such decision shall not nullify or otherwise affect
AstraZeneca’s right to exercise any right or recourse AstraZeneca would otherwise have under the terms of this Agreement, including AstraZeneca’s right to terminate this Agreement pursuant to the provisions of this Agreement.

  

 Page 46 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	11	Business Plan 

  

	11.1	Business Plan 

  

	 	11.1.1	Each Business Plan (other than the Business Plan for the initial Calendar Year) shall set forth, with respect to the applicable annual period, environmental analysis, SWOT,
description of global strategy and positioning implementation for the Territory and the key marketing issues for the Territory in the following operational sub-plans: 

  

	 	(a)	a “Promotional Plan” that specifies the Promotional Materials to be used by the Parties in conducting Promotional activities with respect to the Product;

  

	 	(b)	a Shared Expenses budget that specifies the type and amount of Shared Expenses to be incurred by each Party during each Calendar Quarter during the Calendar Year to which the
Business Plan relates; 

  

	 	(c)	a “Sales Force Management Plan” that specifies, per region or local market within the Territory, (A) the minimum number of Full-Time Representatives (the
“Mandatory Representative Requirement”) and other members of the Designated Sales Forces to be provided by each of Abraxis and AstraZeneca; (B) the minimum qualifications for Representatives (to the extent that such minimum
represents a change from the minimum set forth in Section 4.1.5); (C) the minimum number of Details that each Representative will perform in each Trimester; (D) the manner in which each Party will use members of the Parties’
respective Designated Sales Forces; and (E) the proportion of the working time of the managed care specialty sales forces of each Party, including Representatives and account managers, that will be dedicated to the marketing and Promotion of
the Product; 

  

	 	(d)	 a “Strategic Targeting Plan” that specifies Detailing strategy and obligations of the Parties on a Trimesterly basis, including (A) the
“call deck” size (i.e., the number of Targeted Prescribers to be called on by each 

  

 Page 47 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Representative); (B) identification and prioritization of Targeted Prescribers by deciles; and (C) reach and frequency expectations for the
Targeted Prescribers. The Strategic Targeting Plan shall set forth (i) the working days during each Trimester (each such day, a “Working Day”) and (ii) the target number of Details per Representative for each Working Date
(the “Daily Number of Details per Representative”). The total number of Details to be performed by a Party during a Trimester (the “Mandatory Detail Requirement”) shall be equal to the sum of the Required Daily
Number of Details (as defined below) of such Party for all Working Days during such Trimester. For a Party, its “Required Daily Number of Details” for a Working Day shall be equal to (a) Daily Number of Details per
Representative, multiplied by (y) the number of such Party’s Active Full-Time Representatives (or, if a Primary-Time Election Representative Election is made by such Party, for any Trimester from and after the Primary-Time Effective Date,
eighty percent (80%) of the number of such Party’s Active Primary-Time Representatives) on such Working Day. A Full-Time Representative or Primary-Time Representative shall be deemed to be “Active” on a Working Day if such
Representative has satisfactorily completed a training program described in Section 5.2 and is not on a leave of absence or disability. For purposes of calculating a Party’s Mandatory Detail Requirement, persons substituting for a
Party’s Full-Time Representatives or Primary Time Representatives in accordance with Section 4.1.1 shall be deemed to constitute the number of Full-Time Representatives or Primary-Time Representatives for which such persons are
substituting; 

  

	 	(e)	a managed care plan that specifies strategies and approaches to be implemented by the Parties to maximize the value of the Product in the managed care market;

  

 Page 48 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(f)	a contracting and contract strategy plan that specifies target customers for contracts, highlights the maximum allowable discounts, places clear performance metrics against each
contract and has an associated plan to pull through demand; 

  

	 	(g)	Net Sales forecasts for the Product on a monthly basis; 

  

	 	(h)	a forecast for the Calendar Year to which the Business Plan relates plus the following two Calendar Years with: (A) a Shared Expense forecast, (B) a unit Product forecast,
and (C) a Net Sales forecast; 

  

	 	(i)	a forecast for Net Sales for the Calendar Year to which the Business Plan relates and the following Calendar Year (such two-Calendar Year Period, a “Two-Year Forecast
Period” and such Net Sales forecasts a “Two-Year Net Sales Forecast”); and 

  

	 	(j)	such other plans relating to the marketing and Promotion of the Product in the Territory as the Parties deem necessary or appropriate. 

  

	11.2	Preparation and Adoption of Business Plans. 

  

	 	11.2.1	The Business Plan for the Calendar Year commencing on July 1, 2006 and ending December 31, 2006 is being delivered by the Parties simultaneously herewith.

  

	 	11.2.2	Each subsequent Business Plan shall be prepared by the Joint Brand Team and submitted to the JOC for approval. No Business Plan shall become effective until approved by the JOC
pursuant to Section 10.2.2 or approved pursuant to Section 10.4. 

  

	 	11.2.3	 Notwithstanding any provision to the contrary herein, in the event that the Joint Brand Team general managers and the JOC cannot agree on the (i) aggregate
amount of the Shared Expense budget, (ii) Mandatory Representative Requirement, or (iii) Mandatory Detail Requirement (each, a “Fundamental 

  

 Page 49 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Requirement”) to be set forth in the Business Plan for any Calendar Year during the Term, Abraxis shall determine the amount of such Fundamental
Requirement to be set forth in such Business Plan; provided, however, that in no event shall the amount of any Fundamental Requirement for any Calendar Year determined by Abraxis pursuant to this Section 11.2.3 exceed one hundred
fifteen percent (115%) or be less than one hundred percent (100%) of the Baseline for such Fundamental Requirement for the previous Calendar Year, and in no event shall the amount of the Mandatory Representative Requirement for any
Calendar Year determined by Abraxis pursuant to this Section 11.2.3 exceed [***]. In addition, if the Product receives Marketing Approval from the FDA for the treatment of [***] in a Calendar Year no later than 2010, then, in addition to the
one hundred fifteen (115%) increase above the Baseline for the previous Calendar Year normally permitted pursuant to this Section 11.2.3, Abraxis may increase the Shared Expense budget for any single Calendar Year no later than 2010 (the
“Extraordinary Shared Expense Calendar Year”) by an amount not to exceed twenty percent (20%) of the Baseline for the Shared Expense budget for the previous Calendar Year (the “Extraordinary Shared Expense
Increase”). Abraxis may increase the Shared Expense budget as provided in the previous sentence for only one Calendar Year during the Term. 

  

	11.3	Material Amendments of Business Plan. 

 The Joint
Brand Team from time to time may propose Material Amendments to any Business Plan and submit such amendments to the JOC for approval. No such amendment shall become effective until approved by both Parties. As used herein, “Material
Amendments” means any change to a Fundamental Requirement or any significant deviations in headcount requirements, budget requirements or material changes to the forecast set forth in the Business Plan for the then current Calendar Year.

  

 Page 50 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	11.4	Additional Expenses. 

 Either Party at its option
and expense may expend more than the amount set forth in any Business Plan with respect to any Fundamental Requirement, but no such expenditure shall affect the rate or amount of the Compensation or the Residual Compensation set forth in
Section 9. For the avoidance of doubt, any such expenditures shall not constitute Shared Expenses and shall not be subject to the equal sharing provision of Section 9.3. 
  

	12	Product Supply 

  

	 	12.1	Orders for Products; Terms of Sale. Abraxis shall have the sole responsibility and right to fill orders with respect to the Product. AstraZeneca shall not take orders for the
Product, but if for any reason AstraZeneca should receive sales orders for the Product, AstraZeneca shall promptly direct such orders to Abraxis. All orders for Products shall be subject to Abraxis’ acceptance, in its sole discretion. Abraxis
may cancel any order for Product, or any part thereof, at any time after acceptance without thereby incurring any liability to AstraZeneca. Abraxis shall be solely responsible for responding to requests from physicians for individual patients who
need the Product but are unable to afford it. Any such request received by AstraZeneca should originate from the patient’s physician and be forwarded to Abraxis for processing in accordance with Abraxis’ procedures. Abraxis, taking into
consideration any recommendation from the JOC, shall be solely responsible for establishing and modifying the terms and conditions of the sale of the Product, including the price at which the Product will be sold, whether the Product will be subject
to any trade or quantity discounts, whether any discount will be provided for payments on accounts receivable, whether the Product will be subject to rebates, returns and allowances or retroactive price reductions, the channels of distribution of
the Product, and whether credit is to be granted or refused in connection with the sale of any Product. 

  

	 	12.2	 Returned Product. Abraxis shall have the sole responsibility and right to accept any returned Product. AstraZeneca shall not solicit the return of any
Product, but if for any reason AstraZeneca should receive any returned Products, AstraZeneca shall promptly notify Abraxis. Any Product returned to AstraZeneca shall be shipped by AstraZeneca to 

  

 Page 51 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Abraxis’ designated facility, and all reasonable documented shipping costs incurred by AstraZeneca shall be reimbursed by Abraxis. AstraZeneca shall
advise the customer that made such return that the Product has been returned to Abraxis. AstraZeneca shall fully complete and deliver to Abraxis the returned goods form provided by Abraxis with respect to any returned Products.

  

	12.3	Recalled Product. At Abraxis’ request, AstraZeneca shall assist Abraxis in obtaining any Product, including all samples thereof, that has been recalled or withdrawn from
the market, and Abraxis shall reimburse AstraZeneca for any reasonable documented costs incurred by AstraZeneca in taking such actions. 

  

	12.4	Supply; Regulatory Requirements. Abraxis shall use commercially reasonable efforts to supply Product during the Term in sufficient quantities to satisfy the levels of Product
sales forecasted in the then-current Business Plan. 

  

	 	12.4.1	Abraxis shall manufacture the Product in compliance in all material respects with the FDA’s current Good Manufacturing Practice requirements as promulgated by the FDA under the
Act at C.F.R. (Parts 210 and 211), and as further defined by FDA guidance documents, as such may be amended from time to time, applicable to the manufacture, processing and packaging of the Product (“cGMP Requirements”) and all
other applicable legal requirements. Abraxis shall implement, as soon as reasonably possible, any change to the Product or its methods of manufacturing the Product that are required by the FDA or required by cGMP Requirements.

  

	 	12.4.2	 Abraxis will furnish to AstraZeneca (i) within three (3) Business Days after receipt, applicable portions of any FDA Form 483 (List of Inspectional
Observations) or FDA Warning Letters, in each case that pertain in any material respect to the Product and (ii) not later than five (5) Business Days prior to the time it provides to the FDA, copies of proposed responses or explanations
relating to items in such applicable portions of any such FDA Form 483 or FDA Warning Letter (each, a “Proposed Response”), in each case redacted of trade secrets or 

  

 Page 52 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
other confidential or proprietary information of Abraxis. Abraxis will discuss with AstraZeneca and consider in good faith any comments provided by
AstraZeneca on the Proposed Response. After the filing of any such response with the FDA, Abraxis will notify AstraZeneca of any further material contacts with the FDA relating to the portion of the response that pertains in any material respect to
the Product. 

  

	 	12.4.3	All information obtained by AstraZeneca pursuant to this Section 12.4 shall be treated by AstraZeneca as Confidential Information of Abraxis in accordance with Section 15.

  

	12.5	Failure of Supply. 

  

	 	12.5.1	 If during any Calendar Quarter (a “Supply Deficit Quarter”) during the Term, Abraxis for any reason (other than a Force Majeure event) does not
have available to it sufficient supply of the Product to be able to fulfill at least [***] of the orders of the Product that but for such failure of supply would have been filled in the ordinary course of business during such Calendar Quarter and
generated Net Sales of the Product in the Territory during such Calendar Quarter (provided that such orders do not represent an amount of Product greater than [***] of the amount of orders for the Product forecasted to be filled and to generate Net
Sales of the Product in the Territory during such Calendar Quarter as set forth in the applicable Business Plan), then AstraZeneca shall be entitled to receive additional compensation determined as follows: After the occurrence of the next Full
Supply Period (defined below), the Parties shall calculate the amount of Compensation that AstraZeneca would have been entitled to receive for such Supply Deficit Quarter had Net Sales of the Product in the Territory recognized by Abraxis during
such Calendar Quarter been equal to the Net Sales of the Product in the Territory recognized by Abraxis during such Full Supply Period (the “Alternative Compensation Amount”). Within sixty (60) days after the calculation of
such amount the Alternative Compensation Amount, Abraxis shall 

  

 Page 53 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
pay to AstraZeneca an amount of additional compensation equal to (a) the Alternative Compensation Amount for the applicable Supply Deficit Quarter, less
(b) the amount of Compensation paid to AstraZeneca for such Calendar Quarter pursuant to Section 9.2. “Full Supply Period” means the first three (3) calendar months following the Supply Deficit Quarter during which
Abraxis is able to fulfill either (a) [***] of the orders of the Product that in the ordinary course of business would be filled during such months and generate Net Sales of the Product in the Territory during such Calendar Quarter or
(b) [***] of the amount of orders for the Product forecasted to be filled and to generate Net Sales of the Product in the Territory during such Calendar Quarter as set forth in the applicable Business Plan. 

  

	 	12.5.2	Notwithstanding the foregoing provisions to the contrary, in the event that either: 

  

	 	(a)	for a period of [***], Abraxis for any reason (other than a Force Majeure event) does not have available to it sufficient supply of the Product to be able to fulfill at least fifty
percent (50%) of the orders of the Product that but for such failure of supply would have been filled in the ordinary course of business during such [***] period and generated Net Sales of the Product in the Territory during such [***] period
(provided that such orders do not represent an amount of product greater than one hundred percent (100%) of the amount of orders for the Product forecasted to be filled as to generate Net Sales of the Product during such [***] period), or

  

	 	(b)	 for a period of [***], Abraxis for any reason (other than a Force Majeure event) does not have available to it sufficient supply of the Product to be able to
fulfill at least eighty-five percent (85%) of the orders of the Product that but for such failure of supply would have been filled in the ordinary course of business during such [***] period and generated Net Sales of the Product in the
Territory during such [***] period (provided that such orders do not represent an amount of product greater than one 

  

 Page 54 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
hundred percent (100%) of the amount of orders for the Product forecasted to be filled as to generate Net Sales of the Product during such [***]
period), then 

 AstraZeneca may terminate this Agreement by delivery of a written notice of termination to Abraxis within
thirty (30) days after the completion of such [***] or [***] period. If AstraZeneca terminates this Agreement pursuant to this Section 12.5, Abraxis shall refund to AstraZeneca the Larger Clawback Amount within sixty (60) days of the
effectiveness of such termination in accordance with Section 21.3. A termination of this Agreement by AstraZeneca pursuant to this Section 12.5 shall become effective thirty (30) days after delivery to Abraxis of the applicable notice
of termination. 
  

	13	Regulatory Matters 

  

	13.1	Ownership of Regulatory Documentation and Approvals. Abraxis or its Affiliates, as the case may be, shall own all right, title and interest in and to (a) all regulatory
documentation with respect to the Product and all information contained therein and (b) all regulatory approvals made or granted with respect to the Product, including any IND and NDA with respect thereto. 

  

	13.2	Regulatory Reporting. 

  

	 	13.2.1	 Abraxis shall be solely responsible for the preparation, submission and prosecution of any application, report, submission and response to any Agencies in
connection with the Product, including, to the extent required by Applicable Laws and Guidelines, reporting Adverse Events and Field Alerts; provided that when feasible Abraxis shall consult with AstraZeneca with respect to any such matter and give
due consideration to any comments provided by AstraZeneca. Abraxis shall notify AstraZeneca of all communications with any agency concerning the Product within seven (7) Business Days of receipt of any such communication and shall, to the
extent permitted by Applicable Laws and 

  

 Page 55 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Guidelines, attach copies of all such communications to the notice sent pursuant to this Section 13.2.1. 

  

	 	13.2.2	Unless required by Applicable Laws and Guidelines, AstraZeneca shall not communicate directly with any Agency regarding the Product or otherwise take any action concerning any
application, registration, authorization or approval under which the Product is sold. AstraZeneca shall notify Abraxis promptly of any communications with any Agency concerning the Product within seven (7) Business Days of receipt of any such
communication and shall, to the extent permitted by Applicable Laws and Guidelines, attach copies of all such communications to the notice sent pursuant to this Section 13.2.2. 

  

	 	13.2.3	Abraxis shall be solely responsible for (i) taking all actions and conducting all communication with all third Persons in respect of the Product (other than Promotional
activities performed in accordance with the terms hereof), including responding to all Product Quality Complaints in respect thereof, including complaints related to tampering or contamination, and (ii) investigating all Product Quality
Complaints, Adverse Events, and Field Alerts in respect of the Product, in each case, to the extent required by Applicable Laws and Guidelines. 

  

	 	13.2.4	AstraZeneca shall, at Abraxis’ expense, cooperate with all of Abraxis’ reasonable requests and use its reasonable best efforts to assist Abraxis in connection with
(i) preparing any and all such reports with Agencies, (ii) preparing and disseminating all such communications with third Persons and (iii) investigating and responding to any Product Quality Complaint or Adverse Event related to the
Products. 

  

	13.3	Adverse Event, Field Alert and Product Quality Complaint Notification and Reporting 

  

	 	13.3.1	 AstraZeneca shall, and shall cause each of its Representatives to, provide notice to Abraxis within twenty-four (24) hours from the time it, he or she becomes
aware of an Adverse Event associated with use of a Product (whether or not the reported effect is (i) described in the full prescribing information or the published literature 

  

 Page 56 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
with respect to such Product or (ii) determined to be attributable to such Product) of any information in or coming into its, his or her possession or
control concerning such Adverse Event by contacting the Abraxis Information Center at such telephone number as Abraxis may from time to time designate or by completing the Adverse Event Report Forms provided by Abraxis and submitting such form to
Abraxis. 

  

	 	13.3.2	AstraZeneca shall, and shall cause each of its Representatives to, notify Abraxis within twenty-four (24) hours of the time it, he or she becomes aware of any information that
might necessitate the filing by Abraxis of a field alert report, as required under 21 C.F.R. § 314.81(b)(1) (a “Field Alert”), as such regulation may be amended from time to time, by contacting the Abraxis Information
Center by telephone at such telephone number as Abraxis may from time to time designate. 

  

	 	13.3.3	AstraZeneca shall, and shall cause each of its Representatives to, notify Abraxis within twenty-four (24) hours of the time it, he or she becomes aware of any Product Quality
Complaint associated with use of a Product by contacting the Abraxis Information Center by telephone at such telephone number as Abraxis may from time to time designate in writing. 

  

	 	13.3.4	Abraxis shall provide adverse drug experience information regarding the Product to AstraZeneca to the extent such information is provided by Abraxis to its Representatives. Abraxis
shall also notify AstraZeneca immediately of any formal communication received by Abraxis from the FDA regarding any threatened or pending action that may affect the safety or efficacy claims of the Products or the continued marketing of the
Products, including, but not limited to, any warning letters or untitled letters issued by the Division of Drug Marketing, Advertising, and Communications of the FDA. 

  

	 	13.3.5	 AstraZeneca shall immediately notify Abraxis of any information AstraZeneca receives regarding any threatened or pending action by any Agency that may affect the
safety or efficacy claims of the Product or the continued marketing and 

  

 Page 57 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Promotion of the Product. Upon receipt of any such information, Abraxis shall consult with AstraZeneca in an effort to arrive at a mutually acceptable
procedure for taking appropriate action; provided, however, that nothing herein shall restrict Abraxis’ ability to make a timely report of such matter to any Agency or take other action that it deems to be appropriate or required by Applicable
Laws and Guidelines. 

  

	 	13.3.6	Abraxis shall inform AstraZeneca and the Joint Brand Team shall, in turn, inform the Designated Sales Force of each Party of any information, announcements, reports, submissions,
communications, resolutions, actions, decisions or meetings involving any Agency regarding the Product. 

  

	13.4	Requests for Medical Information. 

  

	 	13.4.1	Abraxis shall have the exclusive right to respond to all questions or requests for information about the Product made by any medical professionals or any other Person to AstraZeneca
or its Representatives that (i) warrant a response beyond the understanding or knowledge of such Representative or (ii) are beyond the scope of the Product Labels and Inserts or other Promotional Materials (a “PIR”).

  

	 	13.4.2	AstraZeneca shall, and shall cause its Representatives to, promptly communicate to the Abraxis Information Center and/or Medical Resources Department all PIRs received by
AstraZeneca or such Representatives. 

  

	 	13.4.3	In connection with the Promotion of the Products, AstraZeneca shall cause its Representatives to inform prescribers that they may contact the Abraxis Information Center regarding
questions or requests for information about the Products by telephone or by completing a Medical Resource Form and faxing the completed form directly to Abraxis’ Medical Resources at the facsimile number provided on such form. Abraxis shall
provide AstraZeneca with sufficient quantities of Medical Resource Forms and AstraZeneca shall cause the Representatives to provide such forms to prescribers. 

  

 Page 58 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	14	Noncompetition 

  

	14.1	Noncompetition 

  

	 	14.1.1	Subject to Section 14.1.4, from the date hereof through expiration of the Term or earlier termination of this Agreement, AstraZeneca shall not, and shall cause its Affiliates
not to, directly or indirectly, (i) market, Promote, distribute, sell or accept orders for the sale of any Competing Product in the Territory, (ii) assist or cooperate in any way with any other Person in connection with the marketing,
Promotion, distribution, selling or acceptance of orders for the sale of any Competing Product in the Territory, or (iii) grant any third party any license under any patent or patent application owned or Controlled by AstraZeneca or its
Affiliates to sell or offer to sell any Competing Product in the Territory. The foregoing shall not be interpreted to prohibit the marketing, Promotion, distribution, sale, or acceptance of orders for the sale of a product that is not itself a
Competing Product (a “Noncompeting Product”), even if such Noncompeting Product can be used for an [***] in combination with a Competing Product (any such Noncompeting Product, a “Combination Product”);
provided that, during the Term, AstraZeneca shall not, and AstraZeneca shall cause its Affiliates not to, (a) permit any Person who is or was a member of the AstraZeneca Designated Sales Force to market, Promote, or Detail any
Combination Product in the Territory or (b) enter into a co-promotion, licensing or other commercial arrangement with any Person for the Promotion or marketing in the Territory of any Noncompeting Product in combination with, or as part of a
treatment regimen with, any Competing Product.  

  

	 	14.1.2	 Subject to Section 14.1.4, during the First Residual Period and the Second Residual Period, AstraZeneca shall not, and shall cause its Affiliates not to,
directly or indirectly, (i) market, Promote, distribute, sell or accept orders for the sale of any Competing Product in the Territory, (ii) assist or cooperate in any way with any other Person in connection with the marketing, Promotion,
distribution, 

  

 Page 59 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
sale or acceptance of orders for the sale of any Competing Product in the Territory, or (iii) grant any third party any license under any patent or
patent application owned or Controlled by AstraZeneca or its Affiliates to sell or offer to sell any Competing Product in the Territory. The foregoing shall not be interpreted to prohibit the marketing or Promotion of a Noncompeting Product, even if
such product is a Combination Product; provided that, during the First Residual Period and the Second Residual Period, AstraZeneca shall not, and AstraZeneca shall cause its Affiliates not to, (a) permit any Person who was a
member of the AstraZeneca Designated Sales Force to market, Promote, or Detail any Combination Product in the Territory or (b) enter into a co-promotion, licensing or other commercial arrangement with any Person for the Promotion or marketing
in the Territory of any Noncompeting Product in combination with, or as part of a treatment regimen with, any Competing Product. AstraZeneca shall have the right to be released from its obligations under this Section 14.1.2 if, in its sole discretion, AstraZeneca elects to forgo its right to receive Residual Compensation under Section 9.5 by
providing written notice thereof to Abraxis. 

  

	 	14.1.3	 Subject to Section 14.1.4, from the date hereof through expiration of the Term or earlier termination of this Agreement, Abraxis shall not, and shall cause its
Affiliates not to, directly or indirectly, (i) market, Promote, distribute, sell or accept orders for the sale of any Competing Product) in the Territory, (ii) assist or cooperate in any way with any other Person in connection with the
marketing, Promotion, distribution, sale or acceptance of orders for the sale of any Competing Product in the Territory, or (iii) grant any third party any license under any patent or patent application owned or Controlled by Abraxis or its
Affiliates to sell, or offer to sell the Product or any Competing Product in the Territory. The foregoing shall not be interpreted to prohibit the marketing or Promotion of a Noncompeting Product, even if such product can be used for an [***] in
combination with a Competing Product; provided that, during the Term, Abraxis shall not, and Abraxis shall cause its Affiliates not to, (a) permit any Person who 

  

 Page 60 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
is a member of the Abraxis Designated Sales Force to market, Promote, or Detail any Combination Product in the Territory or (b) enter into a
co-promotion, licensing or other commercial arrangement with any Person for the Promotion or marketing in the Territory of any Noncompeting Product in combination with, or as part of a treatment regimen with, any Competing Product.

  

	 	14.1.4	In the event that either AstraZeneca or Abraxis or any of their respective Affiliates acquires a Competing Product during the applicable non-competition period specified above as a
result of a merger or an acquisition by such Person or Affiliate of another Person (or substantially all of its assets), such Person or its Affiliate may continue to market, Promote, distribute, sell or accept orders for the sale of such Competing
Product for a period of [***] from the date of such acquisition. After the end of such [***] period such Person or Affiliate shall terminate all detailing, Promotional, marketing, distribution and sale activities relating to such Competing Product,
whether by divesting such Competing Product or otherwise; provided that such Person or Affiliate shall not be required to terminate such activities if the applicable non-competition period expires prior to the end of such [***] period.

  

	 	14.1.5	For a period of [***] after the expiration of the Term or the earlier termination of this Agreement, AstraZeneca shall not permit any Person who was a member of the AstraZeneca
Designated Sales Force to market, Promote or Detail any Competing Product in the Territory for or on behalf of AstraZeneca or any of its Affiliates. Notwithstanding the foregoing, the obligations of this Section 14.1.5 shall not apply with
respect to any product that is not itself a Competing Product, even if such product can be used for an [***] in combination with a Competing Product. 

  

	14.2	[Intentionally Omitted] 

  

 Page 61 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	14.3	Remedies 

  

	 	14.3.1	Each of Abraxis, on the one hand, and AstraZeneca, on the other hand, acknowledges that the temporal and geographic limitations set forth in Section 14.1 is reasonable and
necessary to protect the legitimate interests of the other and agrees not to contest such limitations in any proceeding. 

  

	 	14.3.2	Upon any breach of Section 14.1 by AstraZeneca, Abraxis may, and upon a breach of Section 14.1 by Abraxis, AstraZeneca may, terminate this Agreement by providing written
notice of such termination to the breaching Person in accordance with Section 21.2.1(a). 

  

	 	14.3.3	Abraxis, on the one hand, and AstraZeneca, on the other hand, acknowledge and agree that neither would have entered into this Agreement in the absence of the restrictions set forth
in Section 14.1, and that any breach or threatened breach of any provision of Section 14.1 will result in irreparable injury to the other for which there will be no adequate remedy at law. In the event of a breach or threatened breach of
any provision of Section 14.1 by Abraxis, on the one hand, or AstraZeneca, on the other hand, the other shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent,
specific performance and an equitable accounting of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which it may be entitled in law or equity. The
breaching Party agrees to waive any requirement that the other (a) post a bond or other security as a condition for obtaining any such relief and (b) show irreparable harm, balancing of harms, consideration of the public interest or
inadequacy of monetary damages as a remedy. Nothing in this Section 14.3.3 is intended, or shall be construed, to limit the Parties’ rights to equitable relief or any other remedy for a breach of any provision of this Agreement.

  

 Page 62 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	15	Confidentiality 

  

	15.1	Confidential Information. Except to the extent expressly permitted by this Agreement and subject to the provisions of Sections 15.2 and 15.3, at all times during the Term and
for two (2) years following the expiration or termination hereof, the Receiving Party (a) shall keep completely confidential and shall not publish or otherwise disclose any Confidential Information furnished to it by the Disclosing Party,
except to those of the Receiving Party’s employees, Affiliates, consultants or representatives who have a need to know such information (collectively, “Recipients”) to perform such Party’s obligations hereunder and
(b) shall not use Confidential Information of the Disclosing Party directly or indirectly for any purpose other than performing its obligations hereunder. The Receiving Party shall be liable for any breach by any of its Recipients of the
restrictions set forth in this Agreement. 

  

	15.2	Exceptions to Confidentiality. The Receiving Party’s obligations set forth in this Agreement shall not extend to any Confidential Information of the Disclosing Party:

  

	 	15.2.1	that is or hereafter becomes part of the public domain through no wrongful act, fault or negligence on the part of a Receiving Party or its Recipients; 

  

	 	15.2.2	that is received from a third party without restriction and without breach of any agreement or fiduciary duty between such third party and the Disclosing Party;

  

	 	15.2.3	that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation or restriction on use or disclosure prior to its receipt from the
Disclosing Party; 

  

	 	15.2.4	that is generally made available to third parties by the Disclosing Party without any restriction imposed by the Disclosing Party on disclosure, whether such restriction is by
contract, fiduciary duty or by operation of law; or 

  

	 	15.2.5	that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party without any reference to Confidential Information.

  

 Page 63 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	15.3	Authorized Disclosure. Each Party and its Recipients may disclose Confidential Information to the extent that such disclosure is made in response to a valid order of a court
of competent jurisdiction or other Agency; provided, however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a
protective order requiring that the Confidential Information and/or documents that are the subject of such order be held in confidence by such court or Agency or, if disclosed, be used only for the purposes for which the order was issued; and
provided further that if a disclosure order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information that is legally required to
be disclosed in such response to such court or governmental order. 

  

	15.4	Notification. The Receiving Party shall notify the Disclosing Party immediately, and cooperate with the Disclosing Party as the Disclosing Party may reasonably request, upon
the Receiving Party’s discovery of any loss or compromise of the Disclosing Party’s Confidential Information. 

  

	15.5	Destruction of Confidential Information. Upon the expiration or earlier termination of this Agreement or the written request by the Disclosing Party, whichever occurs first,
the Receiving Party shall (a) destroy all tangible embodiments of Confidential Information of the Disclosing Party, including any and all copies thereof, and those portions of any documents, memoranda, notes, studies and analyses prepared by
the Receiving Party or its Recipients that contain, incorporate or are derived from such Confidential Information and provide written certification of such destruction to the Disclosing Party in a form reasonably acceptable to the Disclosing Party,
provided that the legal department of the Receiving Party shall have the right to retain one copy of any such tangible embodiments for archival purposes, and (b) immediately cease, and shall cause its Recipients to cease, use of such
Confidential Information as well as any information or materials that contain, incorporate or are derived from such Confidential Information. 

  

 Page 64 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	15.6	Remedies 

  

	 	15.6.1	In the event that a Party materially breaches Section 15.1 and, if such breach is curable using reasonable efforts, fails to cure such breach or (y) if such breach is not
curable using reasonable efforts, fails to discontinue such breach, in each case within a reasonable period (not to exceed ninety (90) days) after receiving notification of such breach from the other Party, the other Party may terminate this
Agreement by providing written notice of such termination to the breaching Party. 

  

	 	15.6.2	The Parties acknowledge and agree that the restrictions set forth in Section 15.1 are reasonable and necessary to protect the legitimate interests of the Parties and that
neither Party would have entered into this Agreement in the absence of such restrictions, and that any breach or threatened breach of any provision of Section 15.1 will result in irreparable injury to the other Party for which there will be no
adequate remedy at law. In the event of a breach or threatened breach of any provision of Section 15.1 by a Party, the other Party shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether
preliminary or permanent, specific performance and an equitable accounting of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such Party may
be entitled in law or equity. The breaching Party agrees to waive any requirement that the non-breaching Party (a) post a bond or other security as a condition for obtaining any such relief and (b) show irreparable harm, balancing of
harms, consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing in this Section 15.6.2 is intended, or shall be construed, to limit the Parties’ rights to equitable relief or any other remedy for a breach
of any provision of this Agreement. 

  

	 	15.6.3	 Use of Name and Disclosure of Terms. Each Party shall keep the existence of, the terms of and the transactions covered by this Agreement confidential and
shall not disclose such information to any other Person through a press release or otherwise, or mention or otherwise use the name, insignia, symbol, trademark, 

  

 Page 65 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
trade name or logotype of the other Party or its Affiliates in any manner without the prior written consent of the other Party in each instance (which shall
not be unreasonably withheld). The restrictions imposed by this Section shall not prohibit either Party from making any disclosure that is required by Applicable Law and Guidelines, rule or regulation or the requirements of a national securities
exchange or another similar regulatory body. Further, the restrictions imposed on each Party under this Section 15.6.3 are not intended, and shall not be construed, to prohibit a Party from identifying the other Party in its internal business
communications, provided that any Confidential Information in such communications remains subject to this Section 15. 

  

	16	Intellectual Property Rights. 

  

	16.1	Intellectual Property. Subject to Section 4.7.1, AstraZeneca shall Promote the Products only under the Product Trademarks, Abraxis Trademarks and the AstraZeneca
Trademarks. Abraxis hereby grants AstraZeneca a non-exclusive, royalty-free license under the Product Patents and to use Product Trademarks, Abraxis Trademarks and Product Copyrights solely for purposes of performing AstraZeneca’s obligations
hereunder, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason. AstraZeneca hereby grants Abraxis a non-exclusive, royalty-free license to use the AstraZeneca Trademarks solely for purposes of
performing Abraxis’ obligations hereunder, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason. 

  

	16.2	No Ownership or Rights in Intellectual Property. 

  

	 	16.2.1	 Except for the limited license expressly set forth in Section 16.1, nothing in this Agreement shall give AstraZeneca or any of its Affiliates any right, title
or interest in and to the Products, the Abraxis Trademarks, the Product Trademarks, the Product Copyrights, the Product Patents or any other Trademarks or other intellectual property that Abraxis, or its Affiliates, as the case may be, own, license
or maintain. Except for the limited license expressly set forth in 

  

 Page 66 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Section 16.1, nothing in this Agreement shall give Abraxis or any of its Affiliates any right, title or interest in and to the AstraZeneca Trademarks or
any other Trademarks or other intellectual property that AstraZeneca, or its Affiliates, as the case may be, own, license or maintain. 

  

	 	16.2.2	As between AstraZeneca and Abraxis, AstraZeneca acknowledges and agrees that Abraxis or its Affiliates, as the case may be, are the owners of all rights, title and interest in and
to the Abraxis Trademarks, the Product Trademarks, the Product Copyrights, and Product Patents, including any form or embodiment thereof, and the goodwill now and hereafter associated therewith. AstraZeneca, on its behalf and on behalf of its
Affiliates, hereby irrevocably assigns to Abraxis all of its right, title and interest worldwide in and to any of the Product Copyrights. As between AstraZeneca and Abraxis, Abraxis acknowledges and agrees that AstraZeneca or its Affiliates, as the
case may be, are the owners of all rights, title and interest in and to the AstraZeneca Trademarks, including any form or embodiment thereof, and the goodwill now and hereafter associated therewith. 

  

	 	16.2.3	 AstraZeneca shall not, or knowingly cause another Person or permit any of its Affiliates to, contest or dispute the rights of Abraxis, or any of its Affiliates, as
the case may be, in and to, the Abraxis Trademarks, the Product Trademarks, the Product Copyrights, the Product Patents, any part thereof or the registrations thereof. If AstraZeneca at any time contests or disputes, or knowingly causes another
Person or permits any of its Affiliates to contest or dispute, the validity of, or the rights of Abraxis, or any of its Affiliates, as the case may be, in and to, Abraxis Trademarks, the Product Trademarks, the Product Copyrights, or the Product
Patents, in addition to all other remedies available to it, Abraxis shall have the right to terminate this Agreement immediately by providing written notice of such termination to AstraZeneca. Abraxis shall not, or knowingly cause another Person or
permit any of its Affiliates to, contest or dispute the rights of AstraZeneca, or any of its Affiliates, as the case may be, in and to, the AstraZeneca Trademarks, any part thereof or the registrations thereof. If Abraxis 

  

 Page 67 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
at any time contests or disputes, or knowingly causes another Person or permits any of its Affiliates to contest or dispute, the validity of, or the rights
of AstraZeneca, or any of its Affiliates, as the case may be, in and to, the AstraZeneca Trademarks, in addition to all other remedies available to it, AstraZeneca shall have the right to terminate this Agreement immediately by providing written
notice of such termination to Abraxis. 

  

	 	16.2.4	AstraZeneca acknowledges that all use of Abraxis Trademarks, the Product Trademarks and Product Copyrights by or on behalf of AstraZeneca or any of its Affiliates shall inure to the
benefit of Abraxis or its Affiliates, as the case may be. Neither AstraZeneca nor any of its Affiliates shall be entitled to any compensation for any increase in the value of Abraxis Trademarks, the Product Trademarks or in the goodwill associated
therewith. AstraZeneca (upon written request of Abraxis) shall assist Abraxis, at Abraxis’ cost and expense, and its Affiliates to safeguard their full rights, title and interest in and to Abraxis Trademarks and the Product Trademarks. Abraxis
acknowledges that all use of the AstraZeneca Trademarks by or on behalf of Abraxis or any of its Affiliates shall inure to the benefit of AstraZeneca or its Affiliates, as the case may be. Neither Abraxis nor any of its Affiliates shall be entitled
to any compensation for any increase in the value of the AstraZeneca Trademarks or in the goodwill associated therewith. Abraxis (upon written request of AstraZeneca) shall assist AstraZeneca, at AstraZeneca’s cost and expense, and its
Affiliates to safeguard their full rights, title and interest in and to the AstraZeneca Trademarks. 

  

	 	16.2.5	 Neither AstraZeneca nor any of its Affiliates shall undertake any action to register or renew any of the Abraxis Trademarks, Product Trademarks (or any trademark
similar thereto) or Product Copyrights. Neither AstraZeneca nor any of its Affiliates shall use (except in accordance with the terms hereof) or adopt any Trademark that is confusingly similar to or a colorable imitation of, or that dilutes, any
Abraxis Trademarks or Product Trademark. If a registration or renewal of any of Abraxis Trademarks, Product Trademarks or Product 

  

 Page 68 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Copyrights is secured by Abraxis or AstraZeneca or any of their respective Affiliates, whether or not in its name, such registration or renewal, as the case
may be, shall be effected solely for the benefit of Abraxis. Upon termination of this Agreement or upon earlier request of Abraxis, any such registrations or renewals (or any pending application therefor) shall either be assigned to Abraxis, or
surrendered by AstraZeneca or its Affiliates, as applicable, for cancellation, as Abraxis shall direct in writing. AstraZeneca shall, and shall cause its Affiliates to, as applicable, voluntarily file with appropriate Agencies any statement required
in connection with such assignment, surrender or cancellation. Neither Abraxis nor any of its Affiliates shall undertake any action to register or renew any of the AstraZeneca Trademarks (or any trademark similar thereto). Neither Abraxis nor any of
its Affiliates shall use (except in accordance with the terms hereof) or adopt any trademark that is confusingly similar to or a colorable imitation of, or that dilutes, any AstraZeneca Trademark. If a registration or renewal of any of AstraZeneca
Trademarks is secured by Abraxis or AstraZeneca or any of their respective Affiliates, whether or not in its name, such registration or renewal, as the case may be, shall be effected solely for the benefit of AstraZeneca. Upon termination of this
Agreement or upon earlier request of AstraZeneca, any such registrations or renewals (or any pending application therefor) shall either be assigned to AstraZeneca, or surrendered by Abraxis or its Affiliates, as applicable, for cancellation, as
AstraZeneca shall direct in writing. Abraxis shall, and shall cause its Affiliates to, as applicable, voluntarily file with appropriate Agencies any statement required in connection with such assignment, surrender or cancellation.

  

	16.3	Intellectual Property Infringement. 

  

	 	16.3.1	Each Party shall promptly notify the other Party of any actual infringement of the Product Trademarks, Product Copyrights, Product Patents, Abraxis Trademarks, or AstraZeneca
Trademarks by a third party of which it becomes aware or reasonably believes to exist. 

  

 Page 69 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(a)	In the event of any infringement of any Abraxis Trademark, Product Trademark, Product Copyright, or Product Patent by any Person, then as between Abraxis, on the one hand, and
AstraZeneca and its Affiliates, on the other, Abraxis, at its sole expense, shall have the sole right (but not the obligation) to commence, maintain or terminate, whether by settlement or otherwise, any action to enforce its rights in such Abraxis
Trademark, Product Trademark, Product Copyright or Product Patent and pursue injunctive, compensatory and other remedies and relief against such Person. Abraxis shall have the right to retain all damages and other proceeds resulting from any such
actions. If Abraxis elects to commence any action referred to in this Section 16.3.1(a), AstraZeneca, at Abraxis’ expense, shall use all reasonable efforts to assist and cooperate with Abraxis as requested by Abraxis in such actions.
Abraxis shall not consent to the entry of any judgment or enter into any settlement with respect to any such action without the prior written consent of AstraZeneca (not to be unreasonably withheld or delayed) if such judgment or settlement would
enjoin or grant other equitable relief against AstraZeneca or otherwise materially and adversely affect AstraZeneca. 

  

	 	(b)	 In the event of any infringement of any AstraZeneca Trademark by any Person, then as between AstraZeneca, on the one hand, and Abraxis and its Affiliates, on the
other, AstraZeneca, at its sole expense, shall have the sole right (but not the obligation) to commence, maintain or terminate, whether by settlement or otherwise, any action to enforce its rights in such AstraZeneca Trademark and pursue injunctive,
compensatory and other remedies and relief against such Person. AstraZeneca shall have the right to retain all damages and other proceeds resulting from any such actions. If AstraZeneca elects to commence any action referred to in this
Section 16.3.1(a), Abraxis, at AstraZeneca’s expense, shall use all reasonable efforts to assist and cooperate with AstraZeneca as requested by 

  

 Page 70 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
AstraZeneca in such actions. AstraZeneca shall not consent to the entry of any judgment or enter into any settlement with respect to any such action without
the prior written consent of Abraxis (not to be unreasonably withheld or delayed) if such judgment or settlement would enjoin or grant other equitable relief against Abraxis or otherwise materially and adversely affect Abraxis.

  

	 	16.3.2	Subject to the terms and conditions of this Agreement, including Sections 18, 21.2.1(e) and 21.3, if, as a result of any such action, a judgment is entered by a U.S. court of
competent jurisdiction, or a settlement is entered into by Abraxis, enjoining the marketing or Promotion of the Product in the Territory or the use of any Abraxis Trademark, Product Trademark or Product Copyright in connection with the marketing or
Promotion of the Product in the Territory, then Abraxis, AstraZeneca and its Affiliates shall cease marketing and Promoting the Product in the Territory or using such Abraxis Trademark, Product Trademark or Product Copyright in connection with the
marketing and Promotion of Product in the Territory, as applicable, so long as such injunction remains in effect. Subject to the terms and conditions of this Agreement, including Sections 18, 21.2.1(e) and 21.3, if, as a result of any such
action, a judgment is entered by a U.S. court of competent jurisdiction, or a settlement is entered into by AstraZeneca, enjoining the use of any AstraZeneca Trademark in connection with the Promotional Materials, then Abraxis, AstraZeneca and its
Affiliates shall cease using such AstraZeneca Trademark in connection with the Promotional Materials, so long as such injunction remains in effect. 

  

	17	Representations and Warranties 

  

	17.1	Representations and Warranties of Each Party. 

  

	 	17.1.1	 Each Party represents and warrants to the other Party as follows: (i) it is a duly organized and validly existing corporation under the laws of its
jurisdiction of incorporation; (ii) it has full corporate power and authority and has taken all 

  

 Page 71 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
corporate action necessary to enter into and perform this Agreement; (iii) the execution and delivery of this Agreement and the performance of its
obligations hereunder do not and will not violate, conflict with, or constitute a default under its charter or similar organization document, its by-laws, any Applicable Laws and Guidelines, or the terms or provisions of any material agreement or
other instrument to which it is a party or by which it is bound, or any order, award, judgment or decree to which it is a party or by which it is bound; (iv) this Agreement is its legal, valid and binding obligation, enforceable in accordance
with its terms. 

  

	 	17.1.2	Each Party represents and warrants that it has not been debarred and is not subject to debarment and that it shall not knowingly use in any capacity, in connection with the services
to be performed under this Agreement, any person who has been debarred pursuant to Section 306 of the Act or who is the subject of a conviction described in such section. Each Party shall notify the other in writing immediately if it or any
member of its Designated Sales Forces is debarred or is the subject of a conviction described in Section 306 of the Act, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of either
Party’s knowledge, is threatened, relating to the debarment or conviction of either Party or any member of either Party’s Designated Sales Forces. 

  

	17.2	Representations and Warranties of Abraxis. Abraxis represents and warrants to AstraZeneca as follows: 

  

	 	17.2.1	Product Patents, Product Trademarks and Product Copyrights. As of the execution date of this Agreement: 

 (a) Schedule 17.2.1 sets forth a list of the Product Patents listed by Abraxis in the FDA’s Approved Drug Products with Therapeutic Equivalence
Evaluations (the “Orange Book”) claiming the Product or the method of using the Product, as 

  

 Page 72 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
required by the Act, and existing as of the execution date of this Agreement. Abraxis is the sole and exclusive owner of the entire right, title and interest
in and to the Product Patents assigned to Abraxis as of the execution date of this Agreement and the Product Trademarks and Product Copyrights, in each case, existing in the Territory as of the execution date of this Agreement. 
 (b) The Product Patents assigned to Abraxis as of the execution date of this Agreement and the Product Trademarks and Product Copyrights, in each case,
existing in the Territory as of the execution date of this Agreement, are not subject to any mortgage, lien, security interest or claim of ownership by any third party. 
  

	 	17.2.2	Non-Infringement of Third Party Rights. As of the execution date of this Agreement, Abraxis has not received any written claim alleging that the manufacture, use or sale of
the Product in the Territory or the use of the Product Trademark or Product Copyrights in the Territory infringes or misappropriates the patent rights or other intellectual property rights of any third party, and, to the Knowledge of Abraxis, the
manufacture, use or sale of the Product in the Territory or the use of the Product Trademark or Product Copyrights in the Territory does not infringe or misappropriate the patent rights or other intellectual property rights of any third party.

  

	 	17.2.3	Existing Patents in the Territory. As of the execution date of this Agreement, to the Knowledge of Abraxis, the Product Patents set forth on Schedule 17.2.1 are not subject
to any pending or threatened re-examination, interference or litigation proceedings in the Territory. 

  

	 	17.2.4	EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ABRAXIS MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR VALIDITY, CONCERNING THE PRODUCT, THE PRODUCT PATENTS, THE PRODUCT COPYRIGHTS, OR THE PRODUCT TRADEMARKS. 

  

 Page 73 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	18	Indemnification. 

  

	18.1	Indemnification of Abraxis. AstraZeneca shall defend, indemnify and hold harmless Abraxis, its Affiliates and its and their respective officers, directors, employees and
agents (the “Abraxis Indemnified Parties”) from and against any and all Losses incurred by them to the extent resulting from or arising out of or in connection with (a) any breach of any obligation in this Agreement by
AstraZeneca, (b) the inaccuracy or breach of any representation or warranty made by AstraZeneca in this Agreement, or (c) any claim by a third party alleging that the use of the AstraZeneca Trademarks infringes the intellectual property
rights of such third party. Notwithstanding anything in this Section 18.1 to the contrary, AstraZeneca shall not be obligated to indemnify any Abraxis Indemnified Parties from and against any Losses (i) for which Abraxis has an obligation
to indemnify the AstraZeneca Indemnified Parties pursuant to Section 18.2, as to which Losses each Party shall indemnify the other to the extent of their respective responsibility for such Losses, or (ii) to the extent the Losses arise as
a result of gross negligence or willful misconduct on the part of any Abraxis Indemnified Parties (for the avoidance of doubt, the foregoing limitation shall not apply to any acts that the Abraxis Indemnified Parties are obligated to perform under
this Agreement to avoid a breach by the Abraxis Indemnified Parties of this Agreement). 

  

	18.2	 Indemnification of AstraZeneca. Abraxis shall defend, indemnify and hold harmless AstraZeneca, its Affiliates and its and their respective officers,
directors, employees and agents (the “AstraZeneca Indemnified Parties”) from and against any and all Losses incurred by them to the extent resulting from or arising out of or in connection with (a) any breach of any obligation
in this Agreement by Abraxis, (b) the inaccuracy or breach of any representation or warranty made by Abraxis in this Agreement, (c) product liability or intellectual property infringement claims resulting from the manufacture, promotion or
sale of the Product, and (d) Abraxis’ use of Promotional Materials that have 

  

 Page 74 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
not been approved by AstraZeneca during the transitional period contemplated by Section 4.7.1. Notwithstanding anything in this Section 18.2
to the contrary, Abraxis shall not be obligated to indemnify the AstraZeneca Indemnified Parties from and against any Losses (i) for which AstraZeneca has an obligation to indemnify the Abraxis Indemnified Parties pursuant to Section 18.1,
as to which Losses each Party shall indemnify the other to the extent of their respective responsibility for such Losses, or (ii) to the extent the Losses arise as a result of gross negligence or willful misconduct on the part of any
AstraZeneca Indemnified Parties (for the avoidance of doubt, the foregoing limitation shall not apply to any acts that the AstraZeneca Indemnified Parties are obligated to perform under this Agreement to avoid a breach by the AstraZeneca Indemnified
Parties of this Agreement). 

  

	18.3	Notice of Claim. An Indemnified Party shall give the Indemnifying Party prompt written notice of any Loss or discovery of fact upon which such Indemnified Party intends to
base a request for indemnification under Section 18.1 or 18.2 (an “Indemnification Claim Notice”). In no event shall the Indemnifying Party be liable for any Loss that results from any delay in providing the Indemnification
Claim Notice. Each Indemnification Claim Notice shall contain a description of the claim and the nature and amount of the Loss claimed (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish
promptly to the Indemnifying Party copies of all papers and official documents received in respect of any such Loss. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates or their respective directors,
officers, employees and agents (each, an “Indemnitee”) shall be made solely by such Party to this Agreement. 

  

	18.4	Indemnification Procedures. The obligations of an Indemnifying Party under this Section 18 with respect to a Third Party Claim shall be governed by and contingent upon
the following: 

  

	 	18.4.1	 Assumption of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim by giving written notice to the Indemnified

  

 Page 75 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Party within fourteen (14) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third
Party Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Indemnitee in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of
any defenses it may assert against any Indemnified Party’s claim for indemnification. 

  

	 	18.4.2	Control of the Defense. Upon the assumption of the defense of a Third Party Claim by the Indemnifying Party: 

  

	 	(i)	the Indemnifying Party may appoint as lead counsel in, and control, the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party, which shall be
reasonably acceptable to the Indemnified Party, and 

  

	 	(ii)	except as expressly provided in Section 18.4.3, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such
Indemnified Party or any Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless an
Indemnitee from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including lawyers’ fees and costs of suit) and any Loss incurred by the Indemnifying Party in
its defense of the Third Party Claim with respect to such Indemnified Party or Indemnitee. 

  

	 	18.4.3	 Right to Participate in the Defense. Without limiting Section 18.4.1 or 18.4.2 any Indemnitee shall be entitled to participate in, but not control, the
defense of a Third Party Claim and to retain counsel of its choice for such purpose; provided, 

  

 Page 76 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
however, that such retention shall be at the Indemnitee’s own expense unless, (a) the Indemnifying Party has failed to assume the defense
and retain counsel in accordance with Section 18.4.1 (in which case the Indemnified Party shall control the defense), or (b) the interests of the Indemnitee and the Indemnifying Party with respect to such Third Party Claim are sufficiently
adverse to prohibit the representation by the same counsel of both Parties under Applicable Laws and Guidelines, ethical rules or equitable principles. 

  

	 	18.4.4	Settlement. With respect to all Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of a Third Party Claim in accordance with
Section 18.4.1, (i) the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Losses, provided that it obtains the prior written consent of the Indemnified
Party, which consent shall not be unreasonably withheld or delayed and (ii) no Indemnified Party or Indemnitee shall admit any liability with respect to, or settle, compromise or discharge, any such Third Party Claim without the prior written
consent of the Indemnifying Party, which consent shall not be unreasonably withheld. 

  

	 	18.4.5	Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each other Indemnitee to, reasonably
cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in
connection therewith. Such cooperation shall include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party
Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided, and the Indemnifying
Party shall reimburse the Indemnified Party for all its related reasonable out-of-pocket expenses. 

  

 Page 77 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	18.4.6	LIMITATION OF DAMAGES. THE PARTIES SHALL ONLY BE LIABLE FOR ACTUAL DAMAGES AND SHALL NOT BE LIABLE FOR INDIRECT, SPECIAL, INCIDENTAL OR PUNITIVE DAMAGES OF ANY KIND RELATING
TO OR ARISING OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATION SET FORTH IN THIS SECTION SHALL NOT APPLY TO LOSSES ARISING FROM THIRD PARTY CLAIMS AND SHALL NOT IMPAIR EITHER
PARTY’S RIGHTS TO INJUNCTIVE OR OTHER EQUITABLE RELIEF OR REMEDIES. 

  

	19	Generic Product; Net Sales Failure 

  

	19.1	Generic Product. If there is a Generic Drug version of the Product launched in the Territory, the Parties shall meet within [***] days after the launch of such Generic Drug
version of the Product to discuss in good faith possible amendments to this Agreement to appropriately account for such event. If the Parties are unable to agree on such amendments after negotiating in good faith for a period [***], then either
Party shall have the right to terminate this Agreement by providing [***] prior written notice to the other Party. If the Agreement is terminated by either Party pursuant to this Section 19.1, Abraxis shall refund to AstraZeneca an amount equal
to the Smaller Clawback Amount within sixty (60) days of the effectiveness of such termination in accordance with Section 21.3. In such event AstraZeneca shall not be entitled to receive Residual Compensation pursuant to Section 9.5.

  

	19.2	 Net Sales Failure. If during any Two-Year Forecast Period the aggregate Net Sales during such period are less than [***] of the Two-Year Net Sales Forecasts
for such period in the applicable Business Plan (a “Net Sales Failure” and any such period a “Net Sales Failure Period”) and a Party had a number of Details that was less than [***] of such Party’s
Details Requirement (defined below) for the Net Sales Failure Period, then 

  

 Page 78 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
the other Party shall have the right to terminate this Agreement by providing written notice of termination (a “Net Sales Failure Notice”)
to the first Party. A termination of this Agreement pursuant to this Section 19.2 shall become effective thirty (30) days after the delivery of the applicable Net Sales Failure Notice. Notwithstanding the foregoing, a Party may not
terminate this Agreement pursuant to this Section 19.2 if, during the applicable Net Sales Failure Period, such Party performs a number of Details that is less than [***] of such Party’s Details Requirement for the Net Sales Failure
Period. With respect to any Net Sales Failure Period or other period, a Party’s “Details Requirement” shall be equal to the total of the Mandatory Detail Requirements for each of the Trimesters that fall within such Net Sales
Failure Period or other period, prorated as necessary to take into account any Trimester that only partially falls within such Net Sales Failure Period or other period. 
  

	19.3	Consequences of Termination for Net Sales Failure. 

  

	 	19.3.1	If Abraxis Fails to Meet Detail Minimum. If AstraZeneca terminates the Agreement pursuant to Section 19.2 Abraxis shall refund to AstraZeneca the Larger Clawback Amount
within sixty (60) days of the effectiveness of such termination in accordance with Section 21.3, and AstraZeneca shall be entitled to receive Residual Compensation pursuant to Section 9.5. 

  

	 	19.3.2	If AstraZeneca Fails to Meet Detail Minimum. If Abraxis terminates the Agreement pursuant to Section 19.2, AstraZeneca shall not be entitled to any clawback
amount and shall not be entitled to receive Residual Compensation pursuant to Section 9.5, and AstraZeneca shall refund to Abraxis the Abraxis Clawback Amount within sixty (60) days of the effectiveness of such termination. The
“Abraxis Clawback Amount” means an amount equal to [***] by Abraxis to AstraZeneca from the Effective Date multiplied by a fraction, the numerator of which is (x) AstraZeneca’s Details Requirement for the period from the
Effective Date through the end of the Net Sales Failure Period (the “Measurement Period”), minus(y) the number of Details AstraZeneca actually performed during the Measurement Period, and the denominator of which is
AstraZeneca’s Details Requirement for the Measurement Period. 

  

 Page 79 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	20	Change of Control 

 If Abraxis, on the one hand, or
AstraZeneca or AstraZeneca PLC, on the other hand, undergoes a Change of Control, then the other Party shall have the right from and after the effective date of such Change of Control, until the six (6) months after the effective date of
such Change of Control (the “Termination Period”), to terminate this Agreement by written notice to the other Party. If the other Party elects to so terminate, then such termination shall be effective six (6) months after the
date of such Party’s notice of its election to terminate or such earlier date as such Party may elect and specify in such termination notice. 
  

	21	Term and Termination 

  

	21.1	Term. 

  

	 	21.1.1	Unless earlier terminated in accordance with the terms hereof, the term of this Agreement (the “Term”) shall commence on the Effective Date and continue for a
period of five and one-half years. 

  

	 	21.1.2	No later than [***] prior to the scheduled expiration of the Term, the Parties shall meet to discuss whether the Term shall be extended and the terms and conditions on which such
extension would be made; provided that neither Party shall have any obligation to extend the Term. 

  

	21.2	Termination. 

  

	 	21.2.1	In addition to any other provision of this Agreement expressly providing for termination of this Agreement, this Agreement may be terminated by either Party:

  

	 	(a)	in the event of a material breach of this Agreement by the other Party, which breach remains uncured thirty (30) days after written notice of such breach is given to the
breaching Party (the “Cure Period”); provided, however, that if the breach is capable of being cured and so long as the breaching Party continues to make reasonable efforts to cure such breach the Cure Period shall be extended for
an additional sixty (60) days; 

  

 Page 80 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(b)	immediately upon written notice if the other Party shall file in any court or Agency, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or
insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party
shall be served with an involuntary insolvency petition filed against it in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, or if the other Party shall propose or be a Party
to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of its creditors; or 

  

	 	(c)	upon thirty (30) days’ prior written notice to the other Party in the event the FDA causes the withdrawal of the Product from the market at any time after the Effective
Date for a period in excess of one-hundred twenty (120) days. Such notice of termination must be given within thirty (30) days of the conclusion of such one hundred twenty (120) day period; or 

  

	 	(d)	 by either Party on giving thirty (30) days’ written notice to the other, which shall be effective on the expiration date of such thirty (30) day
period in the event that the other Party (the “Violating Party”) is convicted of a felony for violating, or a final, non-appealable order is issued by a court of competent jurisdiction finding that the Violating Party violated, any
Applicable Laws and Guidelines, the Federal Foreign Corrupt Practices Act or any securities laws or regulations (collectively, the “Relevant Laws”), which are of such a nature that the Violating Party’s violation of any
Relevant Laws would reasonably be expected to be injurious in any material respect to the business reputation of the other 

  

 Page 81 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	 
Party as a consequence of the Parties’ performance of their obligations pursuant to this Agreement, except, however, this clause shall have no
application in the case of civil or criminal proceedings that either Party has disclosed to the other Party in writing prior to the Effective Date or that are otherwise disclosed in either Party’s reports or statements filed pursuant to the
Securities Exchange Act of 1934 prior to the Effective Date. Such notice of termination must be given within thirty (30) days of the terminating Party becoming aware of the circumstances described in this Section 21.2.1(d); or

  

	 	(e)	in the event any court of competent jurisdiction issues a final order or judgment, from which no appeal can be taken or from which no appeal is taken within the time period
permitted for appeal, that the manufacture, use or sale of the Product in the Territory infringes the patent rights or misappropriates the trade secrets of a third party. Such notice of termination must be given within thirty (30) days of the
terminating Party becoming aware of the circumstances described in this Section 21.2.1(d). 

  

	21.3	Effect of Termination or Expiration. 

 Upon the
effective date of termination or expiration of this Agreement, AstraZeneca shall immediately cease all Promotion of the Products and discontinue the use of any Promotional Materials and Product samples. If AstraZeneca terminates this Agreement
pursuant to Sections 12.5.2 (Failure of Supply), Section 19.3.1 (If Abraxis Fails to Meet Detail Minimum), 21.2.1(c) (Regulatory Withdrawal of Product), 21.2.1(d) (Violation of Law) or 21.2.1(e) (IP Infringement), then Abraxis shall refund to
AstraZeneca an amount equal to the Larger Clawback Amount within sixty (60) days of the effectiveness of such termination. If AstraZeneca terminates this Agreement pursuant to Sections 19.1 (Generic Product) or 21.2.1(b) (Insolvency), then
Abraxis shall refund to AstraZeneca an amount equal to the Smaller Clawback Amount within sixty (60) days of the effectiveness of such termination. Notwithstanding anything herein to the contrary, in 

  

 Page 82 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
no event shall Abraxis be required to refund to AstraZeneca the Smaller Clawback Amount, the Larger Clawback Amount or any Signing Fee, if AstraZeneca has
not paid to Abraxis the Signing Fee. 
  

	21.4	Return of All Materials. 

 Upon the termination or
expiration of this Agreement, AstraZeneca shall promptly return to Abraxis all Product samples, all Promotional Materials, and all training materials that Abraxis provided to AstraZeneca pursuant to this Agreement that are in the possession of, or
under the control of, AstraZeneca or its Designated Sales Forces. 
  

	21.5	Survival. 

  

	 	21.5.1	The expiration or termination of this Agreement for any reason shall be without prejudice to any rights or obligations of the Parties that may have accrued prior to such
termination, and the provisions of Sections 4.5, 5.3, 8.1, 8.2, 8.3.4 (but only so long as the First Residual Period and Second Residual Period remain in effect), 8.4, 8.7, 9.2 (with regard to Compensation for the final Calendar Quarter), 9.3 (with
regard to Shared Expenses in the final Calendar Quarter), 9.5, 9.7, 12.5.2 (penultimate sentence), 14.1.2 (except in the case where AstraZeneca elects to be released from its obligation under Section 14.1.2), 14.1.4 (except in the case where
AstraZeneca elects to be released from its obligation under Section 14.1.2), 14.1.5 and 14.3, Sections 15, 16 (other than Sections 16.1 and 16.3.1), 17, 18, 19.1 (penultimate sentence), 19.3, 21.3, 21.4, 22, 24 through 34 and this
Section 21.5 shall survive the expiration or termination of this Agreement for any reason. 

  

	 	21.5.2	Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit the remedies that may otherwise be available in
law or equity. 

  

	22	Governing Law, Jurisdiction; Dispute Resolution 

  

	22.1	Governing Law. The interpretation and construction of this Agreement shall be governed by the laws of the State of Delaware, excluding any conflicts or choice of law rule or
principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

  

 Page 83 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	22.2	Jurisdiction. Subject to Sections 14.3.3 and 15.6.2, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of state and federal courts
located in the State of Delaware for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto
except in such courts. 

  

	22.3	Dispute Resolution. Subject to Section 10.4, in the event of a dispute arising out of or relating to this Agreement either Party may provide written notice of the
dispute to the other, in which event the dispute shall be referred to the executive officers designated below or their successors, for attempted resolution by good faith negotiations within sixty (60) days after such notice is received. Said
designated officers are initially as follows: 

 For Abraxis: its Chief Executive Officer or his designate 
 For AstraZeneca: its Chief Executive Officer or his designate 
 In the event the designated executive officers do not resolve such dispute within the allotted sixty (60) days, subject to Section 10.4, either Party may, after the expiration of the sixty (60) day
period, seek to resolve the dispute in a court of competent jurisdiction in accordance with this Section 22. 
  

	23	Force Majeure 

 No liability shall result
from, and no right to terminate shall arise, in whole or in part, based upon any delay in performance or non-performance, in whole or in part, by either of the Parties to this Agreement to the extent that such delay or non-performance is caused by
an event of Force Majeure. “Force Majeure” means an event that is beyond a non-performing Party’s reasonable control, including an act of God, act of the other Party, strike, lock-out or other industrial/labor dispute, failure
of albumin or paclitaxel supply due to circumstances beyond Abraxis’ control (which shall not be deemed to include Abraxis’ failure to procure supply of albumin or paclitaxel or any other raw 

  

 Page 84 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
material for financial reasons), war, riot, civil commotion, terrorist act, malicious damage, epidemic, quarantine, fire, flood, storm, natural disaster or
compliance with any law or governmental order, rule, regulation or direction, whether or not it is later held to be invalid or inapplicable. The Force Majeure Party shall within ten (10) days of the occurrence of the Force Majeure event, give
written notice to the other Party stating the nature of the Force Majeure event, its anticipated duration and any action being taken to avoid or minimize its effect. Any suspension of performance shall be of no greater scope and of no longer
duration than is reasonably required and the Force Majeure Party shall use reasonable effort to remedy its inability to perform; provided, however, if the suspension of performance continues for sixty (60) days after the date of
the occurrence, and such failure to perform would constitute a material breach of this Agreement in the absence of such event of Force Majeure, the Parties shall meet and discuss in good faith any amendments to this Agreement to permit the other
Party to exercise its rights under this Agreement. If the Parties are not able to agree on such amendments within sixty (60) days and if the suspension of performance continues, such other Party shall have the right, notwithstanding the first
sentence of this Section 23, to terminate this Agreement immediately by written notice to the Force Majeure Party, in which case neither Party shall have any liability to the other except for those rights and liabilities that accrued prior to
the date of termination. 
  

	24	Waiver and Non-Exclusion of Remedies 

 A
Party’s failure to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or
all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by law or otherwise
available except as expressly set forth herein. 
  

 Page 85 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	25	Notices 

  

	25.1	Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer
specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records of delivery,
addressed to the Parties at their respective addresses specified in Section 25.2 or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section 25.1. Such Notice
shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight
delivery service. This Section is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

  

	25.2	Address for Notice. 

  

	 	For :	AstraZeneca UK Limited 

  

	 	    	Address: 15 Stanhope Gate 

  

	 	    	London, England W1K 1LN 

  

	 	    	Facsimile: +44 207-304-5196 

  

	 	    	For the attention of: Graeme HR Musker, Company Secretary and Solicitor 

  

			
	With a copy to: AstraZeneca Pharmaceuticals LP
	
	 Address: 1800 Concord Pike

	
	 Wilmington, DE 19803

	
	 Facsimile: 302-886-2459

	
	 For the attention of: Glenn Engelmann

  

	 	For :	Abraxis Bioscience, Inc. 

  

 Page 86 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	 	Address:	11777 San Vicente Boulevard, Suite 500 

  

	 	    	Los Angeles, CA 90049 

  

	 	Facsimile:	310-826-8525 

  

	 	    	For the attention of: Chief Executive Officer 

  

	 	    	With a copy to: Abraxis Bioscience, Inc. 

  

	 	Address:	11777 San Vicente Boulevard, Suite 500 

  

	 	    	Los Angeles, CA 90049 

  

	 	Facsimile:	310-826-8525 

  

	 	    	For the attention of: General Counsel 

  

	26	Entire Agreement 

 This Agreement constitutes
the entire agreement between the Parties with respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it
is not relying on any representations, warranties or covenants of the other Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules or Exhibits referred
to in this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. In the event of any inconsistency between any such Schedules or Exhibits and this Agreement, the terms of this Agreement shall
govern. 
  

	27	Amendment 

 Any amendment or modification of
this Agreement must be in writing and signed by authorized representatives of both Parties. 
  

	28	Assignment 

 Neither Party may assign its
rights or, except as provided in Section 4.1.4, delegate its obligations under this Agreement, in whole or in part without the prior written consent of the other Party, which consent shall not be unreasonably withheld, except that AstraZeneca
and Abraxis shall always have the right, without such consent, (a) to 

  

 Page 87 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 
perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates (provided that AstraZeneca or
Abraxis, as applicable, shall remain responsible for any failure to perform on the part of any such Affiliates), and (b) on written notice to the other Party, assign any or all of its rights and delegate or subcontract any or all of its
obligations hereunder to any of its Affiliates or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement relates. Any permitted successor of a
Party or any permitted assignee of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to be a
party to this Agreement as though named herein (provided that the assigning or delegating Party shall remain responsible for any failure of the assignee or delegatee to perform its obligations hereunder), whereupon the assigning Party shall cease to
be a party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned rights of a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party
shall be binding on and be enforceable against, the permitted successors and assigns of such Party. Any attempted assignment or delegation in violation of this Section shall be void. Notwithstanding any other provision of this Section, the terms of
this Agreement may be varied, amended or modified or this Agreement may be suspended, cancelled or terminated without the consent of any assignee or delegate that is not deemed pursuant to the provisions of this Section 28 to have become a
party to this Agreement. 
  

	29	No Benefit to Others 

 The provisions of this
Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other persons except as otherwise expressly provided in this Agreement. 
  

 Page 88 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	30	Counterparts 

 This Agreement may be executed
in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same instrument. An executed signature page of this Agreement delivered by facsimile transmission
shall be as effective as an original executed signature page. 
  

	31	Severability 

 To the fullest extent
permitted by applicable law, the Parties waive any provision of law that would render any provision in this Agreement invalid, illegal or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal or
unenforceable, in any respect, then such provision will be given no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by applicable law and if the rights or obligations of any Party will not be
materially and adversely affected, all other provisions of this Agreement shall remain in full force and effect and the Parties will use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or
unenforceable that is consistent with applicable law and achieves, as nearly as possible, the original intention of the Parties. 
  

	32	Further Assurance 

 Each Party shall perform
all further acts and things and execute and deliver such further documents as may be necessary or as the other Party may reasonably require to implement or give effect to this Agreement. 
  

	33	Publicity 

 It is understood that the Parties
intend to issue separate press releases announcing the execution of this Agreement and agree that each Party may desire or be required to issue subsequent press releases relating to the Agreement or activities hereunder. The Parties agree to consult
with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, provided that a Party may not unreasonably withhold consent to such releases, and that either Party may issue such
press releases as it determines, based on advice of counsel, are reasonably necessary to comply with laws or regulations or for appropriate market disclosure. 
  

 Page 89 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

	34	Relationship of the Parties 

 The status of a
Party under this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture, or agency relationship between the Parties or, except as otherwise expressly
provided in this Agreement, as granting either Party the authority to bind or contract any obligation in the name of or on the account of the other Party or to make any statements, representations, warranties, or commitments on behalf of the other
Party. All Persons employed by a Party or any of its Affiliates shall be employees of such Party or its Affiliates and not of the other Party or such other Party’s Affiliates and all costs and obligations incurred by reason of any such
employment shall be for the account and expense of such Party or its Affiliates, as applicable. 
 [Signature Page Follows] 
  

 Page 90 of 91 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

									
	Execution	  		  	
			
	AstraZeneca UK Limited	  		  	Abraxis Bioscience, Inc.
					
	By:	  	  
	  		  	By:	  	  

	Name:	  	Graeme Musker	  		  	Name:	  	Patrick Soon-Shiong, CEO

  

 Page 91 of 91Asset Purchase Agreement

 Exhibit 10.14 
 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN
REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
 Execution Copy 
 ASSET PURCHASE
AGREEMENT 
 between 
 ASTRAZENECA UK LIMITED 
 and 
 ABRAXIS BIOSCIENCE, INC. 
 April 26, 2006 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	ARTICLE I DEFINITIONS	  	1
	 1.1.
	  	Definitions	  	1
	 1.2.
	  	Additional Definitions	  	14
		
	ARTICLE II PURCHASE AND SALE OF ASSETS; PURCHASE PRICE	  	15
	 2.1.
	  	Purchase and Sale of Assets	  	15
	 2.2.
	  	Excluded Assets	  	15
	 2.3.
	  	Assumption of Liabilities	  	16
	 2.4.
	  	Excluded Liabilities	  	16
	 2.5.
	  	Shared Technology; Technology Transfer, Etc.	  	18
	 2.6.
	  	Consideration; Payment	  	19
	 2.7.
	  	Adjustments to Purchase Price	  	20
	 2.8.
	  	Allocation of the Consideration	  	21
	 2.9.
	  	Transfer Taxes	  	21
	 2.10.
	  	Withholding Tax	  	21
		
	ARTICLE III THE CLOSING	  	21
	 3.1.
	  	Time and Place of Closing	  	21
	 3.2.
	  	Payment of Consideration; Deliveries	  	22
	 3.3.
	  	Restricted Assets	  	22
		
	ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE SELLER	  	22
	 4.1.
	  	Organization and Good Standing	  	22
	 4.2.
	  	Power and Authority	  	23
	 4.3.
	  	No Violation	  	23
	 4.4.
	  	Financial Information	  	23
	 4.5.
	  	Contracts	  	24
	 4.6.
	  	Intellectual Property	  	24
	 4.7.
	  	Actions	  	25
	 4.8.
	  	Taxes	  	25
	 4.9.
	  	Title to Property	  	25
	 4.10.
	  	Approvals	  	26
	 4.11.
	  	Regulatory Compliance.	  	26
	 4.12.
	  	Sufficiency of Assets	  	26
	 4.13.
	  	Principal Customers and Suppliers	  	27
	 4.14.
	  	All Transferred Assets As Is	  	27
		
	ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE PURCHASER	  	27
	 5.1.
	  	Organization and Good Standing	  	27
	 5.2.
	  	Power and Authority	  	27
	 5.3.
	  	No Violation	  	28
	 5.4.
	  	Actions	  	28
	 5.5.
	  	Approvals	  	29

  

 i 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

					
	 5.6.
	  	Financing	  	29
		
	ARTICLE VI CERTAIN OBLIGATIONS OF THE SELLER PRIOR TO THE CLOSING	  	29
	 6.1.
	  	Conduct of Business	  	29
	 6.2.
	  	Restricted Activities and Transactions	  	30
	 6.3.
	  	Cooperation	  	30
	 6.4.
	  	No Solicitation of Transaction	  	31
	 6.5.
	  	Access	  	31
	 6.6.
	  	Confidentiality	  	31
	 6.7.
	  	HSR Notification	  	31
	 6.8.
	  	Financials	  	32
	 6.9.
	  	Cooperation Regarding Financial Statements	  	32
	 6.10.
	  	Certain Notifications	  	32
	 6.11.
	  	Distribution Arrangements	  	33
	 6.12.
	  	Tax Matters	  	33
		
	ARTICLE VII CERTAIN OBLIGATIONS OF THE PURCHASER PRIOR TO THE CLOSING	  	34
	 7.1.
	  	Cooperation	  	34
	 7.2.
	  	HSR Notification	  	34
	 7.3.
	  	Insurance	  	34
	 7.4.
	  	Confidentiality	  	34
	 7.5.
	  	Certain Notifications	  	35
		
	ARTICLE VIII CONDITIONS PRECEDENT TO THE OBLIGATIONS OF THE PURCHASER	  	35
	 8.1.
	  	Representations and Warranties True	  	35
	 8.2.
	  	Performance	  	35
	 8.3.
	  	No Material Adverse Change	  	35
	 8.4.
	  	Approvals and Designated Contracts	  	35
	 8.5.
	  	Deliveries	  	36
	 8.6.
	  	Absence of Litigation	  	36
	 8.7.
	  	HSR Act	  	36
	 8.8
	  	Co-Promotion Signing Fee	  	36
		
	ARTICLE IX CONDITIONS PRECEDENT TO THE OBLIGATIONS OF THE SELLER	  	36
	 9.1.
	  	Representations and Warranties True	  	37
	 9.2.
	  	Performance	  	37
	 9.3.
	  	Approvals	  	37
	 9.4.
	  	Deliveries	  	37
	 9.5.
	  	Absence of Litigation	  	38
	 9.6.
	  	HSR Act	  	38
		
	ARTICLE X CERTAIN ADDITIONAL COVENANTS AND AGREEMENTS	  	38
	 10.1.
	  	Books and Records; Access	  	38
	 10.2.
	  	Specific Performance; Injunctive Relief	  	39
	 10.3.
	  	Further Assurances	  	39
	 10.4.
	  	Accounts Receivable, Etc.	  	40
	 10.5.
	  	Post-Closing Confidentiality	  	40

  

 ii 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

					
	 10.6.
	  	The Seller’s Labels	  	40
	 10.7.
	  	Returns, Rebates and Chargebacks	  	41
	 10.8.
	  	Recalls	  	41
	 10.9.
	  	Covenant Not to Compete	  	41
	 10.10.
	  	Right of First Offer	  	42
	 10.11.
	  	Authorized Generic Status	  	43
	 10.12
	  	Obligation to Cooperate Upon Assignment or Sale	  	43
		
	ARTICLE XI SURVIVAL; INDEMNIFICATION	  	44
	 11.1.
	  	Survival	  	44
	 11.2.
	  	Indemnification by the Seller	  	44
	 11.3.
	  	Indemnification by the Purchaser	  	44
	 11.4.
	  	Notice and Payment of Claims	  	45
	 11.5.
	  	Matters Involving Third Parties	  	45
	 11.6.
	  	Limitation of Remedies	  	46
		
	ARTICLE XII TERMINATION	  	47
	 12.1.
	  	Termination	  	47
	 12.2.
	  	Effect of Termination	  	48
		
	ARTICLE XIII MISCELLANEOUS	  	48
	 13.1.
	  	Public Announcements	  	48
	 13.2.
	  	Amendment; Waiver	  	48
	 13.3.
	  	Fees and Expenses	  	49
	 13.4.
	  	Notices	  	49
	 13.5.
	  	Assignment	  	50
	 13.6.
	  	Governing Law; Consent to Jurisdiction	  	50
	 13.7.
	  	Headings	  	51
	 13.8.
	  	Entire Agreement	  	51
	 13.9.
	  	Severability	  	51
	 13.10.
	  	No Third Party Beneficiaries	  	52
	 13.11.
	  	References to Articles, Etc.	  	52
	 13.12.
	  	References to “Herein,” Etc.	  	52
	 13.13.
	  	Counterparts	  	52

  

 iii 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBITS 
  

			
	Exhibit A	  	Manufacturing and Supply Agreements
	Exhibit B	  	Excluded Injectible Products
	Exhibit C	  	Allocation of Consideration
		
	SCHEDULES	  	
		
	Schedule A	  	Products

  

 iv 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 ASSET PURCHASE AGREEMENT 
 This Asset Purchase Agreement, dated April 26, 2006 (the “Agreement”), is entered into between AstraZeneca UK Limited, an English
limited company (the “Seller”), and Abraxis Bioscience, Inc., a Delaware corporation (the “Purchaser”). 
 W I T N E S S E T H: 
 WHEREAS, as of April 26, 2006 and in consideration for Seller and Purchaser entering into this
Agreement, Seller and Purchaser have entered into a Co-Promotion and Strategic Marketing Services Agreement and related agreements, which provides for, among other items, (i) long term product supply agreements and (ii) Seller’s
provision of various services to Purchaser; and 
 WHEREAS, in connection therewith, the Seller desires to transfer, sell, convey, assign and
deliver to the Purchaser, and the Purchaser desires to acquire and assume from the Seller, the Transferred Assets and Assumed Liabilities (as defined herein), respectively, in accordance with the terms and subject to the conditions of this
Agreement. 
 NOW, THEREFORE, for and in consideration of the premises and the mutual covenants and agreements contained herein, and
intending to be legally bound hereby, the parties hereto hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 1.1. Definitions.
The following terms, as used in this Agreement, shall have the following meanings: 
 “acquisition proposal” shall have the
meaning ascribed to such term in Section 6.4 hereof. 
 “Acquisition Agreements” shall mean, collectively, this
Agreement, the Assignment and Assumption Agreement, the Bill of Sale, the IP Assignment Agreement, the Domain Name Assignment Agreement and any and all other transfer, assignment and assumption documents and all certificates delivered in connection
with this Agreement. 
 “Acquisition Documents” shall mean, collectively, the Acquisition Agreements, the Manufacturing and
Supply Agreements, the Cooperation Agreement, the Safety Monitoring Agreement, and any and all other agreements, instruments, certificates and other documents executed and delivered in connection herewith or therewith or contemplated hereby or
thereby. 
 “Act” shall mean the U.S. Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations
promulgated thereunder. 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Action” shall mean any claim, dispute, action (including any action seeking
injunctive or other equitable relief), arbitration, mediation, litigation, proceeding, suit or governmental investigation, and any appeal therefrom. 
 “Affiliate” shall mean, with respect to any Person, another Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such
specified Person. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” means the power to direct or cause the direction of the management
or policies of a Person, whether through ownership of voting securities, by contract, resolution, regulation or otherwise. 
 “Agreement” shall mean this Asset Purchase Agreement together with all of the Schedules and Exhibits attached hereto. 
 “Allocation” shall have the meaning ascribed to such term in Section 2.7 hereof. 
 “Alternative
Facility” shall mean, with respect to any Product or API, any facility of the Purchaser, any of its Subsidiaries or any other Person that is from time to time designated as such by the Purchaser. 
 “ANDA” shall mean, with respect to any Product, any Abbreviated New Drug Application, as defined in and regulated under the Act, for
such Product, as the same may be supplemented or amended from time to time. 
 “Antitrust Division” shall mean the Antitrust
Division of the U.S. Department of Justice or any successor entity. 
 “API” shall mean, with respect to each of the
Products, the active pharmaceutical ingredients used by the Seller or any of its Affiliates to manufacture such Product as of the date of this Agreement and as of Closing Date. 
 “Approval” shall mean any approval, authorization, consent, license, franchise, order or permit of or by, notice to, or filing or
registration with, a Person. 
 “Assignment and Assumption Agreement” shall mean the instrument of assignment and assumption
of the Assumed Liabilities by the Purchaser, in the form to be mutually agreed to by the parties prior to the Closing Date. 
 “Assumed Liabilities” shall have the meaning ascribed to such term in Section 2.3 hereof. 
 “Bill of
Sale” shall mean the bill of sale transferring to the Purchaser the Transferred Assets in the form to be mutually agreed to by the Purchaser and the Seller prior to the Closing Date. 
 “Books and Records” shall mean all books, records, files, documents, data and information (including Formulation Data, Safety Data,
agreements with customers, suppliers, 
  

 2 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 distributors, wholesalers, GPOs and government agencies, customer lists, cost and pricing data, market research
reports, reference catalogs and, to the extent not originals, true and complete copies of all files relating to the filing, prosecution, issuance, ownership, maintenance, enforcement and/or defense of any patents, patent applications, trademarks,
copyrights or other intellectual property rights, whether on paper or in electronic format) Controlled by the Seller or any its Affiliates and relating to the formulating, manufacturing, developing, packaging, labeling and storing of Products or API
for sale in the Territory or the distribution, marketing, sale, promotion, importation or use of Products or API in the Territory. 
 “Business Combination” shall mean any merger, consolidation, sale or transfer of all or substantially all of the assets, or other similar transaction to which the Purchaser is a party unless, following such transaction or
transactions, (i) the individuals and entities who were the beneficial owners of the outstanding voting securities of the Purchaser immediately prior to such transaction beneficially own, directly or indirectly, more than fifty percent
(50%) of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors or similar governing persons of the corporation or other entity resulting from such transaction
(“Successor”) in substantially the same proportions as their ownership immediately prior to such transaction of such outstanding voting securities, and (ii) at least fifty percent (50%) of the members of the Board of
Directors or similar governing body of the Successor were members of the Board of Directors of the Purchaser at the time of the execution of the initial agreement, or the action of the Board of Directors of the Purchaser, providing for such
transaction. 
 “cGMP(s)” shall mean current good manufacturing practices established under applicable Laws and Regulations,
including, without limitation, Regulations of the FDA. 
 “Change of Control” shall mean (a) a Business Combination
involving the Purchaser, (b) a sale and/or transfer of all or substantially all of the Transferred Assets and Licensed Assets, or (c) a change in the beneficial ownership of fifty percent (50%) or more of the Purchaser’s voting
securities (whether in a single transaction or series of related transactions) where, immediately after giving effect to such change, the legal or beneficial owner of more than fifty percent (50%) of the Purchaser’s voting securities is a
Third Party or Group, excluding any equity investments by venture capitalists or investment banks or other non-strategic investors, who alone or with their Affiliates, are not themselves in the business of developing and commercializing
pharmaceutical products. 
 “Clinical Data” shall mean, to the extent available to and Controlled by the Seller and its
Affiliates at any time or from time to time prior to and as of the Closing Date, all clinical studies completed, manuscripts for all clinical studies, dossiers, new indications, regimens, statistical analyses, and summary reports, associated with
and material to the Products in either electronic or hard copy form, whether inside or outside of the Territory to the extent used in a filing for a Transferred Product Registration made in the Territory. 
 “Closing” shall mean the consummation of the transactions contemplated by this Agreement. 
  

 3 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Closing Date” shall mean July 31, 2006 or such earlier date as the parties
shall mutually agree, if the conditions precedent to Closing described in Article VIII and Article IX hereof have been fully satisfied or waived by the appropriate party or parties hereto on or prior to such date (other than those conditions that by
their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions) or, if the conditions precedent to the Closing described in Articles VIII and IX have not been fully satisfied or waived by the
appropriate party or parties hereto on or prior to such date (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions), as promptly as practicable, but in no
event later than two (2) Business Days thereafter. 
 “Co-Promotion Agreement” shall mean the Co-Promotion and
Strategic Marketing Services Agreement between the Purchaser and the Seller, with such changes thereto as may be mutually agreed upon by the parties thereto. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended. 
 “Competing
Product” [***]. 
 “Condition” shall mean any act, omission, occurrence, change, effect, event or any series or
combination thereof. 
 “Contracts” shall mean any and all written binding commitments, contracts, purchase orders, leases,
licenses, commitments, arrangements, undertakings or other agreements. 
 “Control” or “Controlled” shall
mean, with respect to any particular assets described in this Agreement to which this term is applied, that the Seller or its Affiliate owns or has a license to such asset. 
 “Cooperation Agreement” shall mean the agreement between the Purchaser and the Seller to be mutually agreed upon by the parties prior to
the Closing Date. 
 “Current” shall mean the existing, prepared, made or being made, tested or being tested, or physically
reduced to practice or contained in an invention disclosure form prior to or as of the Closing Date. 
 “Damages” shall mean
any direct or out-of-pocket claim, Liability, penalty, debt, cost or expense (including, without limitation, reasonable attorneys’ and accountants’ fees, costs and expenses, including reasonable costs and expenses incurred in pursuing or
defending Third Party Actions or Product Liability Claims under Article X or Article XI hereof, and the reasonable costs and expenses incurred in responding to, defending, satisfying or complying with an injunction or other equitable action or order
or investigation of a Governmental Authority) or damage of any kind or nature whatsoever but excluding in all cases special, incidental, exemplary, punitive and consequential damages other than such damages that are components of awards or judgments
in Third Party Actions or Product Liability Claims that have been finally determined. 
  

 4 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “DEA” shall mean the U.S. Drug Enforcement Administration or any successor entity or
any comparable Governmental Authority having similar jurisdiction outside the Territory. 
 “Diprivan Litigation” shall mean
the ongoing patent litigation, AstraZeneca v. Mayne Pharma (USA) Inc. (fka Faulding Pharmaceutical Co.), Case No. 06-1118 (CAFC)(October 4, 2002). 
 “Diprivan Products” shall mean, collectively, all of the Diprivan Products set forth on Schedule 1.1(a). 
 “DMFs” shall mean, with respect to each Product and API, the Drug Master Files related thereto maintained or Controlled by or on behalf of the Seller or any of its Affiliates. 
 “Domain Name Assignment Agreement” shall mean the agreement between the Purchaser and the Seller to be mutually agreed upon by the
parties prior to the Closing Date. 
 “Domain Names” shall mean the URLs that are material to the formulating,
manufacturing, developing, packaging, labeling or storing any Product or API for sale in the Territory or to the marketing, distributing and selling of any Product or API in the Territory as conducted by Seller and its Affiliates on the Closing Date

 “Effective Time” shall mean 12:01 a.m., New York time on the Closing Date. 
 “Establishment Registration” shall mean the registration of the facilities used in the process of formulating, manufacturing,
developing, packaging, marketing, distributing and selling the Products, as required under the Act and, if required by Law, the DEA and any applicable Governmental Authority. 
 “Excluded Assets” shall have the meaning ascribed to such term in Section 2.2 hereof. 
 “Excluded Liabilities” shall have the meaning ascribed to such term in Section 2.4 hereof. 
 “Ex-Territory Agreement” shall have the meaning ascribed to such term in Section 10.11 hereof. 
 “Ex-Territory Notice” shall have the meaning ascribed to such term in Section 10.11 hereof. 
 “Ex-Territory Response Notice” shall have the meaning ascribed to such term in Section 10.11 hereof. 
 “Foreign Regulatory Authorities” shall mean any regulatory authority outside of the Territory having similar jurisdiction to the FDA.

  

 5 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “FDA” shall mean the U.S. Food and Drug Administration or any successor entity
having similar jurisdiction. 
 “finally determined”, and other correlative terms such as “final determination”,
with respect to any U.S. federal income Tax shall mean a “determination” as defined in Section 1313(a) of the Code, and with respect to any other Action, Liability or Damages shall mean (i) when the parties to such Action or the
parties that have an interest in such Liability or Damages shall have so determined by mutual written agreement or (ii) if disputed, when an order of a Government Authority having competent jurisdiction with respect to such matters shall have
been entered and no appeal therefrom has been, or can be, taken or the time for appeal has expired. 
 “Formulation Data”
shall mean all discoveries, inventions, dosage forms, formulations, and other development work within or outside of the Territory to the extent associated primarily with and material to a Product in the Territory and available to the Seller and its
Affiliates at any time or from time to time, prior to and as of the Closing Date. 
 “FTC” shall mean the U.S. Federal Trade
Commission or any successor entity having similar jurisdiction. 
 “GAAP” shall mean generally accepted accounting
principles in the United States as in effect from time to time. 
 “Governmental Authority” shall mean any foreign, federal,
state, local government or governmental or administrative or regulatory authority, body, agency, court, tribunal or similar entity or self-regulatory organization including any arbitrator or arbitration panel to which a Party has consented for
jurisdiction (whether or not such arbitrator or arbitration panel is affiliated with or part of any government). 
 “GPO”
shall mean group purchasing organization. 
 “Group” shall mean a group of related Persons deemed a “person” for
purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. 
 “HSR Act” shall mean the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder. 
 “IND” shall mean (a) an Investigational New Drug Application, as defined in the Act, which is required to be filed with the FDA before beginning clinical testing of a product in human subjects, or any successor
application or procedure, and (b) all supplements and amendments that may be filed with respect to the foregoing. 
 “Indemnified Party” shall mean any party entitled to indemnification pursuant to Article XI hereof and shall include such party’s Affiliates, successors and permitted assigns and the Representatives of each of them.

  

 6 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Indemnifying Party” shall mean any party responsible for indemnification pursuant
to Article XI hereof and shall include such party’s successors and assigns. 
 “Intellectual Property” shall mean, with
respect to each Product and API, all of the following that, as of the Closing Date, are Controlled by the Seller or any of its Affiliates and that are material to the formulating, manufacturing, developing, packaging, labeling and storing such
Product or API, as applicable, for sale in the Territory or material to the marketing, distributing and selling such Product or API, as applicable, in the Territory, each as conducted by Seller and its Affiliates on the Closing Date: patents and
applications therefor; trademarks (and goodwill associated therewith) and other trade names, labels, trade dress, advertising and package designs, and other trade rights, whether or not registered and all applications therefor; copyrights, whether
or not registered and all applications therefor (including copyrights in computer software, computer software documentation, systems documentation and source code); Know-How, trade secrets, research and results thereof, technology, techniques, data,
methods, processes, instructions, drawings and specifications, inventions, discoveries, improvements, designs, manufacturing plans, processes, formulae, whether patented or patentable or not (whether or not such items have been reduced to written,
computer-readable or other tangible form); shop rights and license agreements and other agreements of every kind and character relating to any of the foregoing; and all claims and causes of action relating to any of the foregoing, including claims
and causes of action for past infringement and all rights under Product Licenses. 
 “IP Assignment Agreement” shall mean
the agreement transferring to the Purchaser certain trademarks, copyrights and patents, in the form to be mutually agreed upon by the parties prior to the Closing Date. 
 “IRS” shall mean the U.S. Internal Revenue Service. 
 “Know-How” shall
mean, with respect to each Product and API, all proprietary information known to the Seller and Affiliates at the Closing Date that is material to the manufacture, testing, assembly, storing, packaging, labeling, supplying, preparation, development
(both research and clinical), or commercialization of such Product or its API for sale in the Territory as used by Seller and its Affiliates on the Closing Date, including the product or ingredient specifications, processes, equipment, compositions,
product designs, plans, trade secrets, ideas, concepts, inventions, formulae, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, stability, safety, quality assurance and quality control data or information, technical
information, research records or information, and all other confidential or proprietary technical and business information, whether or not embodied in any documentation or other tangible materials, each to the extent not generally known and to the
extent Controlled by Seller or its Affiliates. 
 “knowledge” or “known” shall mean with reference to the
Purchaser’s or the Seller’s knowledge, the actual knowledge after reasonable inquiry of the persons listed on Schedule 1.1(b) or Schedule 1.1(c), respectively. 
  

 7 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “labeling” shall mean, with respect to each Product and each API, any and all labels
and other written, printed or graphic matter placed in or upon any container utilized with such Product or API or the packaging therefor. The terms “label” and “labeled” shall have correlative meanings. 
 “Law” shall mean any law, statute, rule, regulation, ordinance, mandatory standard, requirement, administrative ruling or order
promulgated by any Governmental Authority (including, without limitation, any zoning or land use law or ordinance, building code, securities, blue sky, civil rights, occupational health and safety law or regulation and any court or arbitrator’s
order or proceeding). 
 “Liability” shall mean any debt, liability, commitment or obligation of any kind, character or
nature whatsoever, whether known or unknown, secured or unsecured, accrued, fixed, absolute, potential, contingent or otherwise, and whether due or to become due, including any liability for Taxes. 
 “Licensed Assets” shall have the meaning ascribed to such term in Section 2.5 hereof. 
 “Licensed Domain Names” shall mean all Domain Names not included with the Transferred Domain Names. 
 “Licensed Intellectual Property” shall mean all Intellectual Property not included with the Transferred Intellectual Property.

 “Licensed Know-How” shall mean all Know-How not included with the Transferred Know-How. 
 “Licensed Patent Rights” shall mean all Patent Rights not included with the Transferred Patent Rights as set forth on Schedule 1.1(d).

 “Lien” shall mean any lien, statutory lien, pledge, mortgage, deed of trust, security interest, charge, covenant, claim,
restriction, right, option, conditional sale or other title retention agreement, or encumbrance of any kind or nature. 
 “Major
Market Country” [***]. 
 “Managed Market Contracts” shall have the meaning ascribed to such term in
Section 10.8 hereof. 
 “Managed Market Transition Plan” shall mean the transition plan to facilitate the transition
from the Seller to the Purchaser certain managed markets contracts Controlled by the Seller or its Affiliates for the Products in the form to be agreed upon prior to the Closing Date. 
 “manufacturing” shall mean all processes and operations involved in the production, formulation, blending, quality assurance, testing,
filling and packaging of the Products or the API, as such are manufactured for sale in the Territory. The terms “manufacture” and “manufactured” shall have correlative meanings. 
  

 8 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Manufacturing and Supply Agreements” shall mean, collectively, the Manufacturing
and Supply Agreements pursuant to which the Seller shall manufacture the Products for the Purchaser, in the forms attached hereto as Exhibit A, with such changes thereto as may be mutually agreed upon by the parties thereto. 
 “Manufacturing Improvement” shall mean, to the extent Controlled prior to, or any time within the five (5) year period following,
the Closing Date by the Seller or any of its Affiliates in the Territory, any method of manufacturing the composition of matter or articles of manufacture constituting any of the Products or API. 
 “Marks” shall have the meaning ascribed to such term in Section 10.5(a) hereof. 
 “Naropin Products” shall mean, collectively, all of the Naropin Products set forth on Schedule 1.1(e). 
 “New York Court” shall have the meaning ascribed to such term in Section 13.6(b) hereof. 
 “NDA” shall mean, with respect to any Product, any New Drug Application, as defined in the Act, for such Product as the same may be
supplemented or amended from time to time. 
 “NDC Codes” or “NDC Numbers” shall mean National Drug Codes.

 “Non-Competition Period” shall have the meaning ascribed to such term in Section 10.10(a) hereof. 
 “Non-Income Taxes” shall mean all Taxes other than Taxes measured by income or receipts. 
 “Other Products” shall mean all Products other than the Diprivan Products and the Naropin Products. 
 “packaging” shall mean, with respect to each Product and each API, any and all primary containers, cartons, shipping cases, inserts or
other similar material used in packaging or accompanying such Product or API for sale in the Territory. The terms “package” and “packaged” shall have correlative meanings. 
 “Patent Rights” shall mean the following to the extent that they cover the manufacture, testing, assembly, storing, packaging, labeling,
supplying, preparation, development or commercialization of a Product or its API for sale in the Territory, as conducted by Seller and its Affiliates on the Closing Date: (a) all national, regional and international patents and patent
applications, including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming 
  

 9 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted
provisionals, and continued prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents, use patents,
composition of matter patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any
supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)), and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or
introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents. 
 “Permitted Lien” shall mean, with respect to the Transferred Assets, Liens arising in the ordinary course of business which are not yet due and payable as of the Closing Date or are being contested in good faith by
appropriate proceedings which could not, individually or in the aggregate, have a Seller Material Adverse Effect. 
 “Person” shall mean any individual, general or limited partnership, corporation, limited liability company, association, business trust, joint venture, Governmental Authority, business entity or other entity of any kind or
nature. 
 “Post-Closing Tax Period” shall mean any taxable period other than a Pre-Closing Tax Period. 
 “Pre-Closing Tax Period” shall mean any taxable period ending on or before the Closing Date and the portion ending on the Closing Date
of any taxable period that includes (but does not end on) the Closing Date. 
 “Product Family” shall mean the groups of
Products designated and set forth on Schedule A. 
 “Product Improvement” shall mean, to the extent Controlled prior
to the Closing Date by the Seller or any of its Affiliates in the Territory, any: (a) line extension of a Product; or (b) new indication or dosage form of a Product or API. For the avoidance of doubt, the term “Product
Improvement” shall not include any pharmaceutical combination containing the API of such Product and another active ingredient. 
 “Product Liability Claim” shall mean any civil Action by an independent third party (other than a Governmental Authority) based on or relating to product liability, product defect, design, manufacturing, labeling or
packaging defect, product warranty (express or implied), negligence, strict liability, failure to warn including, without limitation, any such Action seeking consequential, special, incidental, exemplary or punitive damages to the extent arising out
of Products or API sold in the Territory. 
 “Product License” shall mean, with respect to each Product and API, the
pending, and/or approved NDAs, ANDAs, INDs and 510(k) clearances, if any, Controlled by the Seller or its Affiliates on or before the Closing Date for the investigation, sale, distribution and or marketing of such Product or API in the Territory,
including all supplements and amendments thereto. 
  

 10 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Products” shall mean, collectively, the products listed on Schedule A, which
includes any Current Product Improvements, supplemental NDAs or labeling changes pending as of the Closing Date. 
 “Purchase
Price” shall have the meaning ascribed to such term in Section 2.6 hereof. 
 “Purchaser” shall have the
meaning ascribed to such term in the preamble to this Agreement. 
 “Purchaser Material Adverse Effect” shall mean any
Condition that taken alone or together with other Conditions has had or is reasonably likely to have a material adverse effect on the Purchaser’s ability to perform its obligations under this Agreement or the other Acquisition Documents to
which it is a party. 
 “Raw Materials and Components” shall mean, with respect to each Product and each API, any and all
raw materials and components (such as chemicals, containers, closures, packaging, labeling, etc.) needed to manufacture, test, assemble, store, package and label such Product or API, as applicable, for sale in the Territory owned by the Seller and
its Affiliates as of the Closing Date. 
 “Recall” shall have the meaning given to such term in 21 C.F.R. 7.3(g).

 “Representative” shall mean, with respect to a Person, any employee, officer, director, stockholder, partner, accountant,
attorney, investment banker, broker, finder, investor, subcontractor, consultant or other authorized agent or representative of such Person. 
 “Restricted Assets” shall have the meaning ascribed to it in Section 3.3(a) hereof. 
 “Safety
Data” shall mean any safety database that may at any time or from time to time prior to and as of the Closing Date, be available to the Seller and its Affiliates in either electronic and hard copy from and adverse drug event files
(including complaints and adverse drug reports) with respect to the Products inside or outside the Territory. 
 “Safety Monitoring
Agreement” shall mean the agreement between the Purchaser and the Seller, in the form to be mutually agreed upon by the parties prior to the Closing Date. 
 “Seller” shall have the meaning ascribed to such term in the preamble to this Agreement. 
 “Seller Material Adverse Effect” shall mean any Condition that taken alone or together with other Conditions has had or is reasonably likely to have a material adverse effect on the Transferred Assets, on the ability of
Purchaser to formulate, manufacture, develop, package and label any of the Products (or have any of the Products formulated, manufactured, developed, packaged or labeled, including under the Manufacturing and Supply Agreements) for sale in the

  

 11 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 Territory after the Effective Time, or the ability of Purchaser to market, distribute or sell any of the Products in
the Territory after the Effective Time or on the Seller’s ability to perform its obligations under this Agreement and the other Acquisition Documents to which it is a party; provided, however, that a Seller Material Adverse Effect shall not
include any adverse changes, events or effects caused by (a) any changes in general economic or political conditions in the Territory; (b) any events, circumstances, changes or effects that affect generally the pharmaceutical industry and
that do not have a materially disproportionate impact on the Seller and its Affiliates relative to other participants in the industry; (c) any changes in any Laws; (d) any outbreak or escalation of hostilities or war or any act of
terrorism; or (e) the announcement or consummation of this Agreement or the Acquisition Documents. 
 “Seller Region”
shall mean each region outside of the Territory in which Products are sold by Seller, each as designated and set forth on Schedule 1.1(f). 
 “Specifications” shall mean, with respect to each Product and each API, the specifications of Raw Materials and Components and the processes and procedures for manufacturing, testing, assembling, storing, labeling and
packaging of such Product or API intended to be marketed, distributed and sold in the Territory, as applicable. 
 “Subsidiaries” shall mean, with respect to any Person, any other Person of which at least a majority of the securities or ownership interests having by their terms ordinary voting power to elect a majority of the board of
directors or other Persons performing similar functions is directly or indirectly owned or controlled by such Person and/or one or more of its respective Subsidiaries. Notwithstanding the foregoing, with respect to the Seller, the term
“Subsidiaries shall only include the following entities: AstraZeneca AB, AstraZeneca Pharmaceuticals LP and AstraZeneca LP. 
 “Tax” or “Taxes” shall mean any (A) foreign, federal, state or local income, gross receipts, franchise, license, severance, occupation, premium, environmental (including taxes under Code
Section 59A), customs, duties, profits, disability, registration, alternative or add- on minimum, estimated, withholding, payroll, employment, unemployment insurance, social security (or similar), excise, sales, use, value-added, goods and
services, occupancy, franchise, real property, personal property, business and occupation, mercantile, windfall profits, capital stock, stamp, transfer, workers’ compensation or other tax, fee or imposition of any kind whatsoever, including any
interest, penalties, additions, assessments or deferred liability with respect thereto, whether disputed or not; (B) liability for the payment of Tax as the result of membership in any combined, unitary, consolidated or other affiliated group;
and (C) transferee, successor or secondary liability in respect of any Tax (whether imposed by Law or contractual arrangement). 
 “Tax Return” shall mean any return, report, declaration, claim for refund, estimate, election, or information statement or return relating to any Tax, including any schedule or attachment thereto, and any amendment thereof.

 “Territory” shall mean the United States and its territories and possessions, including the District of Columbia and the
Commonwealth of Puerto Rico. 
  

 12 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “testing” shall mean, with respect to each Product and each API, any inspection,
examination, and/or testing by manufacturing and/or quality control personnel of any Raw Materials and Components, work-in-progress or finished product of such Product or API, as applicable. The term “test” shall have a correlative
meaning. 
 “Third Party” shall mean any Person other than a Party or an Affiliate of a Party. 
 “Third Party Action” shall mean any Action brought by any Third Party, including any Governmental Authority, against the Seller or the
Purchaser. 
 “Trademarks” shall mean any trademarks, trade names, trade dress, designs and logos that are material to the
manufacture, testing, assembly, storing, packaging, labeling, supplying, preparation, development or commercialization of a Product or its API as conducted by Seller and its Affiliates in the Territory on the Closing Date; provided, however, that
the Trademarks shall not include the AstraZeneca name or logo. 
 “Transfer” shall mean any sale, transfer, conveyance,
assignment, grant, delivery or other disposition, and “Transfer” or “Transferred,” used as a verb, shall each have a correlative meaning. 
 “Transfer Taxes” shall have the meaning ascribed to such term in Section 2.8 hereof. 
 “Transferred Assets” shall have the meaning ascribed to such term in Section 2.1 hereof. 
 “Transferred Books and Records” shall mean (a) copies of all of the Books and Records necessary for, or material to, the research, development, formulating manufacturing, packaging, labeling and storing solely of
Products or API in the Territory or the distribution, marketing, sale, promotion, importation or use solely of Products or API in the Territory, each as conducted by the Seller and its Affiliates on the Closing Date and (b) all originals and
copies of all Books and Records exclusively related to the distribution, marketing, sale, promotion, importation or use solely of Products in the Territory. 
 “Transferred Domain Names” shall mean the URLs set forth on Schedule 1.1(g) of the Seller Disclosure Schedule. 
 “Transferred Intellectual Property” shall mean the Transferred Patent Rights, the Transferred Know-How and the Transferred Trademarks, Transferred Domain Names and all rights to sue and recover
Damages or obtain injunctive relief for future infringement, misappropriation, violation, dilution or breach of any of the foregoing. 
 “Transferred Know-How” shall mean any and all Transferred Manufacturing Know-How and all Know-How that is at any time or from time to time, prior to and as of the Closing Date, Controlled by the Seller or any of its
Affiliates and which is material to, or is necessary for and solely related to, the formulating, manufacturing, developing, packaging, labeling, and storing of the Products or the API for sale in the Territory or the marketing, distributing and
selling of the Products or the API in the Territory, each as conducted by Seller and its Affiliates on the Closing Date. 
  

 13 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 “Transferred Manufacturing Know-How” shall mean the percentages and specifications
of ingredients, the manufacturing processes, specifications, technology, inventions, assays, quality control and testing procedures, know-how and trade secrets Controlled by the Seller or its Affiliates and material to, or necessary for and solely
related to, the formulating, manufacturing, developing, packaging, labeling and storing of any Products or API for sale in the Territory. 
 “Transferred Marketing Materials” shall mean those items of advertising and promotional materials, literature and artwork Controlled by the Seller or any of its Affiliates as of the Closing Date to the extent used in the
advertising and promotion solely of the Products or the API for sale in the Territory. 
 “Transferred Patent Rights” shall
mean, to the extent Controlled by the Seller or any of its Affiliates, those Patent Rights Controlled by the Seller or any of its Affiliates, the practice of which during the making, having made, use, having used, marketing, sale, having sold,
offering to sell and importation of any Products or API as conducted by Seller and its Affiliates on the Closing Date, but no other products or active pharmaceutical ingredients, in the Territory would result in the infringement thereof, each as
listed on Schedule 1.1(h) of the Seller Disclosure Schedule. 
 “Transferred Product Registrations” shall mean (i) the
approvals or registrations which have been received by the Seller or any of its Affiliates as of the date of this Agreement, or which are received by the Seller or any of its Affiliates on or before the Closing Date, for the investigation, sale,
distribution and/or marketing solely of any Product in the Territory (including any pending, and/or approved NDAs, ANDAs, INDs or 510(k) clearances) and can be transferred to Purchaser in accordance with the terms of this Agreement under applicable
Law, including those set forth on Schedule 1.1(i) of the Seller Disclosure Schedule, and (ii) all dossiers, reports, data and other written materials filed as part of such approvals or registrations, or maintained by the Seller or any of its
Affiliates and relating exclusively to such approvals or registrations. 
 “Transferred Trademarks” shall mean the
Trademarks relating exclusively to the marketing and sale of the Products in the Territory and as set forth on Schedule 1.1(j) of the Seller Disclosure Schedule. 
 1.2. Additional Definitions. In addition to the foregoing defined terms, (i) other capitalized terms appearing in this Agreement shall have the respective meanings ascribed to such terms where they first
appear in the text of this Agreement and (ii) all accounting terms not specifically defined in this Agreement shall be construed in accordance with GAAP. 
  

 14 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE II 
 PURCHASE AND SALE OF ASSETS; PURCHASE PRICE 
 2.1. Purchase and Sale of Assets. Subject to the
terms and conditions of this Agreement, and on the basis of the covenants, representations and warranties set forth herein, at and as of the Effective Time, the Seller shall, or shall cause one or more of its Affiliates to, Transfer to the
Purchaser, and the Purchaser shall purchase and accept from the Seller or its Affiliates, as applicable, all of the right, title and interests of the Seller and its Affiliates in and to the following assets, free and clear of all Liens (other than
the Permitted Liens and the Assumed Liabilities), excluding the Excluded Assets (collectively, the “Transferred Assets”): 
 (a) all rights of the Sellers and/or its Affiliates under the Contracts set forth on Schedule 2.1(a) of the Seller Disclosure Schedule (the “Assumed Contracts”); 
 (b) all rights of the Sellers and/or its Affiliates under the Contracts set forth on Schedule 2.1(b) of the Seller Disclosure Schedule, solely to the
extent relating to the Products (“Assumed Contract Rights”); 
 (c) all Transferred Marketing Materials; 
 (d) all Transferred Books and Records; 
 (e)
all Transferred Patent Rights; 
 (f) all Transferred Product Registrations; 
 (g) all Transferred Trademarks; 
 (h) all
Transferred Know-How; 
 (i) all Transferred Domain Names; and 
 (j) any other assets set forth on Schedule 2.1(j) of the Seller Disclosure Schedule. 
 2.2. Excluded
Assets. Notwithstanding anything to the contrary contained herein, including Section 2.1 above, the Seller and its Affiliates shall retain all of its right, title and interest in and to, and shall not Transfer to the Purchaser, the assets
of the Seller set forth below (collectively, the “Excluded Assets”): 
 (a) any accounts receivable of the Seller relating to
Products sold prior to the Effective Time or any other products; 
 (b) any cash, cash equivalents, investments or bank accounts; 

(c) any insurance policies and any rights under such insurance policies; 
  

 15 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 (d) except for claims arising out of the Diprivan Litigation, any claims and causes of action arising
out of the Transferred Assets existing as of the Effective Time (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or become
due), including escrows relating to the foregoing; 
 (e) any inventory, equipment, real property interests, fixture and other tangible
personal property not expressly set forth in Section 2.1 as a Transferred Asset other than the Diprivan inventory transferred under the Initial Firm Order as defined in and pursuant to the terms of the Manufacturing and Supply Agreements; and

 (f) all other tangible and intangible assets of the Seller not explicitly included in the Transferred Assets. 
 2.3. Assumption of Liabilities. Subject to the terms and conditions of this Agreement, the Manufacturing and Supply Agreements, the Cooperation
Agreement and the Safety Monitoring Agreement, at and as of the Effective Time, the Purchaser shall assume only those Liabilities of the Seller which are specifically enumerated below (collectively, the “Assumed Liabilities”):

 (a) all Liabilities of the Seller or any of its Affiliates under the Assumed Contracts, but only to the extent such Liabilities arise from
any event, circumstance or Condition occurring in a period (or portion thereof) on or after the Effective Time; 
 (b) all Liabilities of the
Sellers and/or its Affiliates under the Contracts set forth on Schedule 2.1 (b) of the Seller Disclosure Schedule, solely to the extent relating to the Products, but only to the extent such Liabilities arise from any event, circumstance or
Condition occurring in a period (or portion thereof) on or after the Effective Time (“Assumed Contract Obligations”); 
 (c)
all Liabilities to the FDA arising directly out of the Transferred Assets on or after the Effective Time; 
 (d) all Liabilities with respect
to the Diprivan Litigation; and 
 (e) all other Liabilities arising directly out of (i) the Licensed Assets in the Territory, but only
to the extent such Liabilities arise on or after the Effective Time or (ii) the ownership or control of any of the Transferred Assets, but only to the extent such Liabilities arise on or after the Effective Time, including the obligation to
conduct any Phase IV trials related to the Products. 
 2.4. Excluded Liabilities. Except for the Assumed Liabilities, the Purchaser
shall not assume any, and shall have no liability, responsibility or obligation whatsoever, at any time, for (and the Seller and its Affiliates shall retain and pay, perform and discharge when due) any and all Liabilities of the Seller or any of its
Affiliates arising prior to, as of or after the Effective 
  

 16 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 Time (the “Excluded Liabilities”). Without limiting, but in all cases subject to, the foregoing and
the terms and conditions of the Manufacturing and Supply Agreements, the Cooperation Agreement and the Safety Monitoring Agreement the following shall be Excluded Liabilities: 
 (a) any Liability arising from or relating to the acquisition or use of any Transferred Assets or Licensed Assets by the Seller or any of its Affiliates
prior to the Effective Time, except to the extent that any such Liabilities arise from the Purchaser’s obligation to assume the conduct of the Phase IV trials for the Products pending as of the date of this Agreement; 
 (b) all accounts payable and other Liabilities of the Seller and its Affiliates for materials and services with respect to the manufacture of the
Products prior to the Effective Time; 
 (c) any Liability, arising from or relating to the operation by the Seller or any of its Affiliates
of any activity not related to the Transferred Assets or Licensed Assets prior to or after the Effective Time, or the occupancy, use or operation by the Seller or any of its Affiliates of any properties, assets, other than the Transferred Assets and
the Licensed Assets, at any time prior to or after the Effective Time; except as set forth in the Manufacturing and Supply Agreements, the Cooperation Agreement and the Safety Monitoring Agreement; 
 (d) any Liability of the Seller to any of its Affiliates, except for Assumed Contracts and Assumed Contract Obligations to the extent they constitute
Assumed Liabilities; 
 (e) any Liability for any violation of or failure to satisfy, any Law by the Seller or any of its Affiliates;

 (f) any Liability based on tortious or criminal conduct by the Seller or any of its Affiliates; 
 (g) all Liabilities, if any, of the Seller or any of its Affiliates under Assumed Contracts that are not validly assigned to the Purchaser (other than
through the fault or negligence of the Purchaser), or which according to the terms of any Assumed Contract, relate to periods prior to the Effective Time or are to be paid, performed or ratified in full prior to the Effective Time; 
 (h) all indebtedness of the Seller or any of its Affiliates for money owed or borrowed; 
 (i) all Liabilities for Product Liability Claims and Recalls arising out of Products sold prior to the Effective Time; 
 (j) all Liabilities for returns, rebates, and chargebacks relating to, or arising as a result of, any sale of any of the Products prior to the Effective
Time, except as otherwise agreed by the parties under the Managed Market Transition Plan; 
 (k) all Liabilities arising from the Excluded
Assets; 
  

 17 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 (l) all Liabilities with respect to the Seller’s employees or former employees, or their
dependents; 
 (m) all Tax Liabilities of the Seller, its Affiliates or any member of any affiliated group of which the Seller or any of its
Affiliates is, or has been, a member (including, without limitation, any Tax Liability relating to any of the Transferred Assets or the ownership, control, lease or license of any of the Transferred Assets, other than any such Tax Liability of the
Purchaser that relates to a Post-Closing Tax Period); and 
 (n) all Liabilities with respect to any Action pending or known to be threatened
against the Seller or any of its Affiliates as of the Effective Time, except for any Liabilities arising as a result of the Diprivan Litigation. 
 2.5. Shared Technology; Technology Transfer, Etc. 
 (a) The Seller hereby grants to the Purchaser, as of the Effective Time,
a royalty-free, irrevocable, perpetual, exclusive license (i) to use and access all of Seller’s Books and Records and (ii) under Seller’s interest in the Licensed Patent Rights, Licensed Know-How, Licensed Intellectual Property
and Licensed Domain Names (collectively, the “Licensed Assets”), solely in connection with the formulating, manufacturing, packaging, labeling and storing of the Products or API for sale in the Territory and the marketing,
distributing and/or selling of the Products or API in the Territory; provided, however, that this license does not include the Marks or the Seller’s labels covered by Section 10.7 hereof. Seller hereby grants to Purchaser an exclusive
right of reference to (i) the Clinical Data and (ii) all DMFs related exclusively to the manufacture of Products for the Territory, in each case solely for the formulating, manufacturing, packaging, labeling and storing of the Products for
sale in the Territory and the marketing, distributing and/or selling of the Products in the Territory. The rights granted under this Section may be assigned by the Purchaser in whole or in part, without the Seller’s consent in writing; provided
that Purchaser promptly notifies Seller in writing, in no event later than thirty (30) days after any such assignment. Notwithstanding the foregoing or anything in this Agreement to the contrary, Seller shall retain or be granted by the
Purchaser, as applicable, all rights necessary (i) to manufacture Products or API in the Territory for sale outside of the Territory and (ii) to satisfy its obligations under the Manufacturing and Supply Agreements. 
 (b) At the request of the Purchaser, the Seller shall, and shall cause its Affiliates to, cooperate with the Purchaser and its Subsidiaries and take all
such commercially reasonable actions to support the transfer from time to time during the term of the Manufacturing and Supply Agreement of the Know-How for any Product or API to the Purchaser or its Subsidiaries or any third-party designated by the
Purchaser. Without limiting the foregoing, the Seller agrees that it and/or one or more of its Affiliates, as applicable, shall, to the extent and with respect to those Products and APIs reasonably requested by the Purchaser: 
 (i) convey and disclose to the Purchaser, one or more of its Subsidiaries, or any third-party designated by the Purchaser, as applicable, as soon as
reasonably practicable after receiving a request from the Purchaser, all Know-How necessary or appropriate 
  

 18 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 for the manufacturing, testing, assembling, storing, packaging, labeling and supplying the Products or APIs at
Alternative Facilities in compliance with all applicable cGMPs and Laws such that the Purchaser shall be prepared to utilize the Alternative Facilities to supply the Products for sale in the Territory immediately following the termination of the
Manufacturing and Supply Agreements; 
 (ii) at the Purchaser’s expense, assist the Purchaser or its Subsidiaries or any third-party
designated by the Purchaser to obtain the governmental permits and approvals necessary or appropriate for the manufacturing, testing, assembling, storing, packaging, labeling and supplying the Products or APIs at Alternative Facilities in compliance
with all applicable cGMPs and Laws such that the Purchaser shall be prepared to utilize the Alternative Facilities to supply the Products for sale in the Territory immediately following the termination of the Manufacturing and Supply Agreements; and

 (iii) at mutually convenient times upon reasonable prior notice, arrange from time to time for (A) personnel designated by the
Purchaser to visit the facilities of the Seller and its Affiliates at which the Products and APIs are manufactured, tested, assembled, stored, packaged, labeled and to observe and record the Know-How relating thereto and (B) at the
Purchaser’s expense, qualified employees of the Seller and/or its Affiliates selected in consultation with the Purchaser to visit the Purchaser’s facilities or Alternative Facility to assist with the development of manufacturing, testing,
assembling, storing, packaging and labeling capability for the Products and APIs such that the Purchaser shall be prepared to utilize the Alternative Facilities to supply the Products for sale in the Territory immediately following the termination
of the Manufacturing and Supply Agreements. 
 (c) The Seller shall promptly notify the Purchaser of any Manufacturing Improvement developed,
acquired or licensed by or on behalf of the Seller or any of its Affiliates in any jurisdiction after the date of this Agreement until the fifth anniversary of the Closing Date. Such notification shall describe the Manufacturing Improvement in
reasonable detail and set forth specifications, including the raw materials and components needed, for the manufacture, testing, assembling, storing, packaging and labeling such Manufacturing Improvement. 
 2.6. Consideration; Payment. Subject to Section 2.7 below, the consideration for the Seller’s Transfer to the Purchaser of the
Transferred Assets, the exclusive license from the Seller to the Purchase of the Licensed Assets and the Seller’s performance of its obligations under this Agreement and the other Acquisition Documents, shall equal Three Hundred Fifty Million
Dollars ($350,000,000) (the “Purchase Price”), payable as follows: 
 (i) At the Closing, the Purchaser shall pay to the
Seller and/or to an Affiliate of Seller as designated by the Seller by wire transfer of immediately available funds to an account or accounts identified in writing by the Seller to the Purchaser at least two days prior to the Closing Date amounts in
aggregate equal to Two Hundred Seventy Five Million Dollars ($275,000,000). 
 (ii) On the earlier of (i) the first anniversary of the
Closing Date or (ii) the occurrence of a Change of Control of the Purchaser, the Purchaser shall pay to the Seller 
  

 19 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 and/or to an Affiliate of Seller as designated by the Seller by wire transfer of immediately available funds to an
account or accounts identified in writing by the Seller to the Purchaser at least two days prior to the Closing Date amounts in aggregate equal to Seventy Five Million Dollars ($75,000,000), as such amount may be adjusted pursuant to the terms of
this Agreement (such amount as adjusted, the “Deferred Payment”). Purchaser shall in no circumstances have the right to set off against the Deferred Payment. 
 (iii) The Seller, the Purchaser and their Affiliates agree that, for U.S. federal income tax purposes, the Deferred Payment, if paid to Seller, shall be
composed of an interest element and a principal element, the interest element being computed on the principal element at an interest rate equal to the applicable federal rate per annum computed from the Closing Date to the date such Deferred Payment
is paid to the Seller, and neither the Seller, the Purchaser, nor any of their Affiliates shall take any position on any Tax Return inconsistent therewith. 
 2.7. Adjustments to Purchase Price. 
 (a) The Seller shall be responsible for reimbursing any costs
reasonably incurred by the Purchaser directly as a result of any Phase IV clinical trials for the Naropin Products. The Purchaser shall keep the Seller informed of the status of discussions with the FDA regarding such trials and shall reasonably
consider any comments or suggestions of Seller. Prior to commencing any such Phase IV clinical trials, the Purchaser shall submit any protocol agreed to by the FDA to the Seller for its approval (such approval not to be unreasonably withheld).

 (b) The Purchaser shall use its reasonable best efforts to work in good faith with the FDA to determine the requirement of and necessity
for Phase IV clinical trials for the Diprivan Products. The Purchaser shall keep the Seller informed of the status of such discussions with the FDA and shall reasonably consider any comments or suggestions made by the Seller in regard to such
discussions with the FDA. The Purchaser shall submit the protocol agreed to by the FDA for any Phase IV trials for the Diprivan Products to the Seller for its approval (such approval not to be unreasonably withheld). The Seller agrees to reimburse
the Purchaser for any costs reasonably incurred by the Purchaser directly as a result of such trials. In the event that the FDA notifies the Purchaser in writing that no further Phase IV clinical trials are required with respect to the Diprivan
Products and the amount required to be reimbursed by Seller under this Section is less than [***], the Seller shall pay to the Purchaser [***] promptly following the receipt of such written notice or upon completion of such trials when the final
costs of any such trials can be determined. If the Seller becomes obligated to pay to the Purchaser the [***] pursuant to this Section at a time before the Deferred Payment is made by the Purchaser under this Agreement, then in lieu of the Purchaser
being obligated to make such [***] payment, the amount of the Deferred Payment shall be reduced by [***], and the Deferred Payment shall otherwise be paid by the Purchaser when due in accordance with the terms of this Agreement. 
 (c) The Purchaser shall send monthly invoices to the Seller setting forth in reasonable detail the reimbursable costs, which invoices shall, if requested
by Seller, be accompanied by supporting documentation of the expenses incurred by the Purchaser that are subject to reimbursement. The Seller shall pay any such invoice promptly, but in no event more 
  

 20 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 than thirty (30) days following receipt. For the avoidance of doubt, all payments made by Seller to Purchaser
pursuant to Section 2.7(a) and (b) shall be deemed adjustments to the Purchase Price. 
 2.8. Allocation of the
Consideration. The Purchase Price and Assumed Liabilities shall be allocated among the Transferred Assets and between the Seller and its Affiliates, AstraZeneca AB and AstraZeneca Pharmaceuticals LP, as set forth on the allocation schedule
prepared by the Seller and agreed to by the Purchaser and attached hereto as Exhibit C (the “Allocation”). The Seller, the Purchaser and their Affiliates agree to report, act and file all Tax Returns (including, but not
limited to Internal Revenue Service Form 8594) in all respects and for all purposes consistent with the Allocation, and neither the Seller nor the Purchaser shall take any position for Tax purposes (whether in audits, Tax Returns or otherwise) that
is inconsistent with such Allocation unless, and then only to the extent, required by a final determination. 
 2.9. Transfer Taxes.
Notwithstanding anything herein to the contrary, the Seller and its Affiliates shall be solely liable for, and shall pay when due, any transfer, gains, documentary, sales, use, registration, stamp, value-added or other similar Taxes
(“Transfer Taxes”) payable by reason of the transactions contemplated under this Agreement, and the Seller or its Affiliates shall file, at their expense, all necessary Tax Returns and other documentation with respect to all
Transfer Taxes, provided, however, that if required by applicable Law, the Purchaser will, and will cause its Affiliates to, join in the execution of any such Tax Returns and other documentation. The Seller and the Purchaser agree to
reasonably cooperate with each other to claim any applicable exemption from, or reduction of, any applicable Transfer Taxes. 
 2.10.
Withholding Tax. The Purchaser shall be entitled to deduct and withhold from any consideration otherwise payable to Seller pursuant to this Agreement such amounts as may be required to be deducted and withheld with respect to the making of
such payment under applicable Tax Law. To the extent that amounts are so withheld, such withheld amounts shall be treated as having been paid to the Seller for all purposes of this Agreement. The Seller and the Purchaser agree to reasonably
cooperate with each other, including by completing or filing documents required under the provisions of any applicable income tax treaty or applicable Law, to claim any exemption from, or reduction of, any such Taxes. 
 ARTICLE III 
 THE CLOSING

 3.1. Time and Place of Closing. The Closing shall take place at 10:00 a.m., New York time, on the Closing Date at the offices
of Fried, Frank, Harris, Shriver & Jacobson LLP, One New York Plaza, New York, New York 10004, or at such other time or place as may be mutually agreed upon by the parties hereto. The Closing, the Transfer of the Transferred Assets, the
effectiveness of the documents, agreements, opinions and certificates delivered in accordance with this Agreement, and the consummation of the transactions contemplated hereby shall be deemed to occur at the Effective Time. 
  

 21 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 3.2. Payment of Consideration; Deliveries. At the Closing, the Purchaser shall pay the Closing
Payment and the parties hereto shall deliver such other documents as are required by Article VIII and Article IX hereof. 
 3.3.
Restricted Assets. Notwithstanding anything to the contrary contained in this Agreement, if the Transfer to Purchaser of any Transferred Asset is (i) prohibited by any applicable Law or (ii) would require any authorizations,
approvals, consents or waivers from a third Person and such authorizations, approvals, consents or waivers shall not have been obtained prior to the Closing Date (each, a “Restricted Asset”), this Agreement shall not require or
constitute a Transfer of such Restricted Asset unless and until such authorization, approval, consent or waiver is obtained and Seller shall have no liability for failure to Transfer such Restricted Assets on the Closing Date. The Seller shall, and
shall cause its Affiliates to use commercially reasonable efforts, at the Seller’s expense, to obtain the authorizations, approvals, consents or waivers from a third Person in order to Transfer to Purchaser all Restricted Assets and, pending
such Transfer, to ensure that Purchaser shall receive the benefits, including economic benefits, of such Restricted Assets accruing after the Effective Time and to the extent that Seller receives such benefits, Purchaser shall assume and discharge
the liabilities accruing after the Effective Time corresponding to such economic benefits received. Once authorization, approval or waiver of or consent for the Transfer of any Restricted Asset is obtained, the Seller shall, or shall cause its
Affiliates to Transfer such Restricted Asset to the Purchaser at no additional cost to the Purchaser. 
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF THE SELLER 
 The Seller hereby represents and warrants to the Purchaser as of the date hereof and as of the Closing Date as follows: 
 4.1.
Organization and Good Standing. The Seller is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation. Each of the Subsidiaries of Seller is a corporation or other entity duly
organized, validly existing and in good standing under the laws of its jurisdiction of incorporation, except where the failure to be duly organized, validly existing and in good standing has not had and could not have, individually or in the
aggregate, a Seller Material Adverse Effect. Each of the Seller and its Subsidiaries has the corporate power and authority to own, operate and lease its properties and assets and to conduct its business as they are now being owned, operated, leased
and conducted, except as has not had and could not have, individually or in the aggregate, a Seller Material Adverse Effect. Each of the Seller and its Subsidiaries is duly qualified or licensed to do business as a foreign corporation and is in good
standing as a foreign corporation in every jurisdiction in which the conduct of the business or ownership of its properties requires it to be so licensed or qualified or in good standing except where the failure to be so qualified or licensed or in
good standing has not had and could not have, individually or in the aggregate, a Seller Material Adverse Effect. 
  

 22 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 4.2. Power and Authority. The Seller has the corporate power and authority to execute and
deliver this Agreement and each other Acquisition Document to which it is a party, perform its obligations hereunder and thereunder and consummate the transactions contemplated hereby and thereby. The execution and delivery by the Seller of this
Agreement and each other Acquisition Document, the performance by it of its obligations hereunder and thereunder and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate
actions on the part of the Seller and its Subsidiaries. This Agreement and each other Acquisition Document to which the Seller or any of its Subsidiaries is a party constitutes (or will constitute upon the execution thereof) the legal, valid and
binding obligation of the Seller or its Subsidiary, as applicable, enforceable against the Seller or its Subsidiary in accordance with its terms, except as the same may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws
now or hereafter in effect relating to creditors’ rights generally, by general principles of equity or by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 4.3. No Violation. Except as may be required under the HSR Act or as set forth on Schedule 4.3 hereto, neither the execution and delivery by the
Seller or any of its Subsidiaries, as applicable, of this Agreement or any other Acquisition Document to which the Seller or its Subsidiary is a party, the performance by the Seller or its Subsidiary, as applicable, of its obligations hereunder or
thereunder, nor the consummation by the Seller of the transactions contemplated hereby or thereby, will (i) contravene any provision of the articles and memorandum of association of the Seller, (ii) contravene any provision of the
certificate of incorporation, bylaws or similar organizational documents of any Subsidiary of the Seller; (iii) with or without the giving of notice or the lapse of time or both, violate, be in conflict with, constitute a default under, permit
the termination of, cause the acceleration of the maturity of any debt or obligation of the Seller relating to the Transferred Assets under, require the consent of any other party to, constitute a breach of, create a Liability or loss of a benefit
under, or result in the creation or imposition of any Lien upon any of the Transferred Assets under, any Assumed Contract, other than such violations, conflicts, defaults, terminations, accelerations, breaches, Liabilities or loss of benefits which
has not had and could not have, individually or in the aggregate, a Seller Material Adverse Effect; (iv) violate or conflict with, any Law or any judgment, decree or order of any Governmental Authority to which the Seller is subject or by which
the Seller or any of its assets or properties is bound other than such violations, conflicts or noncompliance with such requirements which could not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect;
or (v) result in the loss of any Approval, other than such losses which have not had, and could not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect. 
 4.4. Financial Information. The Seller has previously delivered to the Purchaser the financial data, reports and statements relating to the sales
by the Seller and its Subsidiaries of the Products in the Territory and the cost and expenses of the Seller and its Subsidiaries incurred by the Seller and its Subsidiaries in connection with the manufacturing, developing, packaging, labeling,
marketing, distributing and selling the Products in the Territory (collectively, the “Financial Data”). Except as may otherwise be indicated therein or on Schedule 4.4, the Financial Data (i) were compiled from the books and
records of the Seller and its Subsidiaries regularly maintained by management and (ii) are true, correct and complete in all material respects. 
  

 23 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 4.5. Contracts. 
 (a) The Assumed Contracts and Assumed Contract Rights purchased hereunder include all Contracts necessary for the use and ownership of the Transferred Assets, as currently used, or owned by Seller in the Territory,
the formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory as currently formulated, manufactured, packaged, labeled and stored by Seller in the Territory and the marketing, distribution or sale of the
Products in the Territory as currently marketed, distributed or sold by Seller in the Territory, except as could not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect. 
 (b) The Seller and its Affiliates, and to the knowledge of the Seller, each other party thereto has performed and is performing its obligations under,
and is not in material default (and would not by the lapse of time or the giving of notice or both be in material default) under, or in breach or violation of, nor has the Seller received notice of any asserted claim of a material default by the
Seller under, or a material breach or violation by the Seller of, any of the Assumed Contracts to which it is a party, except as has not had, and could not reasonably be expected to have, a Seller Material Adverse Effect. 
 4.6. Intellectual Property. Schedule 1.1(d), 1.1(h) and 1.1(j) contains a true and complete list of all Transferred Patents, Transferred
Trademarks and Licensed Patents registered in the United States and included in the Intellectual Property and all pending applications therefor (the “Scheduled IP”). Except as set forth on Schedule 4.6(b), to the knowledge of the
Seller, the Seller owns or has a right or license to use the Intellectual Property, including the Scheduled IP, free and clear of all Liens (other than the Assumed Liabilities and Permitted Liens). The Seller has no knowledge of any claims that are
currently being asserted or threatened, by any Person involving or questioning the Seller’s ownership of any of the Scheduled IP. Except as set forth on Schedule 4.6(c), to the knowledge of the Seller, the use of the Scheduled IP by the Seller
or any of its Subsidiaries or, to the extent contemplated hereby or by the other Acquisition Documents, the Purchaser does not infringe the rights of any Person nor, to the knowledge of the Seller, is any infringing use currently ongoing by any
Person. Neither the Seller nor any of its Subsidiaries is obligated to pay any royalties or fees with respect to the Intellectual Property. Schedule 4.6(a) contains a true and complete list of all licenses of or rights to the Scheduled IP granted to
the Seller or any of its Subsidiaries by others or to others by the Seller or any of its Subsidiaries. To the knowledge of Seller, the Transferred Intellectual Property purchased hereunder and the Licensed Intellectual Property licensed hereunder
includes all Intellectual Property necessary for the use and ownership of the Transferred Assets, as currently operated, used, or owned by Seller in the Territory, the formulating, manufacturing, packaging, labeling and storing of the Products for
sale in the Territory as currently formulated, manufactured, packaged, labeled and stored by Seller in the Territory and the marketing, distribution or sale of the Products in the Territory as currently marketed, distributed or sold by Seller in the
Territory, except as could not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect. 
  

 24 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 4.7. Actions. 
 (a) Except as set forth on Schedule 4.7(a), there is no Action pending against and naming the Seller or any of its Affiliates that (i) questions or challenges the validity of this Agreement or the other
Acquisition Documents or any action taken or proposed to be taken by the Seller or any of its Affiliates pursuant hereto or thereto or in connection with the transactions contemplated hereby or thereby or (ii) relates to any of the Products,
the Transferred Assets, the Licensed Assets or the Assumed Liabilities that if adversely determined, could reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect. 
 (b) To the knowledge of the Seller, there is no Action threatened against the Seller or any of its Affiliates, that (i) questions or challenges the
validity of this Agreement or the other Acquisition Documents or any action taken or proposed to be taken by the Seller or any of its Affiliates pursuant hereto or thereto or in connection with the transactions contemplated hereby or thereby or
(ii) relates to any of the Products, the Transferred Assets, the Licensed Assets or the Assumed Liabilities that if adversely determined, could reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect.

 (c) To the knowledge of the Seller, there is no outstanding judgment, order, decree, writ, award, stipulation, injunction of any
Governmental Authority against the Seller or any of its Affiliates or any of their respective assets or businesses, which, if adversely determined, could reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse
Effect. 
 4.8. Taxes. 
 (a) All sales, use, payroll withholding, unemployment compensation and similar Taxes, and any other Taxes the nonpayment of which would result in a Tax Lien on any Transferred Asset have been paid or will be paid when due, or adequate
deposits have been made with the appropriate taxing authorities with respect thereto, and there are no Liens for Taxes on any Transferred Asset. 
 (b) The Seller has not received any written notice from any Governmental Authority of any pending examination or any proposed Tax deficiency, addition, assessment, demand for payment or adjustment the nonpayment of which could result in a
Tax Lien on any Transferred Asset. 
 4.9. Title to Property. Except as set forth on Schedule 4.9, the Seller or one of its Affiliates
has good title to or otherwise owns all of the Transferred Assets (whether personal, mixed, tangible or intangible), to the Seller’s knowledge, free and clear of all Liens (other than the Assumed Liabilities and Permitted Liens), and upon
Transfer of the Transferred Assets pursuant hereto, the Purchaser will have good title to and ownership of all of the Transferred Assets (whether personal, mixed, tangible and intangible), to the Seller’s knowledge, free and clear of all Liens
(other than the Assumed Liabilities and Permitted Liens and Liens arising solely as a result of actions taken by the Purchaser or any of its Subsidiaries). 
  

 25 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 4.10. Approvals. Except as set forth on Schedule 4.10, and except for any filings under the
HSR Act, no Approval of any Governmental Authority or any Third Party is required to be made, obtained or given by or with respect to the Seller in connection with the execution or delivery by the Seller or any of its Affiliates, as applicable, of
this Agreement and the other Acquisition Documents, the performance by Seller or any of its Affiliates of its obligations hereunder or thereunder or the consummation by Seller or any of its Affiliates of the transactions contemplated hereby or
thereby including without limitation the Transfer of the Transferred Assets (other than the Restricted Assets) and the license of the Licensed Assets to the Purchaser, except where the failure to make, obtain or give such Approval could not
reasonably be expected to have a Seller Material Adverse Effect. 
 4.11. Regulatory Compliance. 
 (a) Except where the failure to comply has not had and would not reasonably be expected to have a Seller Material Adverse Effect, the Products are in
compliance with all applicable statutes, rules and regulations of the FDA and the DEA, and, to the extent applicable, corresponding Foreign Regulatory Authorities. 
 (b) The Seller has all FDA, DEA, and Foreign Regulatory Authority permits, approvals, registrations, licenses, or the like necessary to manufacture and sell the Products in the Territory. All such permits, approvals,
registrations, licenses or the like are in full force and effect. Seller has submitted all reports and taken all other steps reasonably necessary to continue in effect such permits, approvals, registrations, licenses or the like, except where the
failure to do so has not had and would not reasonably be expected to have a Seller Material Adverse Effect. 
 (c) Seller does not have
knowledge of any pending, outstanding, or threatened enforcement action concerning the Products by the FDA, DEA, or, to the extent applicable, any Foreign Regulatory Authority, that would reasonably be expected to have, individually, or in the
aggregate a Seller Material Adverse Effect. 
 (d) To the knowledge of the Seller, the Seller has not made any false statements in, or
omissions from, the applications, approvals, reports and other submissions to the FDA, DEA, or, to the extent applicable, Foreign Regulatory Authorities, or in or from any other documents prepared or maintained to comply with the requirements of the
FDA, DEA, or Foreign Regulatory Authorities, as applicable, relating to the manufacturer or marketing of the Products in the Territory that would reasonably be expected to have a Seller Material Adverse Effect. 
 (e) Neither the Seller nor, to the knowledge of the Seller, any officer, key employee, or agent of the Seller has been convicted of any crime or engaged
in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. Section 335(a). 
 4.12. Sufficiency of
Assets. The Transferred Assets and the Licensed Assets, together with the Purchaser’s rights under this Agreement and the other Acquisition Documents, include all assets Controlled by Seller necessary for formulating, manufacturing,
packaging, labeling and 
  

 26 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 storing of the Products for sale in the Territory as currently formulated, manufactured, packaged, labeled and stored
by Seller in the Territory and marketing, distribution or sale of the Products in the Territory as currently marketed, distributed or sold by Seller in the Territory, except as could not reasonably be expected to have, individually or in the
aggregate, a Seller Material Adverse Effect 
 4.13. Principal Customers and Suppliers. Schedule 4.13 contains a true and complete
list of the top 6 purchasers of each Product Family by purchases during the 12 months ended December 31, 2005 and the aggregate dollar amount of their purchase of such Product Families from January 1, 2006 to the most recent fiscal month
end of the Seller prior to the date hereof. 
 4.14. All Transferred Assets As Is. Except for the representations and warranties
expressly set forth in this Article IV or in any other Acquisition Document, (i) Seller disclaims all other representations and warranties, whether express or implied, oral or written, including any information furnished by Seller with regard
to the Transferred Assets, Licensed Assets, Products or business of the Seller as currently conducted in the Territory, including the future profitability of the Transferred Assets, Licensed Assets, the Products or the business, warranties of
merchantability, fitness for a particular purpose and noninfringement of intellectual property rights, (ii) Purchaser agrees that Seller shall not have any liability to Purchaser resulting from the distribution of or the failure to distribute
any information to the Purchaser, and (iii) all Transferred Assets are being Transferred from Seller to Purchaser and all Licensed Assets are being licensed from Seller to Purchaser on an “AS IS WHERE IS” basis. 
 ARTICLE V 
 REPRESENTATIONS AND
WARRANTIES OF THE PURCHASER 
 The Purchaser hereby represents and warrants to the Seller as of the date hereof and as of the Closing
Date as follows: 
 5.1. Organization and Good Standing. The Purchaser is a corporation duly organized, validly existing and in good
standing under the laws of its jurisdiction of incorporation. The Purchaser has the corporate power and authority to own, operate and lease its properties and assets and to conduct its business as they are now being owned, operated, leased and
conducted, except as has not had and could not have, individually or in the aggregate, a Purchaser Material Adverse Effect. Purchaser is duly qualified or licensed to do business as a foreign corporation, and is in good standing as a foreign
corporation, in every jurisdiction in which the nature of the property owned, leased or operated by it or the nature of the business conducted by it requires it to be so licensed, qualified or in good standing, except where the failure to be so
qualified or licensed or in good standing has not had and could not have, individually or in the aggregate, a Purchaser Material Adverse Effect. 
 5.2. Power and Authority. The Purchaser has the corporate power and authority to execute and deliver this Agreement and each other Acquisition Document to which it is a party, perform its obligations hereunder and thereunder and
consummate the transactions contemplated 
  

 27 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 hereby and thereby. The execution and delivery by the Purchaser of this Agreement and each other Acquisition Document
to which the Purchaser is a party, the performance by the Purchaser of its obligations hereunder and thereunder and the consummation by the Purchaser of the transactions contemplated hereby and thereby have been duly authorized by all necessary
corporate actions on the part of the Purchaser. This Agreement and each other Acquisition Document constitutes (or will constitute upon the execution thereof) the legal, valid and binding obligation of the Purchaser, enforceable against it in
accordance with its terms, except as the same may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws now or hereafter in effect relating to creditors’ rights generally and subject to general principles of equity.

 5.3. No Violation. Except as may be required under the HSR Act or as set forth on Schedule 5.3, neither the execution and delivery
by the Purchaser of this Agreement or any of the other Acquisition Documents to which it is a party, the performance by it of its obligations hereunder or thereunder, nor the consummation by it of the transactions contemplated hereby or thereby,
will (i) contravene any provision of the certificate of incorporation or by-laws of the Purchaser; (ii) with or without the giving of notice or the lapse of time or both, violate, be in conflict with, constitute a default under, permit the
termination of, cause the acceleration of the maturity of any debt or obligation of the Purchaser under, require the consent of any other party to, constitute a breach of, create a Liability or loss of a benefit under, or result in the creation or
imposition of any Lien upon any of the properties or assets of the Purchaser under, any contract to which it is a party or by which it or any of its assets or properties are bound, other than such violations, conflicts, defaults, terminations,
accelerations, breaches, Liabilities or loss of benefits which could not reasonably be expected to have, individually or in the aggregate, a Purchaser Material Adverse Effect; (iii) violate, conflict with or require any Approval under, any Law
or any judgment, decree or order of any Governmental Authority to which the Purchaser is subject or by which it or any of its assets or properties are bound, other than such violations, conflicts or noncompliance with such requirements which could
not reasonably be expected to have, individually or in the aggregate, a Purchaser Material Adverse Effect; or (iv) result in the loss of any Approval, other than such losses which could not reasonably be expected to have, individually or in the
aggregate, a Purchaser Material Adverse Effect. 
 5.4. Actions. 
 (a) There is no Action pending, or, to the knowledge of the Purchaser, threatened, against the Purchaser or any of its Subsidiaries which
(a) questions or challenges the validity of this Agreement or any of the other Acquisition Documents or any action taken or proposed to be taken by the Purchaser or any of its Subsidiaries pursuant hereto or thereto or in connection with the
transactions contemplated hereby or thereby or (b) if adversely determined, could reasonably be expected to have, individually or in the aggregate, a Purchaser Material Adverse Effect. 
 (b) There is no outstanding judgment, order, decree, writ, award, stipulation, injunction of any Governmental Authority against or affecting the
Purchaser or any of its Subsidiaries or any of their respective assets or businesses, which, if adversely determined, has had or could reasonably be expected to have, individually or in the aggregate, a Purchaser Material Adverse Effect. 

 

 28 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 5.5. Approvals. Except as may be required under the HSR Act or as set forth on Schedule 5.5,
no Approval of any Governmental Authority or other Person is required to be made, obtained or given by or with respect to the Purchaser in connection with the execution or delivery by it of this Agreement and the other Acquisition Documents, the
performance by it of its obligations hereunder or thereunder or the consummation it of the transactions contemplated hereby or thereby, except where the failure to make, obtain or give such Approvals could not have, individually or in the aggregate,
a Purchaser Material Adverse Effect. 
 5.6. Financing. Assuming that the Purchaser receives the signing fee contemplated under the
Co-Promotion Agreement, the Purchaser will have available sources of funds sufficient to pay the Purchase Price and related expenses of the transactions contemplated by the Acquisition Documents. 
 ARTICLE VI 
 CERTAIN OBLIGATIONS OF
THE SELLER PRIOR TO THE CLOSING 
 The Seller hereby covenants that, except as otherwise consented to in writing by the Purchaser or as
otherwise contemplated by this Agreement, from and after the date hereof until the Closing or termination of this Agreement: 
 6.1.
Conduct of Business. Except as provided herein, Seller shall cause its Affiliates to: (i) conduct the formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory and the marketing, distribution
or sale of the Products in the Territory in the ordinary course and substantially in the same manner as such process previously has been conducted; (ii) not institute any material new methods of purchase, sale, lease, management, accounting or
operation that will vary substantially from the methods used by the Seller and its Affiliates in the ordinary course of business with respect to formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory
and the marketing, distribution or sale of the Products in the Territory, in each case as of the date of this Agreement; (iii) maintain its Transferred Books and Records in the ordinary course of business in a manner consistent with its past
practices; (iv) maintain its properties and assets (to the extent they are material to the Transferred Assets) in the same condition as they are on the date hereof, except for reasonable wear and tear arising in the ordinary course of business;
(v) use commercially reasonable efforts to preserve the relationships of the Seller and its Affiliates with customers, and other Persons having business dealings with them relating to the marketing, distribution or sale of the Products in the
Territory; (vi) comply in all material respects with all Laws applicable to the Transferred Assets and the formulating, manufacturing, packaging, labeling and storing of the Products and the marketing, distribution or sale of the Products in
the Territory; and (vii) timely comply in all material respects with all of its obligations under the Assumed Contracts or any Contract containing any Assumed Contract Right or an Assumed Contract Liability. 
  

 29 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 6.2. Restricted Activities and Transactions. Notwithstanding Section 6.1 hereof and
except as provided in this Agreement, the Seller shall not, and shall not permit any of its Affiliates to, engage, or agree to engage, in any one or more of the following activities or transactions without the prior written consent of the Purchaser,
which consent shall not be unreasonably withheld: (i) enter into or consummate any “acquisition proposal” (as used in Section 6.4 below); (ii) cause to arise or permit to exist any Lien (other than Permitted Liens) upon any
of the Transferred Assets unless such Lien is discharged prior to the Closing Date; (iii) enter into or amend in any material respect any Assumed Contract or any Contract containing any Assumed Contract Right or Assumed Contract Liability;
(iv) destroy any Books or Records maintained in connection with the Transferred Assets, the Assumed Liabilities, the formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory and the marketing,
distribution or sale of the Products in the Territory; (v) settle any Action if such settlement imposes any continuing Liability or non-monetary obligation on or with respect to any of the Transferred Assets, the Assumed Liabilities, the
formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory or the marketing, distribution or sale of the Products in the Territory; (vi) initiate any litigation, suit, mediation or arbitration relating
to the Transferred Assets, the Assumed Liabilities, the formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory or the marketing, distribution or sale of the Products in the Territory; (vii) or
commit or cause to be committed any Condition that will result in a material breach or violation or (with or without notice or passage of time, or both) constitute a material default under any Assumed Contract or any Contract containing any Assumed
Contract Right or Assumed Contract Liability; (viii) enter into or become bound by any contract or commitment relating to the Transferred Assets, the Assumed Liabilities, the formulating, manufacturing, packaging, labeling and storing of the
Products for sale in the Territory or the marketing, distribution or sale of the Products in the Territory, other than contracts or commitments that are entered into in the ordinary course of the business in a manner consistent with past practices;
(ix) cancel, compromise, release or waive any right of material value of the Seller or any of its Affiliates related to the Transferred Assets, other than in the ordinary course of business and in a manner consistent with past practice;
(x) except as required by Law, make or change any Tax election affecting the Transferred Assets, the Assumed Liabilities, the formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory or the
marketing, distribution or sale of the Products in the Territory, or take any position with respect to the Transferred Assets, the Assumed Liabilities, the formulating, manufacturing, packaging, labeling and storing of the Products for sale in the
Territory or the marketing, distribution or sale of the Products in the Territory on any Tax Return filed after the date of this Agreement, in each case that is inconsistent with the elections made or positions taken in preparing or filing similar
Tax Returns in prior taxable periods; (xi) changes the Specifications for any Product in any material respect, or (xii) take any action or omit to take any action that would knowingly cause the representations and warranties of the Seller
contained in Article IV hereof to be untrue or inaccurate in any material respect. 
 6.3. Cooperation. The Seller shall, and shall
cause its Affiliates to, use their commercially reasonable efforts to cause the transactions contemplated by this Agreement to be consummated, including, without limitation, (i) obtaining, making and causing to become effective all Approvals of
such Governmental Authorities and other Persons as may be necessary or reasonably requested by the Purchaser in order to consummate the transactions contemplated 
  

 30 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 by this Agreement, including, without limitation, under or pursuant to the HSR Act and all Contracts (including the
Restricted Assets) with respect to which the obtaining, making and causing to become effective of an Approval is necessary or advisable, and (ii) giving prompt notice to the Purchaser of (A) any notice of, or other communication relating
to, any default, or any event which, with the giving of notice or the lapse of time or both, would become a default, under any Contract relating to the Transferred Assets, including any Assumed Contract or any Contract containing any Assumed
Contract Right or Assumed Contract Liability, and (B) any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the execution and delivery of this Agreement or the other
Acquisition Documents or the consummation of the transactions contemplated hereby or thereby. The Seller shall use its commercially reasonable efforts to bring about the satisfaction of the conditions precedent to the Closing set forth in Article
VIII hereof. 
 6.4. No Solicitation of Transaction. The Seller shall not, nor shall the Seller permit any of its Affiliates or
Representatives to, initiate, solicit or encourage (including by way of furnishing information), any inquiries or the making of any proposal which constitutes, or may reasonably be expected to lead to, any acquisition proposal (as defined below), or
agree to or endorse any acquisition proposal, or participate in any such discussions or negotiations (other than to express the Seller’s lack of interest in such discussions or negotiations), or provide third parties with any information,
relating to any such inquiry or acquisition proposal. As used herein, “acquisition proposal” shall mean any proposal or offer to acquire from the Seller or its Affiliates in any manner all or any portion of the Transferred Assets or the
business involving the formulating, manufacturing, packaging, labeling or storing of the Products for sale in the Territory or the marketing, distribution or sale of the Products in the Territory. 
 6.5. Access. The Seller shall, and shall cause its Affiliates to, afford the Purchaser and its Representatives reasonable access, upon reasonable
prior notice and at such scheduled times and places during normal business hours as shall be reasonably approved by the Seller (but without any interference with the business operations of the Seller), for reasonable business purposes, to all the
Books and Records, and the properties, facilities and employees of the Seller and its Affiliates relating to the Transferred Assets and the business involving the formulating, manufacturing, packaging, labeling or storing of the Products for sale in
the Territory or the marketing, distribution or sale of the Products in the Territory. Purchaser shall reimburse Seller for any out-of-pocket costs incurred by Seller or its Affiliates in complying with this Section and, to the extent such
compliance requires in excess of ten (10) hours of Seller or Subsidiary personnel time, in the aggregate, in any week, Seller shall be entitled to invoice Purchaser, and Purchaser shall pay, for the reasonable value of such time. 
 6.6. Confidentiality. The Seller shall comply with and not otherwise be in breach of the Amended and Restated Confidentiality and Non-Disclosure
Agreement by and between the Seller and the Purchaser dated as of January 1, 2006. 
 6.7. HSR Notification. The Seller shall as
promptly as reasonably practicable, make all filings that are required of it under the HSR Act. The Seller shall timely and promptly provide any additional information or documentation requested by the FTC, the Antitrust Division or any other
Governmental Authority with similar jurisdiction in connection with a 
  

 31 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 second request or otherwise. The Seller shall furnish to the Purchaser and its counsel such necessary information and
assistance as the Purchaser may reasonably request in connection with its and its Affiliates’ preparation of necessary filings or submissions to the FTC, the Antitrust Division or any such other Governmental Authority. The Seller shall supply
the Purchaser with copies of all correspondence, filings or communications (or memoranda setting forth the substance thereof) between the Seller or its counsel, and the FTC, the Antitrust Division or any such other Governmental Authority with
respect to this Agreement, the Acquisition Documents and the transactions contemplated hereby and thereby. 
 6.8. Financials.

 (a) The Seller shall promptly notify the Purchaser in writing regarding any material change occurring to the financial data, reports and
statements previously made available to Purchaser and relating to the sales by the Seller and its Affiliates of the Products in the Territory and the cost and expenses of the Seller and its Affiliates incurred by the Seller and its Affiliates in
connection with the manufacturing, developing, packaging, labeling, marketing, distributing and selling the Products in the Territory, each as could reasonably be likely to have, individually or in the aggregate, a Seller Material Adverse Effect.

 (b) The Seller shall deliver to the Purchaser promptly upon the completion of each month following the date of this Agreement, and prior
to the Closing Date, a copy of the total monthly net sales recognized by the Seller in connection with the sale of Products by the Seller in the Territory. 
 6.9. Cooperation Regarding Financial Statements. In the event that the Purchaser is required to include any audited financial statements with respect to the Transferred Assets, Assumed Liabilities or
Seller’s business of formulating manufacturing, developing, packaging, labeling, and sharing the Products for sale in the Territory and marketing, distributing and selling the Products in the Territory in any filing to be made by the Purchaser
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, with respect to or as a result of the transactions contemplated by this Agreement, the Seller shall cooperate on a commercially reasonable basis with
the Purchaser at the Purchaser’s sole expense to create and have audited such financial statements in accordance with GAAP. 
 6.10.
Certain Notifications. 
 (a) The Seller has prepared the Schedules in good faith and to the Seller’s knowledge, the Schedules
represent all required disclosures as of the date of this Agreement. Notwithstanding the foregoing, from the date of this Agreement until the date two weeks following the date of this Agreement, the Seller shall have the right to add to, amend
and/or correct the Schedules based upon any additional information that becomes available to the Seller and such additional disclosures shall be deemed to amend and supplement the relevant Schedules for all purposes of this Agreement as if so
amended immediately prior to the date of this Agreement. In the event that Purchaser believes that any such additional disclosure made by the Seller prior to the date two weeks following the date of this Agreement results in a material and
quantifiable change to the valuation of the Transferred Assets, the Seller and the Purchaser agree 
  

 32 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 to negotiate in good faith to determine if such additional disclosure results in a material and quantifiable change
to the valuation of the Transferred Assets. If the parties so agree, the Purchase Price shall be adjusted to account for such valuation change. 
 (b) At all times from the date hereof to the Closing Date, the Seller shall deliver to the Purchaser written notice of the occurrence of any Condition arising following the date two weeks following the date of this Agreement that will or
may result in the failure to satisfy any of the conditions specified in Article VIII or Article IX hereof. In the event that Purchaser believes that any such Condition results in a material and quantifiable change to the valuation of the Transferred
Assets, the Seller and the Purchaser agree to negotiate in good faith to determine if such additional Condition results in a material and quantifiable change to the valuation of the Transferred Assets. If the parties so agree, the Purchase Price
shall be adjusted to account for such valuation change. If after such negotiation (whether or not the Purchase Price has been adjusted pursuant to the preceding sentence), the Purchaser consummates the Closing, each such disclosed breach of, or
inaccuracy in, the Seller’s representations and warranties shall be deemed waived by the Purchaser and shall not be a source of Damages for which the Seller provides indemnification pursuant to Section 11.2(b). 
 6.11. Distribution Arrangements. Promptly following the date of this Agreement and prior to the Closing, the parties agree to explore possible
distribution arrangements and negotiate in good faith regarding the provision by the Seller of transitional distribution services to the Purchaser with respect to the distribution of some or all of the Products in the Territory on terms and
conditions mutually agreed to by the parties. 
 6.12. Tax Matters. (i) The Seller will be responsible for the preparation and
filing of all Tax Returns that include or relate to (A) the operations of the Seller’s business of formulating, manufacturing, developing, packaging, marketing, distributing and selling the Products in the Territory or (B) the
ownership of the Transferred Assets, that are due on or before the Closing Date. The Seller will timely file all such Tax Returns and timely make all payments required to be made with respect to any such Tax Returns. Any Tax Returns prepared and
filed by the Seller or any of its Affiliates pursuant to this Section 6.1 shall, unless otherwise required by Law, be prepared on a basis consistent with the past practices of the Seller. 
 (ii) The Purchaser will be responsible for the preparation and filing of all Tax Returns that include the Transferred Assets and the marketing,
distributing and selling the Products in the Territory and that are due after the Closing Date (other than for Taxes which will be included in the consolidated, unitary, or combined Tax Returns of the Seller or any of its Affiliates). The Purchaser
will timely file all such Tax Returns and timely make all payments required to be made with respect to any such Tax Return; provided, however, that the Seller will reimburse the Purchaser concurrently therewith to the extent any such payments made
by the Purchaser relate to the ownership of the Transferred Assets or the operation of the Seller’s business of formulating, manufacturing, developing, packaging, marketing, distributing and selling the Products in the Territory during a
Pre-Closing Tax Period. 
  

 33 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE VII 
 CERTAIN OBLIGATIONS OF THE PURCHASER PRIOR TO THE CLOSING 
 The Purchaser hereby covenants that,
except as otherwise consented to in writing by the Seller, from and after the date hereof until the Closing: 
 7.1. Cooperation. The
Purchaser shall use its commercially reasonable efforts to cause the transactions contemplated by this Agreement to be consummated, including, without limitation, (i) obtaining, making and causing to become effective all Approvals of such
Governmental Authorities and other Persons as may be necessary or reasonably requested by the Seller in order to consummate the transactions contemplated by this Agreement, including, without limitation, under or pursuant to the HSR Act and in
connection with obtaining Approvals with respect to the Contracts, including the Restricted Assets, and (ii) giving prompt notice to the Seller of any notice or other communication from any Person alleging that the consent of such Person is or
may be required in connection with the execution and delivery of this Agreement or the other Acquisition Documents or the consummation of the transactions contemplated hereby. The Purchaser shall use its commercially reasonable efforts to bring
about the satisfaction of the conditions precedent to Closing set forth in Article IX hereof. In addition, the Purchaser shall not intentionally take any action or omit to take any action that would cause the representations and warranties of the
Purchaser contained in Article V hereof to be untrue or inaccurate in any material respects. 
 7.2. HSR Notification. The Purchaser
shall as promptly as reasonably practicable make all filings that are required of it or any of its Affiliates under the HSR Act. The Purchaser shall timely and promptly provide any additional information or documentation requested by the FTC, the
Antitrust Division or any other Governmental Authority with similar jurisdiction in connection with a second request or otherwise. The Purchaser shall furnish to the Seller and its counsel such necessary information and assistance as the Seller may
reasonably request in connection with its preparation of necessary filings or submissions to the FTC, the Antitrust Division or any such other Governmental Authority. The Purchaser shall supply the Seller with copies of all correspondence, filings
or communications (or memoranda setting forth the substance thereof) between the Purchaser or its counsel, and the FTC, the Antitrust Division or any such other Governmental Authority with respect to this Agreement or the Acquisition Documents and
the transactions contemplated hereby and thereby. 
 7.3. Insurance. From and after the Closing, Purchaser shall procure and maintain,
at its sole expense, insurance policies covering the risks associated with the marketing, sale and distribution of the Products in the Territory, which policies shall be of such character and in such amounts as are customarily maintained by entities
engaged in such activities with respect to products similar to the Products. Purchaser shall, at Seller’s request, provide evidence of such insurance reasonably satisfactory to Seller. 
 7.4. Confidentiality. The Purchaser shall comply with and not otherwise be in breach of the Amended and Restated Confidentiality and
Non-Disclosure Agreement by and between the Seller and the Purchaser dated as of January 1, 2006. 
  

 34 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 7.5. Certain Notifications. At all times from the date hereof to the Closing Date, the
Purchaser shall promptly notify the Seller in writing of the occurrence of any Condition that will or may result in the failure to satisfy any of the conditions specified in Article VIII or Article IX hereof. 
 ARTICLE VIII 
 CONDITIONS PRECEDENT
TO THE OBLIGATIONS OF THE PURCHASER 
 The obligation of the Purchaser to consummate the transactions contemplated by this Agreement
shall be subject to the satisfaction, at the Closing, of each of the following conditions, unless waived (subject to Law) by the Purchaser, in its sole and absolute discretion, at or prior to the Closing: 
 8.1. Representations and Warranties True. All representations and warranties of the Seller, any of its Subsidiaries or Affiliates contained in this
Agreement or any Acquisition Document shall be true and correct (without giving effect to any materiality, Seller Material Adverse Effect or similar qualifier contained therein) as of the date of this Agreement and as of the Closing Date as though
given on and as of such date (or, with respect to such representations and warranties which expressly speak as of an earlier date, as of the earlier date as of which such representations and warranties speak), except for failures of such
representations and warranties to be so true and correct (without giving effect to any materiality, Seller Material Adverse Effect or similar qualifier contained therein) that have not had and could not reasonably be expected to have, individually
or in the aggregate, a Seller Material Adverse Effect, and Purchaser shall have received a certificate to such effect dated the Closing Date and executed by a duly authorized officer of the Seller. 
 8.2. Performance. The Seller and its Affiliates shall have performed and complied in all material respects with all agreements, covenants,
obligations and conditions required by this Agreement or any of the other Acquisition Documents to be performed or complied with by the Seller and/or its Affiliates at or prior to the Closing, and Purchaser shall have received a certificate to such
effect dated the Closing Date and executed by a duly authorized officer of the Seller. 
 8.3. No Material Adverse Change. No changes
or events that have had or could reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect, shall have occurred since the date of this Agreement, and Purchaser shall have received a certificate to such effect
dated the Closing Date and executed by a duly authorized officer of the Seller. 
 8.4. Approvals and Designated Contracts. All
Approvals set forth on Schedule 8.4(a) shall have been obtained or made on terms reasonably satisfactory to the Purchaser and shall be in full force and effect. 
  

 35 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 8.5. Deliveries. The Seller and/or its Subsidiary shall have tendered to the Purchaser, at or
prior to the Closing, and against the deliveries referred to in Section 9.4, the following: 
 (a) an executed counterpart signature page
to the Assignment and Assumption Agreement; 
 (b) the executed Bill of Sale; 
 (c) an executed counterpart signature page to the Manufacturing and Supply Agreements; 
 (d) an executed counterpart signature page to the Safety Monitoring Agreement; 
 (e) an executed counterpart signature page to the IP Assignment Agreement; 
 (f) an executed counterpart signature page to the Domain Name Assignment Agreement; 
 (g) an executed
counterpart signature page to the Cooperation Agreement; and 
 (h) such other bills of sale, assignments and instruments of transfer as
contemplated by this Agreement in form and substance reasonably satisfactory to the Purchaser, as shall be effective to vest in the Purchaser all the Seller’s rights, title and interests in, to and under the Transferred Assets. 
 8.6. Absence of Litigation. There shall be no outstanding court order, injunction or Action pending or, to the knowledge of the Seller or the
Purchaser, threatened before any court or other Governmental Authority which seeks to (i) invalidate or set aside, in whole or in part, this Agreement or any of the other Acquisition Documents or (ii) restrain, prohibit, invalidate or set
aside, in whole or in part, the consummation of the transactions contemplated hereby and thereby. 
 8.7. HSR Act. Any waiting period
under the HSR Act shall have expired or been terminated earlier. 
 8.8. Co-Promotion Signing Fee. The Seller shall have paid the
Purchaser the signing fee required to be paid pursuant to the Co-Promotion Agreement. 
 ARTICLE IX 
 CONDITIONS PRECEDENT TO THE OBLIGATIONS OF THE SELLER 
 The obligation of the Seller to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction, at the Closing, of each of the following conditions, 
  

 36 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 unless waived (subject to Law) by the Seller, in its sole and absolute discretion, at or prior to the Closing:

 9.1. Representations and Warranties True. All representations and warranties of the Purchaser contained in this Agreement or any
Acquisition Document shall be true and correct (without giving effect to any materiality, Purchaser Material Adverse Effect or similar qualifier contained therein) as of the date of this Agreement and as of the Closing Date as though given on and as
of such date (or, with respect to such representations and warranties which expressly speak as of an earlier date, as of the earlier date as of which such representations and warranties speak), except for failures of such representations and
warranties to be so true and correct (without giving effect to any materiality, Purchaser Material Adverse Effect or similar qualifier contained therein) that have not had and could not reasonably be expected to have, individually or in the
aggregate, a Purchaser Material Adverse Effect, and the Seller shall have received a certificate to such effect dated the Closing Date and executed by a duly authorized officer of the Purchaser. 
 9.2. Performance. The Purchaser shall have performed and complied in all material respects with all agreements, covenants, obligations and
conditions required by this Agreement and the other Acquisition Documents to be performed or complied with by it at or prior to the Closing, and the Seller shall have received a certificate to such effect dated the Closing Date and executed by a
duly authorized officer of the Purchaser. 
 9.3. Approvals. All Approvals set forth on Schedule 9.3 shall have been obtained on terms
reasonably satisfactory to the Seller and shall be in full force and effect. 
 9.4. Deliveries. The Purchaser shall have tendered to
the Seller; at or prior to the Closing, and against the deliveries referred to in Section 8.5 hereof, the following: 
 (a) in accordance
with Section 2.6 hereof, the Purchase Price; 
 (b) an executed counterpart signature page to the Assignment and Assumption Agreement;

 (c) an executed counterpart signature page to the Manufacturing and Supply Agreements; 
 (d) an executed counterpart signature page to the Safety Monitoring Agreement; 
 (e) an executed counterpart signature page to the IP Assignment Agreement; 
 (f) an executed counterpart signature page to the Domain Name Assignment Agreement; 
 (g) an executed
counterpart signature page to the Cooperation Agreement; and 
  

 37 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 (h) such other agreements, undertakings and instruments of assumption, in form and substance
reasonably satisfactory to the Seller, as shall be effective to cause the Assumed Liabilities to be binding on the Purchaser and such other documents or certificates as shall be reasonably requested by the Seller or its counsel. 
 9.5. Absence of Litigation. There shall be no court order, injunction or Action pending or, to the knowledge of the Purchaser or the Seller,
threatened before any court or other Governmental Authority which seeks to (i) invalidate or set aside, in whole or in part, this Agreement or any of the other Acquisition Documents or (ii) restrain, prohibit, invalidate or set aside, in
whole or in part, the consummation of the transactions contemplated hereby or thereby. 
 9.6. HSR Act. Any waiting period under the
HSR Act shall have expired or been terminated earlier. 
 ARTICLE X 
 CERTAIN ADDITIONAL COVENANTS AND AGREEMENTS 
 10.1. Books and Records;
Access. 
 (a) Promptly but in no event more than 30 days after the Closing Date, Representatives of the Purchaser shall review all Books
and Records in the Seller’s or its Affiliates’ control with the aim of the Seller and its Affiliates delivering to the custody of the Purchaser all Transferred Books and Records. The parties acknowledge and agree that (i) to the
extent any such Books and Records contain information that relates to any product other than the Products or to any business of Seller and its Affiliates other than the research, development, formulating manufacturing, packaging, labeling and
storing of Products or API or the distribution, marketing, sale, promotion, importation or use of Products or API in the Territory, such Books and Records shall be redacted to delete such information and (ii) to the extent that any such
Transferred Books and Records contain information necessary to permit Seller to perform its obligations under the Manufacturing and Supply Agreements or to make any required filings and respond to any potential inquiry or audit with any Government
Authority, including the FDA and the IRS, Seller may retain copies of such Transferred Books and Records until (i) the Manufacturing and Supply Agreements have expired or terminated and (ii) Seller has satisfied all requirements with
relevant Government Authorities. Seller shall have the right to retain copies of such Transferred Books and Records, as applicable, in connection with the performance of its obligations under the Manufacturing and Supply Agreements and as required
to satisfy its ongoing obligations with relevant Government Authorities; provided that Purchaser shall be provided with access during normal business hours, upon reasonable notice and in a manner that does not unreasonably interfere with the conduct
of Seller’s business to any and all such temporarily retained Transferred Books and Records. 
 (b) For a period of at least five years
following the termination of the Manufacturing and Supply Agreement, unless otherwise consented to in writing by the Purchaser, the Seller shall not, and shall not permit any of its Affiliates to, destroy or otherwise 
  

 38 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 dispose of any original Books and Records in their possession relating to the Transferred Assets, the Assumed
Liabilities, the formulating, manufacturing, packaging, labeling and storing of the Products or the marketing, distribution and/or sale of the Products in the Territory without first offering to surrender such Books and Records to the Purchaser, and
shall maintain such Books and Records in accordance with past practice and in a location consistent with the historical location of such Books and Records. For a period of five years following the termination of the Manufacturing and Supply
Agreement, upon reasonable prior notice, the Seller shall, and shall cause it Affiliates to, afford the Purchaser or its Representatives reasonable access during normal business hours, in a manner that does not unreasonably interfere with the
conduct of Seller’s business, to examine and copy such Books and Records and other materials, including regulatory files, in the possession of the Seller or any of its Affiliates related to the Transferred Assets, the Assumed Liabilities, the
formulating, manufacturing, packaging, labeling and storing of the Products and/or the marketing, distribution or sale of the Products in the Territory, as well as to the employees of the Seller or its Affiliates with knowledge of the relevant
matter, for any commercially reasonable purpose related to (i) the formulating, manufacturing, packaging, labeling and storing of the Products for sale in the Territory or the marketing, distribution and/or sale of the Products in the
Territory, (ii) any Assumed Liability, (iii) any Product Liability Claim or Recall arising out of the sale of Products in the Territory, or (iv) any other matter subject to indemnification or reimbursement pursuant to this Agreement;
provided, however, that to the extent any such Books and Records contain information that relates to any product other than the Products or to any matter other than the foregoing, such Books and Records shall be redacted to delete such information;
provided, however, that to the extent any such Books and Records contain information that relates to any product other than the Products or to any matter other than the foregoing, such Books and Records shall be redacted to delete such information;
provided, further that Purchaser shall reimburse Seller for any out-of-pocket costs incurred by Seller and its Affiliates in complying with this Section 10, and to the extent such compliance requires in excess of ten (10) hours of Seller
or Subsidiary personnel time, in the aggregate, in any week, Seller shall be entitled to invoice Purchaser, and Purchaser shall pay, for the reasonable value of such time. 
 10.2. Specific Performance; Injunctive Relief. Each of the parties hereto acknowledges, understands and agrees that any breach or threatened
breach by it or any of its Affiliates of any of their respective obligations hereunder or under the Acquisition Documents will cause irreparable injury to the other party and that money damages will not provide an adequate remedy therefor.
Accordingly, in the event of any such breach or threatened breach, the non-breaching party shall have the right and remedy (in addition to any other rights or remedies available at law or in equity) to have the provisions of such Sections
specifically enforced by, and to seek injunctive relief and other equitable remedies in, any court having competent jurisdiction. 
 10.3.
Further Assurances. In addition to the actions, documents and instruments specifically required to be taken or delivered by this Agreement or the other Acquisition Documents, whether on or before or from time to time after the Effective Time,
and without further consideration, each party hereto shall take such other actions, and execute and deliver such other documents and instruments, as the other party hereto or its counsel may reasonably request and at the expense of the requesting
party in order to effectuate and perfect the 
  

 39 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 transactions contemplated by this Agreement and the other Acquisition Documents, including without limitation such
actions as may be necessary to Transfer to the Purchaser and to place the Purchaser in possession or control of, all of the rights, properties, assets and businesses intended to be sold, transferred, conveyed, assigned and delivered hereunder.

 10.4. Accounts Receivable, Etc. 
 (a) If, following the Effective Time, the Purchaser receives any payments with respect to accounts receivable relating to Products sold prior to the Effective Time, or any other payments, that under the terms of this
Agreement are allocated to the Seller, the Purchaser shall remit any such payments to the Seller within 30 days of any such receipt. 
 (b)
If, following the Effective Time, the Seller or any of its Affiliates receives any payments, credits or other assets that under the terms of this Agreement are allocated to the Purchaser, the Seller shall, or shall cause its Affiliates to, as
applicable, remit any such payments to the Purchaser within 60 days of any such receipt. 
 10.5. Post-Closing Confidentiality.

 (a) The Seller shall keep confidential, and not use or disclose to others, any proprietary information of or obtained from, the Purchaser
or its Representatives, or Transferred to the Purchaser pursuant to this Agreement or the Acquisition Agreements, to the extent that such proprietary information is not or does not become readily available to the public other than as a result of
disclosure by the Purchaser or its Representatives or is not required to be disclosed by applicable Law or Governmental Authority. 
 (b) The
Purchaser shall keep confidential, and not use or disclose to others, any proprietary information of or obtained from, the Seller or its Representatives (other than with respect to the Transferred Assets and the Assumed Liabilities), to the extent
that such proprietary information is not or does not become readily available to the public other than as a result of disclosure by the Seller or its Representatives or is not required to be disclosed by applicable Law or Governmental Authority.

 10.6. The Seller’s Labels. 
 (a) The Seller hereby grants to the Purchaser effective as of the Effective Time, a royalty-free right and exclusive license to use the corporate names, service mark or logo of the Seller (the
“Marks”) in the same manner as they are used as of the Effective Time in the Territory on all labeling for the Products, in the ordinary course of business as follows: the Purchaser may label Products for sale in the Territory using
the Marks until the first anniversary of the Closing Date and may sell Products in the Territory bearing the Marks that were manufactured by the Seller prior to the Effective Time or by the Purchaser prior to the first anniversary of the Closing
Date, until the earlier of (i) the expiration date of such Products and (ii) the first anniversary of the Closing Date. Thereafter, subject to the Seller having converted to the use of the Purchaser’s own labels under the
Manufacturing and Supply Agreement, the Purchaser shall have no rights to utilize the Marks or to sell any Products bearing such Marks. 
  

 40 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) In the sale of Products bearing the Seller’s labels or the Marks, the Purchaser shall comply
with all applicable Laws including; without limitation, those requiring that the Purchaser disclose that it is the manufacturer of those Products that it manufactures. 
 (c) Within forty-five (45) days following the Closing Date, appropriate Purchaser Representatives shall meet with appropriate Seller Representatives to discuss and agree upon a plan pursuant to which the
Purchaser shall be obligated to, as promptly as possible but in no event later than the first anniversary of the Closing Date, obtain its own NDC Numbers, convert to its own labeling, eliminate its use of Seller’s labels and Marks and remove
the Seller’s NDC numbers from all Product labeling. 
 10.7. Returns, Rebates and Chargebacks. The Seller and the Purchaser agree
to comply with the Managed Market Transition Plan to be agreed upon prior to the Closing Date, with respect to the transition of certain rights and obligations of the parties with respect to the managed market contracts described therein (the
“Managed Market Contracts”). Pursuant to the Managed Market Transition Plan, the Seller shall be responsible for all Damages arising out of or related to returns, rebates or chargebacks (whether by agreement, government mandate or
otherwise) for Products sold prior to the Effective Time and the Purchaser shall be responsible for all Damages arising out of or related to returns, rebates or chargebacks (whether by agreement, government mandate or otherwise) for Products sold
after to the Effective Time, unless the parties otherwise agree to account for the returns, rebates or chargebacks for Products in some other manner under such Managed Market Transition Plan. 
 10.8. Recalls. The Seller shall be responsible for all Damages (including, but without duplication, the reimbursement for returned Products)
arising out of or related to Recalls that arise from Products that were sold by the Seller prior to the Effective Time. With respect to Products sold after the Effective Time, the responsibility for Recalls shall be determined in accordance with the
Manufacturing and Supply Agreements. 
 10.9. Covenant Not to Compete. 
 (a) Subject to subsection (b) below, during the period from the Closing Date through [***] (the “Non-Competition Period”), the
Seller shall not, and shall cause its controlled Affiliates not to, directly or indirectly, (i) market, promote, distribute, sell or accept orders for the sale of any Competing Product in the Territory or (ii) assist or cooperate in any
material way with any other Person in connection with the marketing, Promotion, distribution selling or acceptance of orders for the sale of any Competing Product in the Territory. 
 (b) In the event that the Seller or any of its controlled Affiliates acquires a Competing Product during the Non-Competition Period as a result of a
merger or an acquisition by the Seller or its Affiliate of another Person (or substantially all of its assets), the Seller or such Affiliate may continue to market, promote, distribute, sell or accept orders for the sale of such Competing Product
for a period of [***] from the date of such acquisition. After the end of such [***] period the Seller or such Affiliate shall terminate all detailing, Promotional, marketing, distribution and sale activities relating to such Competing Product,
whether by divesting such 
  

 41 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 Competing Product or otherwise; provided that the Seller or such Affiliate shall not be required to terminate such
activities if the Non-Competition Period expires prior to the end of such [***] period. 
 (c) The Seller acknowledges that the temporal and
geographic limitations set forth in this Section are reasonable and necessary to protect the legitimate interests of the Purchaser and agrees not to contest such limitations in any proceeding. 
 (d) The Seller acknowledges and agrees that the Purchaser would not have entered into this Agreement in the absence of the restrictions set forth in
subsection (a), and that any breach or threatened breach of subsection (a) will result in irreparable injury to the Purchaser for which there will be no adequate remedy at law. In the event of a breach or threatened breach of subsection
(a) by the Seller, the Purchaser shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and shall be entitled to seek an equitable accounting
of all earnings, profits or other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which it may be entitled in law or equity. The Seller agrees to waive any requirement that the
Purchaser (i) post a bond or other security as a condition for obtaining any such relief and (ii) show irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing in
this subsection (d) is intended, or shall be construed, to limit the Purchaser’s rights to equitable relief or any other remedy for a breach of any provision of this Agreement. 
 10.10. Right of First Offer. The Seller agrees that it shall notify the Purchaser in writing at least thirty (30) days before the Seller
enters into any definitive agreement (or series of related agreements) granting any Person (other than any Affiliate of the Seller) the right to commercially sell, or to promote exclusively or together with the Seller or any of its Affiliates:

 (a) any of the [***] or any of the [***] in any Major Market Country; 
 (b) any combination of [***] in any country or combination of countries outside of the Territory if the contemplated transaction (or series of related
transactions) includes [***] accounting for at least [***] of the net sales of all [***] sold in the Seller Region in which such country or countries are located; 
 (c) any [***] or any [***] in any country or combination of countries outside of the Territory if the contemplated transaction (or series of related transactions) includes [***] or [***], as applicable, accounting for
at least [***] of the net sales of all [***] or the net sales of all [***], as applicable, sold in the Seller Region in which such country or countries are located; or 
 (d) all or substantially all of the [***] in any Major Market Country; 
 (any of the above such agreements being an
“Ex-Territory Agreement”). 
 Any such notice (an “Ex-Territory Notice”) shall identify the Product or
Products and the country or countries proposed to be subject to the Ex-Territory Agreement and shall set forth 
  

 42 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 proposed terms for an Ex-Territory Agreement between the Seller and the Purchaser with respect to such countries. The
Purchaser may notify the Seller of the Purchaser’s interest in negotiating an Ex-Territory Agreement with respect to the countries covered by the Ex-Territory Notice. In the event that the Purchaser delivers such notice (an
“Ex-Territory Response Notice”) to the Seller within ten (10) business days of its receipt of the Ex-Territory Notice, the Seller shall negotiate in good faith with the Purchaser proposed principal terms of an Ex-Territory
Agreement with respect to the Products and the countries covered in the Ex-Territory Notice during the thirty (30) day period after the Seller’s receipt of the Ex-Territory Response Notice. In the event that the Purchaser and the Seller
are unable to negotiate mutually acceptable principal terms of a Ex-Territory Agreement during such thirty (30) day period or the Purchaser fails to deliver a Ex-Territory Response Notice to the Seller within the required ten (10) business
day period, the Seller may, at any time during the one hundred eighty (180) day period after the conclusion of such ten (10) business day or thirty (30) day period, as applicable, subject to Section 10.12, enter into a
Ex-Territory Agreement with any Third Party covering the Product or Products and the country or countries subject to the Ex-Territory Notice on any terms so long as in the reasonable judgment of the Seller the transaction subject to the Ex-Territory
Agreement and all related transactions are no less favorable to the Seller than those last offered by the Purchaser as to such Ex-Territory Agreement. 
 10.11. Authorized Generic Status. The Seller hereby grants a right of first negotiation to the Purchaser as to all of the injectible products of the Seller or its Affiliates in the Territory for which patent
exclusivity will expire on the last patent covering any aspect of the composition, formulation or manufacture of such injectible product within ten years from the Effective Date, other than those injectible products of the Seller identified on
Exhibit B which shall be excluded from the provisions of this Section. Twelve months prior to the anticipated expiration of market exclusivity for each injectible product, the Parties shall negotiate in good faith an agreement detailing the
terms pursuant to which the Purchaser shall be appointed as the Seller’s exclusive authorized generic distributor for such injectible product in the Territory. In the event the Parties cannot agree upon the terms of each authorized generic
opportunity by the six month prior to each anticipated loss of exclusivity, the Seller may enter into an authorized generic agreement with any Third Party on any terms that the Seller believes in good faith are, based on all relevant factors, no
less favorable to the Seller than those last offered by the Purchaser as to such injectible product. Any authorized generic agreement between the Parties shall be subject to applicable Law. 
 10.12. Obligation to Cooperate Upon Assignment or Sale. If either the Seller or the Purchaser intends to sell intellectual property covering the
Products to a Third Party, both parties agree to cooperate in good faith with respect to the matters covered by the Safety Monitoring Agreement and Cooperation Agreement. 
  

 43 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 ARTICLE XI 
 SURVIVAL; INDEMNIFICATION 
 11.1. Survival. 
 (a) The representations and warranties of the parties hereto contained in this Agreement shall survive the execution and delivery of this Agreement, any
due diligence investigation made by any party hereto in respect of the transactions contemplated hereby and the Closing. The representations and warranties of the Purchaser and the Seller contained in this Agreement shall survive until eighteen
months following of the Closing Date. 
 (b) The covenants and agreements of the parties hereto contained in this Agreement and required to
be performed prior to the Closing Date shall survive the execution and delivery of this Agreement and the Closing until eighteen months following the Closing Date unless otherwise specifically stated with respect to a covenant or agreement or, if
earlier, until fully performed or fulfilled (unless noncompliance with such covenant or agreement is waived in writing by the parties hereto entitled to such performance), it being understood that the covenants and agreements by the Seller and the
Purchaser to be performed on or after the Closing Date, including those with respect to the Excluded Liabilities and Assumed Liabilities and, subject to Section 11.1(c) below, the parties’ indemnification obligations pursuant to this
Agreement, shall survive without limitation. 
 (c) No Action for indemnification pursuant to this Article XI alleging an inaccuracy in or a
breach of the representations, warranties, covenants and agreements contained in this Agreement may be brought after the expiration date thereof; provided, however, that if prior to such expiration date a party hereto has notified the
other party hereto in writing of a claim for indemnification hereunder based on a breach thereof (whether or not formal legal action shall have been commenced based upon such claim), such claim shall continue to be subject to indemnification in
accordance with this Article XI. 
 11.2. Indemnification by the Seller. Within the time periods specified in Section 11.1, and
subject to other provisions of this Article XI, from and after the Closing, the Seller and its successors and assigns shall jointly and severally indemnify and hold harmless and defend the Purchaser, and its Affiliates, successors and permitted
assigns, and the Representatives of each of them, from and against any and all Damages incurred thereby or caused thereto based on, arising out of or resulting from: 
 (a) any Excluded Liability; 
 (b) the inaccuracy in or a breach of a representation and warranty of the
Seller contained herein or in any Acquisition Agreement, which shall be determined without giving effect to a “Seller Material Adverse Effect” or “materiality” qualification or limitation (e.g., “in all material
respects”; “material”); 
 (c) the breach of any covenant or agreement of the Seller contained herein or in any other
Acquisition Agreement; and 
 (d) any Taxes required to be paid to a Governmental Authority which Taxes were required to be, but were not,
deducted and withheld from the Purchase Price. 
 11.3. Indemnification by the Purchaser. Within the time periods specified in
Section 11.1 and subject to the other provisions of this Article XI from and after the Closing, the 
  

 44 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 Purchaser and its successors and assigns shall indemnify and jointly and severally hold harmless and defend the
Seller, and its Affiliates, successors and permitted assigns, and the Representatives of each of them, from and against any and all Damages incurred thereby or caused thereto based on, arising out of or resulting from: 
 (a) any Assumed Liability; 
 (b) the
inaccuracy or the breach of a representation and warranty of the Purchaser contained herein or in any other Acquisition Agreement, which shall be determined without giving effect to a “Purchaser Material Adverse Effect” or
“materiality” qualification or limitation (e.g., “in all material respects”; “material”); 
 (c) breach of any
covenant or agreement of the Purchaser contained herein or in any other Acquisition Agreement. 
 11.4. Notice and Payment of Claims.

 (a) The Indemnified Party shall notify the Indemnifying Party promptly (but in no event more than 30 days) after becoming aware of, and
shall provide to the Indemnifying Party as soon as practicable thereafter any and all information and documentation in the possession or control of the Indemnified Party, necessary to support and verify, any Damages that the Indemnified Party shall
have determined have given rise to, or could reasonably be expected to give rise to, a claim for indemnification hereunder; provided, however, that the right of the Indemnified Party to indemnification shall be reduced in the event of
its failure to give timely notice only to the extent the Indemnifying Party is prejudiced thereby. 
 (b) Any Liability for indemnification
by the Indemnifying Party under this Article XI shall be paid by the Indemnifying Party on demand in U.S. dollars after such Liability shall have been finally determined. 
 11.5. Matters Involving Third Parties. 
 (a) If any third party shall commence a Third Party Action
against any Indemnified Party with respect to any matter which may give rise to a claim for indemnification against any Indemnifying Party under this Article XI, the Indemnified Party shall notify the Indemnifying Party thereof in writing as soon as
practicable, but in no event more than ten days after the Indemnified Party shall have been served with legal process or otherwise received notice of the commencement of such Action; provided, however, that the right of the Indemnified Party to
indemnification shall be reduced in the event of its failure to give timely notice only to the extent the Indemnifying Party is prejudiced thereby. 
 (b) The Indemnifying Party shall have the right to defend the Indemnified Party against the Third Party Action with counsel and other Representatives of its choice so long as (i) the Indemnifying Party shall notify the Indemnified
Party in writing (within the 10-day period after its receipt of notice of the Third Party Action) that it will indemnify the Indemnified Party from and against any Damages the Indemnified Party may suffer arising out of the Third Party Action; and
(ii) the Indemnifying Party diligently conducts the defense of the Third Party 
  

 45 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 Action in the reasonable opinion of the Indemnified Party. In the event the Indemnifying Party does not comply with
clauses (i) or (ii) of the preceding sentence, the Indemnified Party may defend against the Third Party Action preserving its rights to indemnification hereunder including, without limitation, for the cost of such defense. 
 (c) So long as the Indemnifying Party is diligently conducting the defense of the Third Party Action in accordance with Section 11.5(b) above,
(i) the Indemnified Party may retain separate co-counsel, at its sole cost and expense, and participate in the defense of the Third Party Action, (ii) the Indemnified Party shall not consent to the entry of any judgment or enter into any
settlement with respect to the Third Party Action without the prior written consent of the Indemnifying Party, which consent shal1 not be unreasonably withheld or delayed, (iii) the Indemnified Party shall fully cooperate within reason with the
Indemnifying Party’s defense of such Third Party Action including, without limitation, providing any and all required information and documents and access to Representatives of the Indemnified Party with knowledge of issues relevant to the
claim or litigation (any such activities required to discharge this obligation to cooperate shall be incurred at the sole expense of the Indemnified Party) and (iv) the Indemnifying Party shall not consent to the entry of any judgment or enter
into any settlement with respect to the Third Party Action without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. For the avoidance of doubt, it shall be reasonable for an Indemnified
Party or an Indemnifying Party hereunder, as applicable, to withhold or delay consent to the entry of any judgment or any settlement in connection with which an order, injunction or other equitable relief or relief for other than monetary damages
would be issued or would involve an admission of liability or wrongdoing by such Indemnified Party or Indemnifying Party, as applicable, or would be reasonably likely to materially adversely affect the properties or business of such party.

 (d) Anything contained in Section 11.5 to the contrary notwithstanding, an Indemnified Party shall be entitled to assume the defense
of any Third Party Action (and the Indemnifying Party shall be liable for the reasonable fees and expenses incurred by the Indemnified Party in defending such claim) if the Third Party Action seeks an order, injunction or other equitable relief or
relief for other than money damages against the Indemnified Party, which the Indemnified Party determines, after conferring with its counsel, cannot be separated from any related claim for money damages and which, if successful, would materially
adversely affect the properties or the business of the Indemnified Party; provided, however, if such equitable relief portion of such Third Party Action can be so separated from that for money damages, the Indemnifying Party shall be entitled to
assume the defense of the portion relating to money damages. 
 11.6. Limitation of Remedies. 
 (a) In no event shall the Indemnifying Party be liable for any Damages for a breach by such Indemnifying Party of its representations, warranties or
covenants hereunder unless and until the aggregate amount of all such Damages exceeds [***] (the “Threshold Loss Amount”), in which case Seller shall be liable for all such Damages in excess of [***]. 
  

 46 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 (b) In no event shall the Seller be liable for Damages (i) pursuant to a breach of its
representations and warranties in excess of [***] in the aggregate (the “Cap”) or (ii) pursuant to a breach of its obligations under [***] hereof in excess of [***]. In no event shall the Purchaser be liable for Damages
pursuant to a breach of the representations and warranties in excess of the Cap. 
 (c) The amount of any Damages under Section 11.2
shall be reduced by (i) the amount of any actual Tax benefits received by the Indemnified Party within three (3) years from the Closing Date that result from the Liability that gave rise to such indemnity and (ii) the amount of any
insurance proceeds paid to the Indemnified Party relating to such claim. 
 (d) The indemnification provided for in this Article XI shall be
the sole and exclusive remedy of the Purchaser and the Seller and in lieu of any other remedies that may be available to the Purchaser or the Seller pursuant to any statutory or common law with respect to any Damages of any kind or nature, incurred
indirectly or directly, resulting from or arising out of any breach of the Acquisition Agreements, including inaccuracies in or breaches of representations and warranties (but excluding any claims for actual fraud); provided, however, that Purchaser
and Seller may seek appropriate equitable relief in a court of proper jurisdiction. 
 (e) Notwithstanding anything to the contrary contained
herein, although a party may be entitled to make a claim for indemnification pursuant to more than one section of this Article XI, a party shall not be entitled to recover indemnification for the same claim under more than one section of this
Article XI. 
 ARTICLE XII 
 TERMINATION 
 12.1. Termination. This Agreement may be terminated at any time prior to the Closing: 
 (a) by the mutual written consent of the Purchaser and the Seller; 
 (b) by either the Purchaser or the Seller, upon at least ten days prior written notice, if there shall have been a material breach by the other party of any of the representations, warranties, covenants or other
obligations under this Agreement which shall not have been waived by the non-breaching party and which breach cannot be cured by the date set forth in Section 12.1(c) below so long as the terminating party is not in breach of this Agreement;

 (c) subject to Sections 12.1(d) below, by either the Purchaser or the Seller, provided such party is not in material breach of any of the
representations, warranties, covenants or other obligations under this Agreement which shall not have been waived by the non-breaching party, upon written notice, if the Closing shall not have occurred on or before July 31, 2006 for any reason;
and 
  

 47 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 (d) by either the Purchaser or the Seller if any Governmental Authority having competent jurisdiction
shall have issued an order, decree or ruling or taken any other action restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement or the other Acquisition Documents, and such order, decree, ruling or other action
shall have become final and non-appealable. 
 12.2. Effect of Termination. In the event of the termination of this Agreement pursuant
to Section 12.1 hereof, 
 (a) such termination shall be the sole remedy (except as set forth in Section 12.2(b) below) and, except
with respect to Section 6.6 (Confidentiality), Section 10.4 (Specific Performance; Injunctive Relief), Section 12.1 (Termination), Section 12.2 (Effect of Termination), Section 13.1 (Public Announcements), Section 13.3
(Fees and Expenses) and Section 13.8 (Entire Agreement) hereof, this Agreement shall forthwith become void. The non-breaching party may seek only those remedies available to it at law or equity. 
 (b) If the Seller shall default in its obligations to Transfer to the Purchaser the Transferred Assets in accordance with the terms hereof, and provided
that the Purchaser shall have performed all of its obligations hereunder and shall have been ready, willing and able to fulfill the conditions set forth in Article IX hereof, then the Purchaser shall be entitled to all of its rights and remedies at
law or in equity including, without limitation, specific performance of this Agreement. 
 ARTICLE XIII 
 MISCELLANEOUS 
 13.1. Public
Announcements. Except as required by applicable Law or any Governmental Authority with competent jurisdiction, prior to the Closing, neither party hereto, nor any of their respective Affiliates and Representatives, shall issue any press release
or make any public announcement or disclosure with respect to this Agreement or the transactions contemplated hereby without the prior written consent of the other party hereto, which consent shall not be unreasonably withheld or delayed. The Seller
and the Purchaser shall agree on the content of the press release announcing the execution of this Agreement and the consummation of the transactions contemplated hereby prior to any release. 
 13.2. Amendment; Waiver. Neither this Agreement, nor any of the terms or provisions hereof, may be amended, modified, supplemented or waived
except by a written instrument signed by all of the parties hereto (or, in the case of a waiver, by the party granting such waiver). No waiver of any of the terms or provisions of this Agreement shall be deemed to be or shall constitute a waiver of
any other term or provision hereof (whether or not similar), nor shall such waiver constitute a continuing waiver. No failure of a party hereto to insist upon strict compliance by another party hereto with any obligation, covenant, agreement or
condition contained in this Agreement shall operate as a waiver of, or estoppel with respect to, any subsequent or other failure. Whenever this Agreement requires or permits consent by or on behalf of a party hereto, such consent shall be given in a
manner consistent with the requirements for a waiver of compliance as set forth in this Section 13.2. 
  

 48 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 13.3. Fees and Expenses. Except as otherwise expressly provided in Sections 2.8 of this
Agreement, each of the parties hereto shall bear and pay all fees, costs and expenses incurred by it or any of its Affiliates in connection with the origin, preparation, negotiation, execution and delivery of this Agreement and the other Acquisition
Documents and the transactions contemplated hereby or thereby (whether or not such transactions are consummated), including, without limitation, any fees, expenses or commissions of any of its Representatives. 
 13.4. Notices. 
 (a) All notices,
requests, demands and other communications required or permitted under this Agreement shall be in writing and mailed or facsimiled or delivered by hand or courier service: 
  

	 	(i)	If to the Seller, to: 

 AstraZeneca UK
Limited 
 15 Stanhope Gate 
 London, W1K 1LN, England 
 Telephone No.: 011 44 20 7304 5000 
 Facsimile No.: 011 44 20 7304 5151 
 Attention: General Counsel 
 with a copy to: 
 Ropes & Gray LLP 
 One International Place 
 Boston, MA 02110-2624 
 Telephone No.: (617) 951-7000 
 Facsimile No.: (617) 951-7050 
 Attention: Marc Rubenstein, Esq. 
  

	 	(ii)	If to the Purchaser, to: 

 Abraxis
Bioscience, Inc. 
 11777 San Vicente Boulevard, #500 
 Los Angeles, CA 90049 
 Telephone No.: (310) 826-8505 
 Facsimile No.: (310) 826-8525 
  

 49 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 with a copy to: 
 Fried, Frank, Harris, Shriver & Jacobson LLP 
 One New York Plaza 
 New York, NY 10004 
 Telephone No.: (212) 859-8000 
 Facsimile No.: (212) 859-4000 
 Attention: Philip Richter, Esq. 
 (b) All notices and other communications required or permitted under this
Agreement which are addressed as provided in this Section 13.4 (i) if delivered personally against proper receipt or by confirmed facsimile transmission shall be effective upon delivery and (ii) if delivered (A) by certified or
registered mail with postage prepaid shall be effective five business days or (B) by Federal Express or similar courier service with courier fees paid by the sender, shall be effective two business days following the date when mailed or
couriered, as the case may be. Any party hereto may from time to time change its address for the purpose of notices to such party by a similar notice specifying a new address, but no such change shall be deemed to have been given until it is
actually received by the party sought to be charged with its contents. 
 13.5. Assignment. This Agreement and all of the terms and
provisions hereof shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, and neither this Agreement nor any of the rights, interests or obligations hereunder of the parties hereto
may be assigned by any of the parties hereto without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed; provided, that the Purchaser may, without the consent of the Seller and subject to
Section 10.12, assign all of its rights hereunder to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the generic pharmaceutical business of the Purchaser and may assign its
rights with respect to any Product or Products to any Person to which the right to market, promote or sell such Product is granted or transferred. Any assignment made in contravention of the terms of this Section 13.5 shall be void ab
initio. 
 13.6. Governing Law; Consent to Jurisdiction. 
 (a) This Agreement and the legal relations among the parties hereto shall be governed by and construed in accordance with the internal laws of the State
of New York, without giving effect to the conflicts of laws principles thereof. 
 (b) Each party to this Agreement hereby irrevocably
submits to the exclusive jurisdiction of any State or Federal Court sitting or located in the State of New York (a “New York Court”) in any Action arising out of or relating to this Agreement or the other Acquisition Documents
(except as otherwise provided for therein), except as expressly provided otherwise herein, and each such party hereby irrevocably agrees that all claims in respect of such Action shall be heard and determined in such New York Court. Each party, to
the extent permitted by applicable laws, hereby expressly waives any defense or objection to jurisdiction or venue based on the doctrine of Forum Non Conveniens, and stipulates that any New York Court shall have In 
  

 50 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 Personam jurisdiction and venue over such party for the purpose of litigating any dispute or controversy
between the parties arising out of or related to this Agreement or the other Acquisition Documents. In the event any party shall commence or maintain any Action arising out of or related to this Agreement in a forum other than a New York Court,
except as expressly provided otherwise herein, the other party shall be entitled to request the dismissal or stay of such Action, and each such party stipulates for itself that such Action shall be dismissed or stayed. To the extent that any party
to this Agreement has or hereafter may acquire any immunity from jurisdiction of any New York Court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise) with respect
to itself or its property, each such party hereby irrevocably waives such immunity. 
 (c) Each party irrevocably consents to the service of
process of any of the Delaware Courts in any such Action by any means permitted by the rules applicable in such Delaware Court including, if permissible, personal delivery of the copies thereof or by the mailing of the copies thereof by certified
mail, return receipt requested, postage prepaid, to it at its address specified in accordance with Section 13.4 above, such service to become effective upon the earlier of (i) the date ten calendar days after such mailing or (ii) any
earlier date permitted by applicable law. 
 13.7. Headings. The headings contained in this Agreement and the Schedules hereto are for
convenience of reference only and shall not constitute a part hereof or define, limit or otherwise affect the meaning of any of the terms or provisions hereof. 
 13.8. Entire Agreement. Other than as set forth in this Section 13.8 or any other Acquisition Document, this Agreement and the other Acquisition Documents embody the entire agreement and understanding
between the parties hereto with respect to the subject matter hereof and supersede all prior agreements, commitments, arrangements, negotiations or understandings, whether oral or written, between the parties hereto, their respective Affiliates or
any of the Representatives of any of them with respect thereto. There are no agreements, covenants or undertakings with respect to the subject matter of this Agreement and the other Acquisition Agreements other than those expressly set forth or
referred to herein or therein and no representations or warranties of any kind or nature whatsoever, express or implied, are made or shall be deemed to be made herein by the parties hereto except those expressly made in this Agreement and the other
Acquisition Agreements. 
 13.9. Severability. Each term and provision of this Agreement constitutes a separate and distinct
undertaking, covenant, term and/or provision hereof. In the event that any term or provision of this Agreement shall be determined by a court of competent jurisdiction to be unenforceable, invalid or illegal in any respect, such unenforceability,
invalidity or illegality shall, to the fullest extent permitted by Law, not affect any other term or provision hereof, but this Agreement shall be construed as if such unenforceable, invalid or illegal term or provision had never been contained
herein. Moreover, if any term or provision of this Agreement shall for any reason be held by a court of competent jurisdiction to be excessively broad as to time, duration, activity, scope or subject, the parties request that it be construed, by
limiting and reducing it, so as to be enforceable to the fullest extent permitted under applicable Law. 
  

 51 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 13.10. No Third Party Beneficiaries. Except as and to the extent otherwise provided herein,
nothing in this Agreement is intended, nor shall anything herein be construed, to confer any rights, legal or equitable, in any Person other than the parties hereto and their respective successors and permitted assigns. 
 13.11. References to Articles, Etc. All references herein to Articles, Sections, Exhibits and Schedules shall be to Articles and Sections of and
Exhibits and Schedules to this Agreement. 
 13.12. References to “Herein,” Etc. As used in this Agreement, the words
“herein”, “hereof”, “hereby” and “hereunder” shall refer to this Agreement as a whole, and not to any particular section, provision or subdivision of this Agreement. 
 13.13. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which, when
taken together, shall constitute one and the same instrument. 
 [Remainder of page left blank intentionally] 
  

 52 

 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT 
 MARKED [***] HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. 
 SECURITIES AND EXCHANGE COMMISSION. 
  

 IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as
of the date first written above. 
  

			
	ASTRAZENECA UK LIMITED
		
	By:	 	 /s/ Graeme Musker

	Name:	 	Graeme Musker
	Title:	 	Secretary
	
	ABRAXIS BIOSCIENCE, INC.
		
	By:	 	 /s/ Patrick Soon-Shiong

	Name:	 	Patrick Soon-Shiong
	Title:	 	Chairman and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]